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ABSTRACT 
Finding effective life style interventions is paramount in the control of obesity and its 
comorbidities such as NAFLD. In this thesis I investigate the effects of a short chain fatty 
acid (SCFA) on obesity and liver fat, using firstly two different carbohydrates, inulin (an 
indigestible but fermentable carbohydrate) and isomaltulose (a digestible carbohydrate). I go 
on to investigate the effects of acetate, through the development and implementation of a 
novel nanoparticle carrier to study the effects of this SCFA on hepatic metabolism.  
To study the effects of isomaltulose and inulin on adiposity, magnetic resonance imaging 
(MRI) and spectroscopy (MRS) techniques were used on mice fed on a high fat diet 
supplemented with these two carbohydrates. Manganese enhanced MRI (MEMRI), was 
used to monitor hypothalamic brain activation. A significant decrease in hypothalamic 
activation was detected in both inulin and isomaltulose supplemented animals in the 
absence of detectable phenotypic changes, including body adiposity and liver fat.  As some 
of the effects of fermentable carbohydrates are thought to occur through the increased 
production of SCFAs, the potential physiological effects of one of the SCFA, acetate, were 
further explored. PET imaging was employed to study whole body 11C-acetate biodistribution 
on a murine model. The highest uptake of 11C-acetate was observed in the heart followed by 
liver, colon, brown adipose tissue (BAT), brain, fat and muscle (20, 10, 4, 3.6, 3, 2.9 and 2 
peak %ID/g respectively). Colonic administration caused significant difference in uptake 
pattern of heart, liver, brain and BAT (p=0.001), muscle (p=0.0001) and colon (p=0.004) 
compared with i.v. No difference was observed in fed vs fasted animals. Pre-administration 
of “cold” acetate prior to systemic administration of 11C-acetate increased uptake of the latter 
in the liver, heart, brain and BAT suggesting that priming with CA saturates either the 
GPR43/41 receptors or the transport system of acetate  
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In order to assess the potential beneficial effects of acetate, it was necessary to administer 
this SCFA in a chronic and consistent manner. Administration of large concentrations of pure 
SCFA to mice or human is known to have significant detrimental effects, so an alternative 
nanoparticle based strategy was developed for this purpose.  Acetate was encapsulated in 
liposomal nanoparticles, capable of carrying millimolar concentrations of SCFA. In a murine 
model fed on normal fat diet, liposomal-encapsulated acetate significantly decreased liver 
adiposity, but not total body fat, while serum markers of obesity were reduced although they 
did not reach significance. In a murine model fed on high fat diet, liposomal-encapsulated 
acetate decreased whole body adiposity, liver fat content and serum free fatty acid (FFA) 
concentrations and serum markers of liver disease were significantly reduced whereas 
ketone concentrations in serum were significantly increased. 
 This thesis shows that alterations in dietary carbohydrate composition can lead to significant 
effects on appetite, probably through the increase production of SCFAs. Furthermore, the 
use of liposomal-nanoparticles for direct SCFA delivery appears a potentially fast and 
effective way to treat some of the physiological and metabolic abnormalities associated with 
obesity. 
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ABBREVIATIONS 
ACC    acetyl-CoA carboxylase 
ACO    acyl-CoA oxidase 
AgRP    agouti related peptide 
ALT    alanine aminotransferase 
AMP   adenosine monophosphate 
AMPK   AMP-activated protein kinase 
AP    anterior pituitary 
ARC    arcuate nucleus 
AST    aspartate aminotransferase 
AT   adipose tissue 
BAT   brown adipose tissue 
BBB    blood brain barrier 
BMI   body mass index 
CA   “cold” acetate 
Ca+2   calcium ion 
CART    cocaine and amphetamine regulated transcript  
CCD    charge coupled device 
CNS    central nervous system 
CPT-1   carnitine palmitoyl transferase-1  
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CT   computed tomography 
CVD    cardiovascular disease 
DAPI   4',6-diamidino-2-phenylindole 
DMEM   Dulbecco's Modified Eagle Medium 
FAS    fatty acid synthase 
FBP   filtered back-projection 
FFA    free fatty acid 
FOV    field of view 
Gd    gadolinium 
GEE    generalized estimating equations 
GI    glycemic Index 
GLP-1   glucagon-like peptide 1  
GTT   glucose tolerance test 
i.p.   intraperitoneal 
i.v.   intraveneous 
ID   injected dose 
IHCL   intrahepatocellular lipid 
IL-6   interleukin-6  
IM20_HS(20)  20% isomaltulose, 20% sucrose, no maltodextrin 
IM20_NS(0)  20% isomaltulose, no sucrose, (20% maltodextrin) 
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IM7.5_HS(20)  7.5% isomaltulose, 20% sucrose, (12.5% maltodextrin) 
IM7.5_LS(12.5) 7.5% isomaltulose, 12.5% sucrose, (20% maltodextrin)  
IN   Inulin 
LPL    lipoprotein lipase 
LSO    lutetium oxyorthosilicate 
LYSO    LSO doped with yttrium 
M0   longitudinal magnetization 
MCP-1   monocyte chemoattractant protein-1 
MEMRI  manganese enhanced MRI 
Mn2+   manganese ion 
MnCl2   manganese chloride 
MRI   magnetic resonance imaging 
MRS   magnetic resonance spectroscopy 
MXY    transverse magnetization 
MZ    recovered longitudinal magnetization 
NAFLD   non-alcoholic fatty liver disease 
NMR   nuclear magnetic resonance 
NPY    neuropeptide Y 
OCT   optimal cutting temperature  
PCA    perchloric acid 
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PEG    polyethyleneglycol 
PET   positron emission tomography 
POMC   pro-opiomelanocortin 
PPARα  peroxisome proliferator-activated receptor α 
ppm   parts per million 
PVN    paraventricular nucleus 
PYY    peptide YY 
RF    radio-frequency 
ROI   region of interest 
ROS    reactive oxygen species 
RS    resistant starch 
SCFA   short chain fatty acid 
SE    spin echo 
SEM   standard error of mean 
SI    signal intensity 
SNR    signal to noise ratio 
SPECT  single photon emission computed tomography 
SREBP-1  sterol regulatory element binding protein 
SW    spectral width 
T    Tesla 
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T1   relaxation time in longitudinal direction 
T2   decay time in transverse direction 
TCA    tricarboxylic acid 
TE   echo time 
T.E.P.    triethyl phosphate 
TG    triglyceride 
TNF-α    tumour necrosis factor-α 
TOF   time-of-flight 
TR    recovery time 
UCP-2   uncoupling protein-2 
VAT    visceral adipose tissue 
VGCC    voltage-gated calcium channels 
VMH    ventromedial nucleus 
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CHAPTER 1. INTRODUCTION 
1.1 Obesity 
Obesity is a rising public health concern worldwide; according to the estimations of the world 
health organisation, in 2010 there were 1.5 billion overweight adults and 43 million obese 
children worldwide (WHO, 2011). A more recent study carried out in 2011 confirmed these 
findings and that the prevalence of obesity in 2008 was almost doubled from 1980 (Finucane 
et al., 2011).  
Obesity arises from a positive energy balance, whereby food intake exceeds the energy 
expenditure and is associated with liver fat accumulation, insulin resistance, type-2 diabetes, 
cardiovascular disease (CVD), and certain types of cancer (NICE, 2006b). In addition, 
obesity lowers the quality of life by causing physical impairment and various psychological 
issues including poor self-esteem and depression (Aronne et al., 2009). 
Body mass index (BMI) is a widely used measure of body fat content based upon the height 
and weight of an individual.  An adult with a BMI between 18.5- 25 kg/m2 is considered 
normal, 25-30 kg/m2 is classified as overweight and a BMI greater than 30kg/m2 is 
considered as obese (WHO, 2004). The current treatments for obesity include lifestyle 
changes, pharmacological therapies and surgical procedures, such as stomach stapling, 
stomach banding and gastric bypass. In terms of long term efficacy, more than 50% of the 
patients who have lost weight with lifestyle changes such as dieting and exercising have 
returned to their starting weights within 5 years (Aronne et al., 2009). Surgery is the only 
current method that offers a sustainable, long term reduction in body-weight (Waseem et al., 
2007, Mun et al., 2001). Under present medical guidelines a patient should have a BMI 
greater than 40 kg/m2 or BMI between 35 and 40 kg/m2 accompanied by a significant 
disease such as diabetes to be eligible for surgery in UK. If the patient‟s BMI is greater than 
24 
 
50, surgery becomes the first option of treatment (NICE, 2006b). As reported by the Health 
Select Committee in 2002, the cost of obesity in England is about 4 billion GBP (NICE, 
2006a). It is therefore urgent to understand the aetiology of obesity and to develop effective 
novel treatments. 
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1.2 Adiposity and Adipokines 
White adipose tissue is formed of adipocytes, connective tissue, nerve fibres, vascular cells, 
lymph nodes, immune cells, fibroblasts and preadipocytes. It is responsible for energy 
storage. Adipocytes store triacylglycerol as a large lipid droplet. The size of the cells can be 
changed depending on the needs (Torres-Leal et al., 2010). 
White adipose tissue is not only a store for energy but has now been established as an 
endocrine tissue secreting a large number of adipokines including leptin, adiponectin, 
resistin, tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), monocyte chemoattractant 
protein-1 (MCP-1), which play an important role in the metabolic syndrome (Shoelson et al., 
2007) 
Adipose tissue has been shown to be infiltrated by macrophages as a result of obesity 
(Weisberg et al., 2003). This appears to be the source of inflammatory process associated 
with excess fat accumulation in different fat depots and impairs the secretion of adipokines. 
Figure 1.1 shows how adipose tissue becomes inflamed (Ouchi et al., 2011). 
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Figure 1.1. Modulation of adipose tissue with obesity. 
Adipose tissue changes its morphology with increased obesity and it can be phenotyped into 
three distinct groups, lean with normal metabolic function, obese with mild metabolic 
dysfunction and obese with full metabolic dysfunction. As obesity develops the adipocytes 
gets bigger due to increased storage of triglycerides, the number of macrophages increase 
and start expressing M1 (suggested to promote insulin resistance) rather than M2 
(suggested to protect against insulin resistance) in lean adipose tissue, the vasculature 
decreases, anti-inflammatory adipokines (adiponectin and secreted frizzled-related protein 5 
(SFRP5)) are replaced with pro-inflammatory adipokines (leptin, resistin, RBP4 (retinol-
binding protein 4), Lipocalin 2, angiopoietin-like protein 2 (ANGPTL2), TNF, IL-6, CC-
chemokine ligand 2 (CCL2), CXC-chemokine ligand 5 (CXCL5) and nicotinamide phospho 
ribosyltransferase (NAmPT)). In obese adipose tissue with full metabolic dysfunction crown 
like structures are seen which are M1 macrophages circling around the necrotic 
adipocytes.(Ouchi et al., 2011) 
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1.2.1 Abdominal Obesity and Ectopic Fat 
The location of fat in the body is an important factor when defining the health risks of obesity. 
Visceral adipose tissue (VAT) appears to play a major role in the pathogenesis of insulin 
resistance, diabetes, dyslipidaemia, inflammation, hypertension and CVD whereas 
subcutaneous adipose tissue (layer just below the skin) is thought to have a less detrimental 
effect (Miyazaki et al., 2002, Chiba et al., 2007, Nomura et al., 2010). It has been shown that 
patients with a large proportion of visceral adiposity are more likely to develop fatty liver than 
those with greater adiposity in other regions (Ayonrinde et al., 2011, Stranges et al., 2004, 
Katsuhisa et al., 2002, Francque et al., 2011). 
Adipose tissue does not function solely as fat storage but different fat cells act differently as 
has been reviewed by Perrini et al (Perrini et al., 2008). Visceral adipocytes show increased 
lipolytic action compared with subcutaneous adipocytes. Increased lipolysis results in 
circulation of higher concentration of free-fatty-acids (FFA), impairing liver function and 
leading to insulin resistance (Perrini et al., 2008). 
 
1.2.2 Ectopic Fat  
Accumulation of lipids outside the classical adipose tissue depots such as liver, muscle and 
pancreas is known as ectopic fat (Ravussin and Smith, 2002). Accumulation of lipid in the 
liver that is not due to alcohol intake is known as non-alcoholic fatty liver disease (NAFLD) 
(Angulo, 2007). NAFLD is associated with insulin resistance, obesity, type 2 diabetes and 
elevated lipid concentrations (Bugianesi et al., 2002) and may progress into more serious 
conditions such as cirrhosis (Matteoni et al., 1999) and hepatocellular carcinoma (Cheung 
and Sanyal, 2010). NAFLD is found in both children and adults from many different ethnic 
backgrounds (Fishbein et al., 2003). It is often considered to be a precursor of type II 
diabetes (Stefan et al., 2008) and its causes and consequences therefore need to be fully 
investigated.  
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Increased fatty acid concentrations in circulation and inflammation are thought to be one of 
the causes of increased fat deposition in the liver. A simplified diagram of increased 
adiposity and its effects on adipokine secretions and insulin resistance is shown in figure 1.2. 
Adipose tissue in obese subjects is thought to lead to increased concentrations of FFA 
deposition due to increased rate of lipolysis. Furthermore in the liver increased lipogenesis 
can also contribute to an elevation in triglyceride concentrations (Duvnjak et al., 2007). 
Fabbrini et al. have further suggested that increased liver fat is an independent indicator of 
multi-organ insulin resistance and postulate that the observed relationship between 
increased visceral fat and metabolic disease is essentially a confounding factor due to the 
correlation between visceral and liver fat (Fabbrini et al., 2009). More recently, Magkos et al. 
have shown that increased adiposity, without an increase in liver fat, does not cause 
abnormalities in adipose tissue, skeletal muscle and hepatic insulin sensitivity, or VLDL 
metabolism (Magkos et al., 2010). 
When inflamed, adipose tissue has been associated with increased pro-inflammatory 
cytokines such as tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6). TNF-α and IL-6 
have been shown to be involved in liver regeneration and are undetectable in normal 
functioning liver (Tilg and Moschen, 2011, Qureshi and Abrams, 2007). Increased oxidative 
stress of hepatocytes, characterized by reactive oxygen species (ROS), is believed to be 
another trigger of inflammation in the liver following lipid accumulation, which in turn can lead 
to liver fibrosis. Inflammation of the liver can however be positively modulated by the anti-
inflammatory adipokine secreted by the adipose tissue, adiponectin, (Tsochatzis et al., 
2009). Adiponectin has been shown to lower adiposity in the liver (Fukushima et al., 2009). 
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Figure 1.2. Increased adiposity, adipokine secretions and insulin resistance. 
As a result of overnutrition, adipose tissue becomes larger and inflated by macrophages. 
This causes dysregulated adipokine secretion; leptin, resistin and free fatty acid 
concentrations increase, adiponectin level decreases, adipocytokines TNF-α and IL-6 also 
increases. This causes inflammation, lipid accumulation and eventually insulin resistance in 
tissues such as liver and muscle. In inflamed and insulin resistant liver the rates of 
glycogenolysis and gluconeogenesis increase which causes increase in the plasma glucose 
concentrations. Dysregulated adipokines also affect energy expenditure, food intake and 
glucose production through their effects on hypothalamus. All of these changes contribute to 
the formation of systemic insulin resistance (Galic et al., 2010). 
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Measurement of liver fat has therefore become an important issue in light of the above 
discussion. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
concentrations are generally used as biochemical markers of NAFLD. In patients with 
NAFLD, ALT serum level might be increased up to 5 fold whereas AST might be elevated 10 
times compared with normal values. Alkaline phosphate concentrations also appear to be 
elevated (up to 3 times) in patients with NAFLD (Falck-Ytter et al., 2001). However, a 
number of studies have shown that in many cases there is no direct association between 
changes in liver function test and hepatic fat content, requiring more direct method to 
determine this fat depot (Thomas et al., 2005). 
The lipid content of the liver can be evaluated by a number of invasive and non-invasive 
methods. (Roldan-Valadez et al., 2008, Stefan et al., 2008, Cotler et al., 2007). Until 
recently, needle biopsy, in combination with electron microscopy/oil staining was the most 
commonly used technique for determining ectopic fat content. However, this technique has 
limited application in tissues such as the heart and pancreas, as well as the practical and 
ethical issues associated with longitudinal studies, potential bleeding and inflammation and 
the fact that analysis of repeated measurements is subject to significant inter-observer 
variability (Demetris et al., 1991, Metavir, 1994, Thomas et al., 2005). Non-invasive methods 
available include ultrasound which tends to be regarded as an initial screening tool for 
hepatic steatosis due to being non-invasive, inexpensive and widely available. However, 
poor sensitivity and specificity of ultrasound, particularly for mild to moderate (<20%) 
concentrations of fat infiltration have led many to question whether it is an appropriate 
screening tool for fatty liver disease. Today, the advent of CT, and magnetic resonance 
imaging (MRI) and MR spectroscopy (MRS) have revolutionised the study of ectopic fat, 
allowing fast and reproducible non-invasive quantitative measurement of lipids in the muscle, 
liver, heart and pancreas. Increased availability and access to MR scanners has made it a 
more viable alternative as a clinical screening tool, rather than a pure research 
measurement. 
31 
 
1H MRS is a non-invasive technique which has been successfully applied to assess the 
hepatocellular lipid content of liver (Szczepaniak et al., 2005, Thomas et al., 2005, 
Szczepaniak et al., 1999, van Werven et al., 2010) and has become the most preferred in 
clinical research. CT attenuation is used to assess the level of steatosis in the liver but it 
involves exposure to ionising radiation. MRI has also been used to quantify liver fat but the 
reproducibility of the technique is still under investigation (Kim et al., 2008, Ishizaka et al., 
2011). Nevertheless imaging methods cannot be used to distinguish NASH (non-alcoholic 
steatohepatitis) from NAFLD and a biopsy is required. NASH is progressed form of NAFLD 
and therefore distinguishing between them may be important to monitor the progress of 
disease or the effect of a treatment.  
As previously discussed by Hebbard and George, animal models can provide a good model 
to study NASH (Hebbard and George, 2011). Maintenance of rodents on high fat feed has 
been shown to increase inflammation, oxidative stress and lipogenesis and also display a 
decrease in adiponectin concentrations. The alterations in these mechanisms then progress 
to insulin resistance, obesity, steatosis, steatohepatitis and fibrosis (Hebbard and George, 
2011). In a study by Xu, high fat feeding of animals caused elevated concentrations of 
glucose, insulin, FFA, triglyceride (TG), ALT, TNF-α and finally liver steaostosis (Xu et al., 
2010).  
The fat content in the liver has been shown to be reduced by life style changes such as 
dieting and exercising (Stefano et al., 2008, Kim et al., 2009, Chen et al., 2008, Thomas et 
al., 2006).  
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1.2.3 Adipokines 
Leptin is an adipokine that amongst other functions regulates food intake through the central 
nervous system (CNS) (Spanswick et al., 1997). Animals which lack leptin display 
hyperphagia and administration of leptin to these animals decreases food intake (Saladin et 
al., 1995, Weigle et al., 1995). It has also been shown that increased adiposity correlates 
with increased concentrations of leptin (Frederich et al., 1995). 
Resistin regulates glucose metabolism and has been shown to induce insulin resistance in 
animals (Steppan et al., 2001). In humans, its functions are not as clear yet. In animals it is 
produced in the adipocytes but in humans it is mostly produced by macrophages (Schwartz 
and Lazar, 2011).  
Adiponectin is an anti-inflammatory adipokine and its concentrations are decreased in 
obesity (Hotta et al., 2000). Its production is inhibited by inflammatory factors such as TNF-α 
and IL-6 and increased by PPARγ (Ouchi et al., 2003). 
TNF-α and IL-6 are inflammatory factors. TNF-α concentrations are increased in obese 
subjects and is associated with impaired glucose homeostasis (Cartier et al., 2008, Uysal et 
al., 1997). Although there are controversial results, as it has been suggested that TNF-α 
might improve insulin sensitivity (Uysal et al., 1997). In animals, the expression of TNF-α in 
adipocytes is increased by obesity and insulin resistance (Xu et al., 2003, Cai et al., 2005) 
and blockage of TNF-α signal was shown to improve insulin sensitivity (Liang et al., 2008). 
IL-6 is positively correlated with obesity and diabetes (Fried et al., 1998, Cai et al., 2005). It 
is also related to adiposity as the increased concentrations in obese subjects are reduced 
after weight loss (Esposito et al., 2003).  
MCP-1 concentrations are also shown to be affected by obesity (Xu et al., 2003). The 
concentrations are higher in white adipose tissue of obese mice compared with lean controls 
and insulin causes an increase in the MCP-1 concentrations of both normal and insulin 
resistant adipocytes (Sartipy and Loskutoff, 2003). 
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1.3 Brain and Adiposity 
Energy homeostasis is governed principally by the central nervous system (CNS), which 
senses metabolic status from a wide range of blood borne and neuronal signals. Given the 
considerable number of potential inputs involved in the regulation of energy balance, a 
complex system has evolved with the hypothalamus, located at the base of the brain, as a 
key region for integration of these signals. 
 
1.3.1  Appetite Centres 
Studies introducing discrete lesions into specific nuclei of the hypothalamus were the first to 
demonstrate a link between the hypothalamus and the regulation of appetite. Lesions or 
surgical transection within specific nuclei of the hypothalamus such as the arcuate nucleus 
(ARC), ventromedial nucleus (VMH) and paraventricular nucleus (PVN) disrupted daily food 
intake resulting in permanently enhanced appetite (Grundmann et al., 2005, Dube et al., 
1999, Penicaud et al., 1983). 
More recent work has shown that these nuclei express a number of key neuropeptides and 
their receptors are involved in the regulation of appetite (Parkinson et al., 2009b). 
Furthermore, exogenous administration of these neuropeptides into the ARC, VMH and PVN 
has been shown to alter appetite and ultimately body weight (Kim et al., 2000, Kalra et al., 
1991, Biebermann et al., 2006, Stanley and Leibowitz, 1984). The expression of 
hypothalamic neuropeptides has been shown to reflect nutritional status with high 
concentrations of NPY observed in the PVN before feeding time and a subsequent decrease 
following feeding (Kalra et al., 1991). It has been shown that two sets of neurons exists in 
the ARC; orexigenic neuropeptides Neuropeptide Y (NPY) and Agouti Related Peptide 
(AgRP) increase food intake and induce obesity, whereas Pro-opiomelanocortin (POMC) 
and Cocaine and Amphetamine Regulated Transcript (CART) inhibit food intake 
(Biebermann et al., 2006, Chaudhri et al., 2008, Fan et al., 1997, Parkinson et al., 2009b) 
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and these signals from the ARC projects to other nuclei (Parkinson et al., 2009b). It has 
been suggested that the position of the ARC, being close to the median eminence which has 
an incomplete blood brain barrier (BBB), makes it susceptible to the effects of circulating 
factors crossing the BBB (Cone et al., 2001). (Figure 1.3) 
The brain stem makes up the lower part of the brain, adjoining and structurally continuous 
with the spinal cord. There are extensive reciprocal connections between the brainstem and 
forebrain. By interfacing with hypothalamic circuits, the brainstem plays a principal role in the 
regulation of energy homeostasis. It is able to function as a junction point for afferent signals 
from the periphery (Mercer et al., 1998, Fan et al., 2004). 
 
 
Figure 1.3. Effects of appetite regulating circuits in hypothalamus and brainstem. 
Circulating factors in the blood such as endocrines and adipokines get into the 
hypothalamus through the incomplete blood brain barrier. Once in hypothalamus by either 
activating or inactivating the NPY/AgRP (orexigenic) or POMC/CART (anorexic) neurons. 
Adopted from (Parkinson et al., 2009b) 
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1.4 Carbohydrates and Adiposity 
Over consumption of diets containing high fat with/without high refined carbohydrate, 
coupled to decrease physical activity, is considered to be the main cause of high body fat 
content. 
Carbohydrates can be classified into two main groups; digestible or indigestible depending 
where in the gastrointestinal track they are digested (Lairon et al., 2007). Those absorbed at 
the small intestine are known as digestible (or available) carbohydrates whilst those that 
escape the small intestine are known as indigestible (or resistant) carbohydrates (Englyst et 
al., 2007).  
Some of the indigestible carbohydrates are fermented in the colon by bacteria. In rodents, 
dietary supplementation of the fermentable indigestible carbohydrate, resistant starch (RS), 
resulted in lower abdominal adiposity and an increased expression of anorexigenic (appetite 
suppressing) gut hormones (Keenan et al., 2006) as well as lower lipid concentrations in 
liver cells and a decreased insulin response compared with animals fed with low RS diet (So 
et al., 2007). The fermentation process of these carbohydrate have been shown to result in 
the production of a number of products including the  short chain fatty acids (SCFA) acetate, 
propionate and butyrate (Keenan et al., 2006, Wong et al., 2006). It has also been 
suggested that increased production of SCFAs may play an important role in adipose tissue 
remodelling (Robertson, 2007). Inulin is another example of an indigestible carbohydrate 
which is fermented in the colon and that can significantly affect body composition 
(Roberfroid, 2007). 
The glycemic Index (GI) is a measure of the effect of a carbohydrate on blood glucose 
concentrations following ingestion (Bell and Sears, 2003). It has been shown that sustained 
dietary consumption of carbohydrates with a low GI index results in a reduced body weight 
and body fat when compared with high GI carbohydrates (McMillan-Price et al., 2006, 
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Pawlak et al., 2004). Isomaltulose is an example of a digestible carbohydrate which is 
digested slowly and therefore has a low GI. 
 
1.4.1 Inulin 
Inulin is a term applied to a heterogeneous blend of fructose polymers found widely 
distributed in nature as plant storage carbohydrates in wheat, onion, banana and garlic. 
Inulin is a polydisperse β(2-1) fructan, made up of fructose units linked by β(2-1) bonds with 
a glucose molecule linked at the end of each fructose chain via an  α(1-2) bond. These β(2-
1) linkages are the essential component that prevent its digestion (Niness, 1999). The 
chemical structure is shown on figure 1.4. 
 
Figure 1.4. Chemical structure of inulin. 
Inulin is made up of fructose units linked by β(2-1) bonds and a glucose molecule (GFn) 
linked at the end of each fructose chain (Fm) via an  α(1-2) bond. 
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Inulin is an indigestible but fermentable carbohydrate which  passes through the small 
intestine without being digested, whereupon it is fermented in the colon by microflora 
bacteria, producing SCFA and lactate (Juśkiewicz et al., 2007). Oligofructose belongs to a 
subgroup of inulin, consisting of polymers with a degree of polymerization formed following 
hydrolysis of inulin (Roberfroid et al., 1998). 
Consumption of inulin and oligofructose in rats has been shown to decrease FFA and insulin 
concentrations in plasma (Kok et al., 1996). Sustained consumption of an oligofructose 
supplemented diet in human subjects resulted in a reduced body weight, satiety, higher 
concentrations of the anorexigenic appetite regulating gut hormones, glucagon-like peptide 1 
(GLP-1) and peptide YY (PYY) and lower concentrations of the orexigenic or appetite 
stimulating hormone ghrelin (Cani et al., 2006, Parnell and Reimer, 2009). In a recent study 
performed by our laboratory we demonstrated that animals fed with a high fat inulin 
supplemented diet gained less weight and had lower whole body and liver adiposity than 
high fat fed control animals. In addition, animals fed with the inulin supplemented diet 
showed lower activation in the hypothalamic appetite centres, arcuate, paraventricular and 
the periventricular nuclei compared with high fat control animals (Anastasovska et al., 2012).      
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1.4.2 Isomaltulose 
Isomaltulose (Palatinose™) is a disaccharide formed through the α-1,6 linkage of glucose 
and fructose with the chemical name, 6-0-α-D-glucopyranosyl-D-fructose (Jonker et al., 
2002, Kashimura et al., 2008, Lina et al., 2002, Sato et al., 2007). It is manufactured from 
sucrose by enzymatic rearrangement of the glycosidic α(1,2)-linkage to α(1,6)-linkage and 
crystallization (Jonker et al., 2002, Lina et al., 2002). The chemical structure is shown in 
figure1.5. Isomaltulose is naturally found in honey (Arai et al., 2004, Oizumi et al., 2007) and 
tastes similar to, but is half as sweet as sucrose (Jonker et al., 2002, Lina et al., 2002). 
 
Figure 1.5. Chemical structure of isomaltulose. 
Isomaltulose is formed through the α-1,6 linkage of glucose and fructose. 
 
 
Isomaltulose being a digestible carbohydrate is hydrolyzed in the small intestine into 
monosaccharides glucose and fructose and is absorbed. However its rate of digestion is 
much slower than sucrose resulting in an attenuated glucose and insulin response (Jonker et 
al., 2002, Lina et al., 2002, Arai et al., 2004).  
It has been shown in previous studies that animals fed with isomaltulose based diets had 
lower body weights (Arai et al., 2004, Matsuo et al., 2007, Sato et al., 2007, Fujiwara et al., 
2007), less abdominal and liver adiposity (Sato et al., 2007, Arai et al., 2004, Fujiwara et al., 
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2007), lower plasma insulin and glucose concentrations (Sato et al., 2007, Arai et al., 2004, 
Fujiwara et al., 2007) and  lower respiratory quotient (Fujiwara et al., 2007) when compared 
with animals fed with control diets. In an experiment carried out on human subjects, long 
term consumption of an isomaltulose based formula resulted in lower concentrations of 
plasma FFAs and decreased volume of VAT (Oizumi et al., 2007). 
A proposed explanation of how isomaltulose decreases adiposity is linked to the fact that it is 
digested slowly. Insulin stimulates the uptake of fat from blood by increasing the lipoprotein 
lipase (LPL) activity of adipose tissue. As isomaltulose is digested slowly, it results in a 
reduced elevation in insulin secretion post-prandially; it is therefore less likely that ingested 
fat accumulates as fat tissue (Fujiwara et al., 2007). 
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1.5 Short Chain Fatty Acids and Adiposity 
Fermentation of dietary fibres produces SCFAs, mainly acetate, propionate and butyrate 
(Miller and Wolin, 1979, Stjernholm and Flanders, 1962). Figure 1.6 shows their chemical 
structures. 
 
Figure 1.6. Molecular structure of SCFAs.  
Molecular structure of acetic acid, propionic acid and butyric acid (Al-Lahham et al., 2010). 
 
 
The average concentration of SCFAs in human colon is c.a. 100mM on a Western diet (but 
higher,  c.a. 250mM, on a traditional African tribe diet) (Cummings et al., 1987). The ratio of 
acetate:propionate:butyrate produced in human colon is close to 60:20:20 (Cummings et al., 
1979). Although this ratio does depend on conditions such as bacteria populations present in 
the colon and the passage time, it is relatively constant. In a study of human subjects, it was 
shown that the fasted acetate level in serum was on average 60µmol/L and propionate and 
butyrate concentrations were less than 2µmol/L and the arterial serum level of acetate was 
almost twice as that of venous serum concentrations in the same study (Pomare et al., 
1985). In another study fasted serum acetate concentrations were measured as 77µmol/L 
(Wolever et al., 1991). Cummings et al investigated SCFAs concentrations post mortem, 
taking samples from colon and blood from portal, hepatic and peripheral veins. In the large 
intestine the concentrations of acetate, propionate and butyrate were around 60, 20 and 20 
mmol/kg, respectively. The mean blood concentrations for acetate, propionate and butyrate 
were 258, 88 and 29 in portal vein, 115, 21 and 12 in hepatic vein and 70, 5 and 4 (µmol/L) 
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in peripheral vein (Cummings et al., 1987). These concentrations show that the butyrate 
produced does not leave the colon while most of the acetate and propionate is taken up by 
the blood. Concentrations of SCFA in peripheral blood increase with increase intake of 
resistant starch (Robertson et al., 2005). 
SCFA concentration in cecal content of rodents has been reported as 110µmol/g of sample 
(Demigné and Rémésy, 1985, Sonoyama et al., 2009). Arterial acetate level in rats is about 
0.1µmol/ml but the same study was unable to detect propionate and butyrate in arterial 
blood (Demigné and Rémésy, 1985). A study of inulin supplementation found that in control 
animals the cecal concentration of acetate, propionate and butyrate concentrations were 55, 
20 and 10 mmol/L, respectively. All of these values were increased significantly after inulin 
supplementation (Levrat et al., 1991). 
SCFAs produced in the colon are absorbed by colon mucosal cells (figure 1.7). Butyrate is 
the preferred energy source of the colonocytes but acetate and propionate have also been 
shown to be utilised by these cells (Roediger, 1980). The remaining propionate and acetate 
is metabolized in the liver, with some acetate been taken up by peripheral tissues 
(Mortensen and Clausen, 1996). However, due to technical limitation, no full bio-distribution 
of these SCFAs have been carried out to date. 
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Figure 1.7. SCFA absorption. 
The absorption of 3 main SCFA produced in the colon are shown. Most of the butyrate 
produced is used by colonocytes as an energy source. The proportion of propionate and 
acetate taken up by the colon is less compared with butyrate. Propionate is taken up by the 
liver. Acetate is mostly taken up by the liver with some also taken up in the peripheral tissue 
such as heart (Mortensen and Clausen, 1996).  
 
 
SCFAs have been shown to have effects in different parts of the body. Two different groups 
of researchers have shown that G protein coupled receptors GPR41 and GPR43 are 
activated by acetate, propionate and butyrate (Le Poul et al., 2003, Brown et al., 2003). Both 
receptors decrease adenylyl cyclase concentrations in cells and increase Ca+2 
concentrations. The receptors exert their functions by coupling with Gi/o and/or Gq (Pertussis 
toxin-insensitive protein families); GPR41 with Gi/o and GPR43 with both. It has also been 
shown that acetate is less potent to GPR41 than propionate and butyrate and GPR43 is 
activated similarly by the three SCFAs (Le Poul et al., 2003). 
There are contradictory results regarding the effects of SCFAs on adipocyte metabolism. 
While some studies showed that administration of SCFAs acetate and propionate, inhibit 
lipolysis through GPR43 receptors (Ge et al., 2008, Hong et al., 2005), others have shown 
that acetate decreased fat accumulation through modification of AMPK and enzymes 
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involved in fatty acid oxidation (Yamashita et al., 2009, Kondo et al., 2009). Figure 1.8 shows 
the basic reactions that result in the formation of SCFA.  
 
1.5.1 Butyrate Formation and Metabolism 
A simplified diagram of SCFAs formation in the colon, including butyrate, is shown figure 1.8. 
Pyruvate is first fermented into acetoacetyl-CoA and then butyryl-CoA which then is turned 
to butyrate. 
 
Figure 1.8. Formation of SCFAs. 
Production of acetate, propionate and butyrate are displayed. When a fermentable 
carbohydrate is consumed it is passed to the colon undigested where it is broken down to 
SCFAs and lactate and ethanol by microbiota. 
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70% of the energy source for colonocytes comes from SCFA oxidation. Butyrate is the 
preferred fuel over the other SCFAs produced in the colon of both human and rats, 
propionate and acetate in a ratio of 90:30:50 (Roediger, 1980, Cook and Sellin, 1998).  
Many in vitro and animal studies have shown that butyrate has a positive effect on treating 
colon cancer (Wong et al., 2006, Scheppach et al., 1995). 
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1.5.2 Propionate Formation and Metabolism 
Dietary fibres are composed of hexoses and pentoses which are metabolized into pyruvate 
by microboata. Pyruvate is then further metabolized to form propionate by two pathways: 
fixation of CO2 from succinate or from lactate and acrylate (summarized in figure 1.9) (Wong 
et al., 2006). In ruminants, after production propionate is converted into propionyl-CoA and 
enters to the kreb‟s cycle, eventually causing increased production of glucose in the liver 
(Leng and Annison, 1963). 
 
Figure 1.9. Production and metabolism of propionate.  
Pyruvate is metabolized from dietary fibres and it further metabolizes into succinate and 
lactate which then forms propionate (Al-Lahham et al., 2010). 
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Propionate has been shown to reduce blood glucose concentrations (Tobin et al., 1972, 
Todesco et al., 1991). Propionate has effect on lipolysis and lipid accumulation and it has 
been shown that this action could be through GPR41 and GPR43 receptors (Hong et al., 
2005). GPR41 receptors expressed in white adipose tissue have been shown to be 
stimulated by propionate, directly influencing leptin production (Xiong et al., 2004). 
 
47 
 
1.5.3 Acetate Formation and Metabolism 
As well as being one of the main SCFAs produced by the fermentation of dietary fibres in the 
colon, consumption of ethanol also increases the level of acetate in the blood. In addition to 
the production thorough food intake, acetate is also produced in liver and brown adipose 
tissue by fatty acid oxidation. However, the main source of high concentrations of circulating 
acetate are primarily from fermentation (Ballard, 1972). A simplified diagram of acetate 
formation is shown in figure 1.10. 
 
Figure 1.10. Production of acetate.  
Different ways by which acetate is formed is displayed. It is formed from ethanol, acetylated 
compounds, acetyl-CoA (Ballard, 1972). 
 
Acetate is metabolized to a lesser extent in the colon compared with butyrate and is 
transferred to the liver (Mortensen and Clausen, 1996).  
Chronic administration of acetate (injection, 5 days a week for 6 months) has been shown to 
lead to decreased body weight and lower glucose, triglycerides, cholesterol, leptin and 
insulin concentrations in the plasma of rats (Yamashita et al., 2007).  
Acetate feeding under fed conditions is thought to lead to increased uptake into the blood 
from the intestine and is absorbed into different tissues producing acetyl-CoA. Synthesis of 
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acetyl-CoA, leads to increased formation of AMP. This increases the AMP/ATP ratio which in 
turn causes the phosphorylation of AMPK (Yamashita et al., 2007). AMPK is a multi-
substrate enzyme and is considered to be a cell‟s “low fuel warning system” since it is 
activated by the low concentrations of ATP (Hardie and Carling, 1997). It is a heterotrimer 
formed of a catalytic subunit α and regulatory subunits β and γ. The α2β2γ1 form of AMPK 
induces transcription of peroxisome proliferator-activated receptor α (PPARα) gene (Suzuki 
et al., 2007). PPARα has downstream effects on upregulating fatty acid oxidation enzymes, 
such as acyl-CoA oxidase (ACO), carnitine palmitoyl transferase-1 (CPT-1), and uncoupling 
protein-2 (UCP-2).  Activation of AMPK has also been shown to suppress the activity of 
lipogenic enzymes, including the transcription of acetyl-CoA carboxylase (ACC), sterol 
regulatory element binding protein (SREBP-1) and downstream of SERBP-1 fatty acid 
synthase (FAS) (Zhou et al., 2001). A proposed effect of acetate in fatty acid metabolism in 
liver is shown figure 1.11.  
In a study in mice fed with high fat diet, treatment with acetic acid (orally), led to a decrease 
in liver triglyceride concentrations. Also the mRNA concentrations of PPARα , ACO and 
CPT-1, UCP-2 were significantly higher than those not treated with acetic acid (Kondo et al., 
2009).  
Rats fed a cholesterol rich diet supplemented with acetic acid had reduced concentrations of 
mRNA  for the lipogenic enzymes SERBP-1, ACC and FAS (Fushimi et al., 2006). 
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Figure 1.11. Effect of acetate in fatty acid synthesis in liver. 
A proposed mechanism of effect of acetate on fatty acid synthesis in liver is shown in the 
figure.  Acetate through activation of AMPK, inhibits fat synthesis in the liver. Fatty acids are 
synthesized from excess glucose in the liver. Glucose is turned into pyruvic acid which goes 
into TCA cycle. Once citrate is formed it generates cytosolic acetyl-CoA and malonyl-CoA 
which then forms fatty acids. (Yamashita et al., 2007) 
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1.6 Imaging Methods in in vivo Research 
Imaging modalities play an important role in this thesis for assessing obesity. Therefore the 
importance of molecular imaging and different imaging modalities will be described in this 
section. 
 
1.6.1 Molecular Imaging 
With the advent of imaging modalities biological events can now be monitored in real time, in 
vivo. Different imaging techniques are used in both clinical and research settings depending 
on the application as each technique has its own advantages and disadvantages.  
The assessment of diseases is dependent on anatomical and physiological changes which 
usually occur at the last stage of disease progression. Finding early molecular markers of a 
disease by using imaging methods can increase the possibility of treatment (Weissleder and 
Mahmood, 2001). Moreover imaging methods can also be used to assess therapy progress 
after treatment (Weissleder and Mahmood, 2001). 
 
1.6.2 Molecular Imaging Modalities 
Table 1.1 summarizes the advantages and disadvantages of molecular imaging techniques 
together with most commonly used contrast agents (Pysz et al., 2010). These techniques will 
be explained further in the rest of this section. 
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Technique Advantages Disadvantages Common contrast 
agents 
Optical  No ionizing irradiation 
 Real-time imaging/short 
acquisition time (sec-min) 
 Relatively high spatial 
resolution 
 Can be applied externally or 
internally (endoscopy) 
 Inexpensive 
 Highly quantitative and 
sensitive 
 Multiplexing 
 Limited depth penetration (<1 
cm) 
 Whole-body imaging not 
possible 
 Fluorescent 
molecules and 
dyes 
 Light-absorbing 
nanoparticles 
Ultrasound  No ionizing irradiation 
 Real-time imaging/short 
acquisition time (min) 
 High spatial resolution 
 Can be applied externally or 
internally (endoscopy) 
 Inexpensive 
 Highly sensitive 
 Whole-body imaging not 
possible 
 Contrast agents currently 
limited to vasculature 
 Operator dependency 
 Contrast 
microbubbles 
Computed 
tomography 
 Unlimited depth penetration 
 High spatial resolution 
 Whole-body imaging possible 
 Short acquisition 
time(minutes) 
 Moderately expensive 
 Anatomical imaging 
 Radiation exposure 
 Poor soft-tissue contrast 
 Probably not used for 
molecular imaging; currently 
only anatomical and functional 
imaging 
 Barium 
 Iodine 
 Krypton 
 Xenon 
Single photon 
emission computed 
tomography 
 Unlimited depth penetration 
 Whole-body imaging possible 
 Quantitative molecular 
imaging 
 Theranostic: can combine 
imaging and radiotherapy 
 Can be combined with CT for 
anatomical information 
 Radiation exposure 
 Low spatial resolution(0.3-1 
mm; 12-15 mm
3
) 
 Long acquisition time 
 
99m
Tc 
 
123
I 
 
111
In  
 
177
Lu 
Positron emission 
tomography 
 Unlimited depth penetration 
 Whole-body imaging possible 
 Quantitative molecular 
imaging 
 Can be  combined with CT or 
MRI for anatomical 
information 
 Radiation exposure 
 Expensive 
 Low spatial resolution (1-2 
mm; 4-8mm
3
) 
 Long acquisition times(minutes 
to hour) 
 
11
C 
 
18
F 
 
64
Cu 
 
68
Ga 
Magnetic resonance 
imaging 
 Unlimited depth penetration 
 Whole-body imaging possible 
 No ionizing irradiation 
 Excellent soft-tissue contrast 
 High spatial resolution 
 Expensive 
 Long acquisition time (min-
hours) 
 Limited sensitivity for detection 
of molecular contrast agents 
 Gadolinium 
(Gd
3+
) 
 Iron oxide 
particles (SPIO, 
USPIO) 
 Manganese oxide 
 
19
F 
Magnetic resonance 
spectroscopy 
 Whole-body imaging possible 
 No ionizing irradiation 
 Expensive 
 Long acquisition time(min-
hours) 
 Low sensitivity 
 
Table 1.1. Advantages and disadvantages of imaging techniques used in clinical and 
research settings. 
Main advantages and disadvantages of imaging techniques are summarized in the table 
together with commonly used contrast agents. (Pysz et al., 2010) 
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1.6.2.1 Optical Imaging 
Optical imaging is one of the cheapest techniques used in molecular imaging. There are two 
main groups that this technique is broadly divided into; fluorescence and bioluminescence.  
Bioluminescence is the light produced from luciferin by luciferase oxidation. Firefly and sea 
pansy luciferase enzymes are used in bioluminescence imaging. They emit light in 
wavelengths of 560nm and 480nm. D-luciferin from firefly is water soluble and gets absorbed 
by the cell membranes of mammals (Hutchens and Luker, 2007). 
A sensitive charge coupled device (CCD) camera is used to detect light emitted from 
luciferase in vivo (Shah and Weissleder, 2005, Hutchens and Luker, 2007). The applications 
of this technique include cell tracking, gene expression and tumour imaging (Canel et al., 
2010, Yoon et al., 2011, Fan et al., 2011).  
Fluorescence imaging involves fluorescent molecules emitting light upon irradiation at a 
specific wavelength. When irradiated with light electrons of the molecule move to a higher 
energy state, and then when relaxing back to their ground state they emit energy as 
photons. The wavelength of emitted light is higher than the wavelength of irradiated light. By 
using filters that only allows a specific wavelength, only emitted light is captured by the CCD 
camera (Massoud and Gambhir, 2003). 
 
1.6.2.2 Ultrasound 
Because of its low cost and availability, ultrasound is very widely used in both in clinical and 
research settings. Being non-invasive and relatively safe is also an advantage in clinical 
medicine. It is one of the few techniques that provide real time imaging (Massoud and 
Gambhir, 2003).  
A transducer placed against the skin is used to emit ultrasound waves (>20kHz) which are 
reflected back from the internal organs (Massoud and Gambhir, 2003). The reflected waves 
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are then detected with the transducer and converted to images. The magnitude of the 
reflected waves depends on acoustic impedance of the tissue and the attenuation.  
 
1.6.2.3 Computed Tomography 
The computed tomography (CT) system is formed from an x-ray source and detector. The 
subject is placed between the source and the detector. The energy of the x-ray source used 
for research (small animal imaging) is 30-60kVp. The detector is formed of an array of CCD 
cameras (Paulus et al., 2000). The first generation of scanners had single detector and a 
single source with parallel beam. The second generation had multiple detectors and a 
source with small fan beam. The third and 4th generations are the ones used nowadays. The 
third generation had an array of detectors and a source with a large fan beam and both were 
rotating in circular motion around the subject. The fourth generation has a ring of detectors 
which is fixed and a source with a large beam which rotates around the subject. 
The four main methods of image reformation are; filtered back-projection (FBP), iterative, 
fourier and algebraic reconstruction techniques (Shung, 1992).  
 
1.6.2.4 Single Photon Emission Computed Tomography  
Both SPECT and PET detect emitted gamma (γ) ray emission. Molecules can be labelled 
with isotopes which are then administered to the subject. Isotopes are at an unstable state. 
In SPECT, isotopes are excited and decay to their stable state by emitting energy in the form 
of γ rays. Emitted γ rays are detected by a gamma camera which is rotated around to the 
subject to obtain 2D or 3D images. Collimators are attached to the detector and are used in 
detection of the direction of γ rays. Although they are necessary to position the origin of the 
signal, they decrease the sensitivity of the SPECT system. The images are formed with FBP. 
(Massoud and Gambhir, 2003) 
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1.6.2.5 Positron Emission Tomography 
In PET, isotopes decay emitting a positron and neutrino. The positron is annihilated when it 
comes in contact with an electron emitting 2 anti-parallel γ rays. The energy of the γ rays 
emitted is 511keV (shown in figure 1.12) (Surti and Karp, 2010). 
 The radioisotopes used in PET imaging include 18F and 11C and are produced by a 
cyclotron. In a cyclotron (which is formed of two magnets and two hollow D-shaped 
electrodes) ions are accelerated and forced onto a target. The reaction between the ions and 
the target produces the desired radioisotopes. 
Because the radioisotopes used in PET produce two positrons in anti-parallel direction, in 3D 
PET, collimators are not used. Instead time-of-flight (TOF) detection is employed. Two 
photons received in detectors 1800 apart are counted as events only if they occur during a 
very short time interval (figure 1.12). Because the collimator design is not used in PET, it is 
usually 10 times more sensitive than SPECT (Rowland and Cherry, 2008).  
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Figure 1.12. Basic physics of PET. 
When a radionuclide delivered to the subject decays, a positron is emitted. The positron after 
travelling a very short distance annihilates with an electron in the tissue and as a result two 
gamma rays (511keV) in opposite direction are emitted. A PET scanner is formed of a ring of 
gamma ray detectors which using TOF detect simultaneous emissions and location of the 
emissions. Then by using events detected and computed tomography methods, cross-
sectional images are formed. (Cherry and Gambhir, 2001) 
 
 
The detectors are formed of scintillation crystals and photomultiplier tubes. Scintillation 
crystals are used to form light from γ rays. The light is turned to electrons and accelerated 
trough the photomultiplier tube. As crystals, sodium iodide activated with thallium (NaI(Tl)) 
and bismuth germinate (BGO) were used in clinical systems. In recent small animal 
scanners they are replaced by lutetium oxyorthosilicate (LSO) or LYSO (LSO doped with 
yttrium) which have excellent timing resolution and good energy resolution (Cherry, 2006).  
The main application of PET is tumour imaging together with 18F-FDG (fluorodeoxyglucose) 
(Torizuka et al., 1995, Ford et al., 2009).  
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1.6.2.6 Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is a non-invasive imaging technique that can not only 
image functional, anatomical and molecular changes but also has high spatial resolution and 
soft tissue contrast (Makowski et al., 2009).  The disadvantage compared with other 
mentioned imaging techniques is its lower sensitivity (Pysz et al., 2010, Makowski et al., 
2009). MRI and MRS (magnetic resonance spectroscopy) have many applications  
MRI and MRS allow accurate measurement of whole body fat and specific internal stores of 
adipose tissue, in vivo. Body mass index (BMI) is the benchmark for obesity classification; 
however like all anthropometric measurements it only offers a proxy measure of body 
adiposity (Prentice and Jebb, 2001). Waist circumference is widely used as a surrogate of 
central fat distribution but whilst easily obtainable, it is unable to distinguish between VAT 
and abdominal subcutaneous adipose tissue (ASAT) deposition. MRI and MRS studies have 
demonstrated significant variation among individual adiposity compartments that is not 
predicted by total body fat or standard anthropomorphic characteristics; such as skin-fold 
measurements, BMI, and waist-to-hip ratio (WHR) (Thomas et al., 1998, Machann et al., 
2005, Goldstone et al., 2002) . 
MRI offers high physiochemical information and high anatomical resolution. Its use is critical 
in localisation of tissue of interest  and monitoring the changes caused by a treatment such 
as a drug or dieting (Nick Van Bruggen, 2003). Use of contrast agents in MRI increases the 
contrast between the tissue of interest and the surrounding, giving more physiological or 
functional data. The most commonly used contrast agents used includes manganese, 
gadolinium and iron. 
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1.6.2.6.1 Basic Principles of MRI 
MRI is based on the theory that every spinning charged particle creates an electromagnetic 
(EM) field. The main particle used is the hydrogen nucleus which is a positively charged 
proton and has a tiny magnetism (spin). Normally the magnetic fields of the hydrogen nuclei 
are arranged randomly and cancel each other out. When an external magnetic field (B0) is 
applied, they are arranged in two orientations because the hydrogen atom has two energy 
states. Some spins arrange themselves parallel to the applied magnetic field and create a 
magnetic field in the same direction to that. Some protons spin antiparallel to the applied 
magnetic field and create a magnetic field in the opposite direction. When there are an odd 
number of protons a net magnetic field (longitudinal magnetization, M0) is produced. 
Applying a radio-frequency (RF) signal (B1) at the Larmor frequency forces some of the 
spins to change their alignment and as a result a transverse magnetization (MXY) is 
produced. B0 is referred to as the field strength of the magnet, measured in Tesla (T). Higher 
B0 results in more protons aligning themselves with the field, which improves the signal to 
noise ratio (SNR). An enhanced SNR offers either higher spatial or temporal resolution by 
decreasing imaging time without sacrificing image quality. (McRobbie Donald W., 2005) 
After the RF pulse, spins go back to their original alignment emitting EM radiation at Larmor 
frequency. This signal then can be measured by a receiver coil. The time it takes for the 
magnetization to recover in the longitudinal (MZ) plane is called the T1 relaxation time. This is 
due to spins losing their energy by interactions with the surroundings. As the longitudinal 
magnetization recovers, the transverse magnetization decays. The time it takes for the 
transverse magnetization to decay is termed T2 decay. It is shorter than T1 and occurs due to 
the interactions between spins (figure 1.13). Decay of MXY is also affected field 
inhomogenities. The decay time becomes faster than T2 and is called T2
*  (McRobbie Donald 
W., 2005). 
 
58 
 
 
Figure 1.13. Longitudinal and transverse magnetizations. 
Longitudinal magnetization (M0) is formed when magnetic spins align themselves with 
external magnetic field (B0), shown on (a). When an RF signal (B1) is applied to (a), M0 is 
transferred to the xy plane, producing, transverse magnetization (MXY), shown on (c). When 
RF signal is turned off, M0 starts to recover and the time that takes for it to recover is T1 
relaxation time, (b). At the same time MXY starts to decay, called the T2 decay, (d). Modified 
from Hornak, J. P. (Hornak et al., 1996). 
 
 
The rate of T1 recovery and T2 decay varies with the local chemical and physical nature of 
the specimen and as such, can be exploited to give contrast to the image. The dissipation of 
energy in the form of T1 recovery and T2 decay within each voxel is recorded by the RF coil. 
The signal received is in the form of free induction decay (FID) is called echo. Without slice 
selection and spatial encoding, this signal would be from the whole subject. By using 
gradients signal from each specific voxel is obtained. The gradient applied in z direction (Gz) 
is used for slice selection in axial slices. The bandwidth of the RF pulse is increased or 
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decreased to adjust the slice thickness together with the slope of the gradient. To select a 
slice a gradient is applied in z direction at the same time as an RF pulse with the same 
frequency as the slice. Therefore only that slice is excited transmitting back the FID signal. 
Gradients applied in x and y direction (Gx and Gy) are used for spatial encoding. Gx which is 
usually applied during echo time is for frequency encoding. 'This gradient results in nuclear 
spins within a voxel resonating at a particular Larmor frequency, which depends on its 
location along the gradient. Gy is the phase encoding gradient, which is applied between the 
excitation and readout pulses, and generates a net phase angle on spins within a voxel, the 
magnitude of which is dependent on its location along the gradient. The FID signal from 
each voxel is stored, and an MR image is generated based on frequency and phase 
information, via complex Fourier transformation. (Hashemi Ray H., 2004, McRobbie Donald 
W., 2005)  
The available contrast in the MRI signal is not limited to endogenous differences within the 
sample; specialised agents can be used to change the relaxation times in specific regions so 
that they appear brighter or darker depending on where they accumulate. These contrast 
agents can be paramagnetic, ferromagnetic or superparamagnetic. When in tissue they 
cause the magnetic field experienced by the tissue to change which leads to a change in 
relaxation time and signal received from the tissue. Gadolinium, manganese and iron are 
examples of paramagnetic contrast agents which mainly affect T1 contrast. Iron oxide is an 
example of a superparamagnetic contrast agent which mainly affects T2 and T2
*.(Modo et al., 
2005) 
As T1 varies with local chemical and physical nature, each organ has different T1 values. 
Calculating T1 values is useful for characterising tissues; such as tumour from normal tissue, 
adjusting the contrast; allows exciting or suppressing specific tissue and detecting presence 
and concentration of contrast agents (Kaldoudi and Williams, 1993). Most commonly and 
accurate methods used to measure T1 are saturation recovery and inversion recovery 
methods. Both methods uses the spin echo sequence which uses a 900 RF pulse to flip M0 
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to the xy plane and then 1800  pulse to refocus the signal (figure 1.14). With the saturation 
recovery method, images are obtained with varying the recovery time (TR), which is the time 
allowed for the longitudinal magnetization to recover and keeping TE (echo time) constant. 
As long as TR>>TE, T2 effects can be neglected and equation 1.1 can then be used to 
calculate T1, where S is signal intensity.(Kaldoudi and Williams, 1993, Hornak et al., 1996) 
                                                     𝑺 = 𝑴𝟎 × 𝒆
(−𝑻𝑬 𝑻𝟐 ) ×  𝟏 − 𝒆 −𝑻𝑹 𝑻𝟏                                            (eqn. 1.1) 
 
 
Figure 1.14. Spin echo sequence. 
A simplified representation of spin echo sequence is shown in the figure. A 900 RF pulse is 
applied on M0, which flips the magnetization into the transverse plane (MXY). An 180
0 pulse is 
then used to refocus the spins that start dephasing. When most of the spins are in phase at 
time TE, the signal is obtained from the tissue. (Hornak et al., 1996). 
 
For the inversion recovery method of obtaining T1, an 180
0 RF pulse (inversion pulse) is 
used before the 900 pulse, inverts M0 in –z direction. In this case Mz starts to recover after 
the 900 pulse from the –M0 instead of zero, shown in figure 1.15. Images are obtained with 
varying inversion time (which is the time between inversion and 900 pulses). Again assuming 
zero T2 effects, T1 can be calculated from equation 1.2. 
                                         𝑺 = 𝑴𝟎 × 𝒆
(−𝑻𝑬 𝑻𝟐 ) ×  𝟏 − 𝟐 × 𝒆 −𝑻𝑰 𝑻𝟏  + 𝒆−𝑻𝑹 𝑻𝟏                            (eqn. 1.2) 
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Figure 1.15. Relaxation curves for longitudinal magnetization after 1800 inversion 
pulse. 
Shows the recovery curve for two different tissues, with short and long T1. The dotted lines 
represent the negative part of the magnetization. Absolute value is taken and the graphs 
above the 0 line are more commonly used. A and B represents two points a scan that can be 
carried out at. At A, the signal from short T1 tissue is lower, whereas the signal from long T1 
tissue is higher. At time B, this contrast is reversed. From Kaldoudi et al. 
 
 
1.6.2.6.2 Body Composition 
It has been shown that MRI provides similar results when compared with chemical analysis 
in assessing adipose tissue concentrations (Ross et al., 1991, Fowler et al., 1992). 
Furthermore, MRI showed less than 0.1% difference in adipose tissue level measurement 
compared with determination via dissection in an experiment carried out on human cadavers 
with a reproducibility above 90% (Abate et al., 1994). Currently, the most accurate method of 
measuring total fat content is to perform a whole body MRI scan; certain MRI protocols that 
use only one abdominal slice to estimate total body fat have been shown to provide an 
inaccurate representation of total body fat (Thomas et al., 1998).  
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In most of the studies a fast T1-weighted spin echo sequence is used for imaging (Ross et 
al., 1993, Liou et al., 2006, Thomas et al., 1998, Gronemeyer et al., 2000, Jack et al., 1991, 
Abate et al., 1994, Tang et al., 2000) where a 90° pulse is followed by a 180° degree pulse 
and data acquisition. After the acquisition of images different automated or semi-automated 
segmentation methods are applied to differentiate fat from other tissues. After that whole fat 
tissue is segmented to internal and subcutaneous fat.    
 
1.6.2.6.3 MRS 
Whereas MRI gives information about the structure of the body (i.e. the distribution of water 
and fat), MRS provides biochemical information. MRS detects signals from different 
chemical nuclei within the body based upon their aforementioned Larmour frequencies. Even 
compounds which have the same atoms have slightly different Larmor frequencies. The 
reason for this is electron cloud (shielding) formed by the interactions between electrons 
around the nucleus. When atoms are placed in a magnetic field, negatively charged 
electrons also start to spin and produce small magnetic fields which add to or subtract from 
the applied magnetic field. Therefore the nucleus starts to precess at this slightly different 
magnetic field. This chemical shift phenomenon which causes image artefact in MRI forms 
the basis of MRS. (Mukherji, 1998) 
MRS has been performed using different nuclei such as 1H, 31P and 13C and has many 
applications from brain function to tumour activity. 1H MRS is used to study fat metabolism. It 
can be used to assess the whole body, liver and muscle fat contents (Mario and Raj, 1996, 
Szczepaniak et al., 1999, Ostberg et al., 2005).  
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1.6.2.6.4 Gadolinium Contrast Agent  
Gadolinium (Gd) is one of the most used contrast agents in MRI. Its unpaired six electrons 
make it paramagnetic, shortening proton T1 and therefore increasing the signal intensity. 
Because Gd is toxic, it is chelated to make its use safe. When chelated the lethal dose of Gd 
increases by 100 times. (Makowski et al., 2009) Gadolinium contrast agents have many 
applications including tumour imaging (Swanson et al., 2008, Kamaly et al., 2007) and 
neuroimaging (Shinohara et al., 2011, Poduslo et al., 2004).  
 
1.6.2.6.5 Manganese Enhanced MRI and Brain activity 
Manganese-enhanced MRI (MEMRI) is increasingly being used for functional MRI in animals 
due to the unique T1 contrast generated by the paramagnetic analogue Mn
2+. Mn2+ ions 
cause a shortening of the proton T1 signal, yielding an increased signal intensity (SI) in T1-
weighted MRI scans (Kuo et al., 2005, Lin and Koretsky, 1997). This change in the 
longitudinal relaxation rate is proportional to the concentration of manganese ions and as 
such contrast enhancement in specific tissues can yield a quantitative measure of the 
transport and accumulation of Mn2+. In addition to the increase in T1-contrast, another key 
property of the divalent manganese ion is its ability to mimic Ca2+ ions. Mn2+ ions can 
permeate presynaptic voltage-gated calcium channels (VGCC) and induce neurotransmitter 
release from depolarised nerve terminals (Narita et al., 1990, Nicholls, 2001). Therefore, 
Mn2+ ions can either substitute for Ca2+ ions in the exocytotic process, or induce the release 
of Ca2+ from intracellular stores. Our laboratory has previously demonstrated changes in SI 
by MEMRI, as a surrogate for neuronal activity in specific hypothalamic nuclei following both 
anorexigenic and orexigenic gut peptide administration (Kuo et al., 2007) and imaging non 
brain organs (Lee et al., 2010). 
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1.7 Liposomes 
Liposomes were first visualized by Bangdam in the 1960s by electron microscopy,  who 
observed that lamellar channels in lecithin were widened by the addition of charged 
molecules. Furthermore the lipid spherules while forming were trapping the ionic solution 
from the aqueous solution in which they were dissolved in (Bangham et al., 1965, Bangham 
and Horne, 1964). Liposomes can be formed by various lipid molecules. When in an 
aqueous environment, a lipid bilayer will be formed similar to a membrane. The stability and 
biodistribution of liposomes depends on properties such as surface charge, surface 
hydration and size of liposomes which can all be determined by use of different 
combinations of lipids and the preparation processes.  
The surface charge can be adjusted to be neutral, positive or negative. Neutral liposomes 
have a lower tendency to be picked up by the mononuclear phagocyte system but they tend 
to aggregate. Negative liposomes are the solution for aggregation and can be adjusted to 
not be taken up by the macrophages but they do not have specific cellular uptake and are 
taken up by most cells. Positive liposomes are also taken up by the mononuclear phagocyte 
system and washed out (Miller et al., 1998, Gabizon and Papahadjopoulos, 1988). 
The surface hydration of liposomes can also be adjusted to reduce aggregation and uptake 
by macrophages. Hydrophilic polymers such as Polyethyleneglycol (PEG) are coupled with 
lipids. Addition of PEG to the lipid membrane increases the hydration of the liposomes which 
makes them unrecognizable to the macrophages. (Levchenko et al., 2002, Dadashzadeh et 
al., 2008). Figure 1.16 shows a schematic representation of liposomes with and without 
PEG. 
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Figure 1.16. Schematic representation of liposomes. 
(a) represents a liposome formed by lipid bilayers. Lipids have a hydrophilic head (in yellow) 
and a hydrophobic tail (in black). When put in liquids these lipids form different molecules 
including liposomes. (b) shows a liposome which is has PEG lipids in its formation. PEG 
makes liposomes unrecognizable to macrophages. (Mulder et al., 2006) 
 
 
The size of the liposomes affects their distribution and clearance. Larger liposomes are 
taken up more by the phagocytes. The size of the liposomes is usually 50-100µm. (Lian and 
Ho, 2001) 
Another important feature of liposomes is the transition temperature (temperature at which 
liposomes pass from gel form to fluid form). At this temperature, they are very leaky. 
Cholesterol can be used (>30% mol) to overcome this problem by decreasing the leakage 
and increasing the value for cut off temperature. (Keller et al., 2003, Lian and Ho, 2001) 
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1.8 Hypothesis and Aims of Thesis 
The hypotheses are: 
1. Supplementation of acetate by the use of a novel nanoparticle technology delivery 
system has positive effects on obesity and lipid metabolism in the liver, similar to 
those observed with dietary supplementation of high on fermentable carbohydrates. 
The aims of this thesis are: 
1. To investigate the effects of carbohydrate supplementation (inulin and isomaltulose) 
on adiposity and hypothalamic activation.  
2. To investigate the biodistribution of acetate in a murine model under different 
physiological conditions. 
3. To investigate the metabolism of acetate under colonic administration.  
4. To develop and apply the use of nanotechnology based delivery system to efficiently 
deliver SCFAs in vivo. 
5. To assess the effectiveness of the system and to investigate the effects of SCFAs in 
normal and obesity murine models. 
67 
 
CHAPTER 2. CARBOHYDRATE FEEDING STUDY 
2.1 Inulin and Isomaltulose Study 
Previous studies have shown that animals on diets rich on fermentable carbohydrate have 
reduced body weight, adiposity and plasma insulin and glucose concentrations. In the first 
instance some of these studies would be reproduced, then the results would be used to 
assess the similarity/differences which may arise from the use of the nanotechnology 
delivery system that was being developed. The absorbable disaccharide isomaltulose has 
been show by other groups to effect body weight and body composition.  This offers the 
opportunity to use this compound as a positive control. The hypothesis was that 
supplementation of the fermentable carbohydrate inulin and the low GI carbohydrate 
isomaltulose would reduce adiposity and modulate appetite by different mechanisms, and 
that the former would take place through the increase in SCFAs in colon and in circulation. 
 
2.1.1 Methods 
The timeline of the experiment is summarized in Figure 2.1. At week 1, each cage was 
randomly assigned one of six diets (Table 2.1). During 8 subsequent weeks of feeding, food 
intake and body weights were measured weekly. During week 8, adiposity scans on a 4.7T 
MRI scanner were carried out and a week after that MEMRI of the brains were performed on 
the 9.4T MRI scanner. 
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Figure 2.1. Timeline of Isomaltulose feeding study. 
Animals were caged 4 mice per cage and acclimatized for a week. At week 1, each cage 
was assigned to a diet group randomly. During 8 week of feeding period, food intake and 
body weights were measured 3 times a week. During the 8th week, adiposity scans on 4.7T 
MRI scanner were carried out and a week after that MEMRI of the brains were done on the 
9.4T MRI scanner. 
 
 
2.1.1.1 Animals  
The experiment was carried out in compliance with the Animals (Scientific Procedure) Act 
1986. 8-10 weeks old C57BL/6 male mice (Harlan, UK) were used for this experiment. The 
animals were caged 4 mice per cage and acclimatized for a week before they were started 
on diet. Mice were assigned to 6 different groups and each group had 8 mice. 
 
2.1.1.2 Diets 
There were 6 different diet groups which all contained 21% fat. All diets were isocaloric 
(4.5kcal/g) except for the inulin diet (4.3kcal/g). The main constituents of the diets are 
summarized in Table 2.1. The Control group was a normal high fat diet which did not contain 
any inulin (IN) or isomaltulose (IM). The other four groups were isomaltulose diets with 
different concentrations of isomaltulose, sucrose and maltodextrin. Because the diets were 
isocaloric the change in isomaltulose was compensated by a change either in sucrose or 
maltodextrin contents. Table 2.2 shows the nutritional breakdown of protein, carbohydrate 
and fat for each diet. Commercial mineral and vitamin mixes were used in all diets which 
were AIN-76 (170915) and Tekland (40060), respectively. 
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Ingredient Control 
(%) 
IN 
(%) 
IM7.5_LS(12.5) 
(%) 
IM20_NS(0) 
(%) 
IM7.5_HS(20) 
(%) 
IM20_HS(20) 
(%) 
raw corn starch 10 2.5 10 10 10 10 
sucrose 20 20 12.5 0 20 20 
maltodextrin 20 20 20 20 12.5 0 
Palatinose
TM
 - - 7.5 20 7.5 20 
Inulin - 7.5 - - - - 
 
Table 2.1. Changes in ingredient percentages of different groups. 
The table shows the main differences in the ingredients of the diets. All diets were high fat 
(21%) and isocaloric. The Control group was a normal high fat diet without any isomaltulose 
or inulin in it. IN was the only diet containing inulin. Palatinose™ is a commercial form of 
isomaltulose. The other four groups were isomaltulose diets with different concentrations of 
isomaltulose, sucrose and maltodextrin. Each diet had the same energy density of 4.5kcal/g 
except for the IN diet which had 4.3kcal/g. 
 
 
 
Nutrient 
Control 
(% 
kcal) 
IN 
(% kcal) 
IM7.5_LS(12.5) 
(% kcal) 
IM20_NS(0) 
(% kcal) 
IM7.5_HS(20) 
(% kcal) 
IM20_HS(20) 
(% kcal) 
Protein 14.8 15.4 14.8 14.9 14.8 14.8 
Carbohydrate 43.1 40.6 43 42.6 43.1 43.1 
Fat 42.1 44 42.2 42.5 42.1 42.1 
 
Table 2.2. Nutrient information of diets used.  
Table shows caloric percentage (% kcal) of protein, carbohydrate and fat for each diet. Fat 
used in this study was anhydrous milk fat. 
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2.1.1.3 Whole Body MRI and 1H MRS and Localised 1H MRS of Liver and Muscle 
In order to determine the effects of IN and IM on body adiposity animals underwent whole 
body MRI, whole body 1H MRS and localized liver and muscle 1H MRS scans. Prior to 
scanning animals were fasted overnight. On the day of the scan anaesthesia was induced 
using a 4-3% isoflurane-oxygen mix and maintained at 1.75-2%. Animals were then placed 
into a whole body birdcage coil, and scanned in a 4.7T Unity Inova MR scanner (Varian Inc, 
USA). The animal setup is shown figure 2.2. Respiration and body temperature were 
monitored during the scan, using a breathing pad and a rectal probe respectively.  
 
Figure 2.2. 4.7T body scan animal setup. 
Animals were placed on a bed and kept anaesthetised during the scan using a face mask 
with a 2-2% isoflourine-oxygen mix. Breathing was monitored with a breathing pad fixed 
around the chest. A rectal probe was used to maintain the body temperature at 370C. 
Animals were placed in the RF coil. 
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A T1-weighted spin echo (SE) sequence was used to acquire the whole body images of the 
mice with parameters: repetition time (TR) 2.2s, echo time (TE) 20ms, field of view (FOV) 
45mm x 45mm, matrix size 256 x 192, 2 averages, slice thickness 2mm and 50 slices in 
axial orientation. The images acquired were then converted to a readable format by Image J 
(Rasband) to be used in SliceOmatic™ Version 4.2 (Tomovision®), the program used for 
image segmentation (figure 2.3).  
From the segmented volume, the mass of AT was calculated using the equation 2.1. 
                                                      AT mass (g)= AT volume (𝑚𝑚3) × 0.92                                (eqn. 2.1) 
where 0.92 (g/mm3) is the density of AT. 
 
 
Figure 2.3. Image segmentation. 
An example slice of T1 weighted SE image is shown in (a). (b) shows the same image 
segmented into internal (in red) and subcutaneous fat (in green). 
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Whole body 1H MRS was carried out by using the SPULS sequence with the following 
parameters: TR 10 s, Pulse angle 45°, 4 averages and spectral width (SW) 20,000 Hz. 
Localized 1H MRS of liver and muscle was also performed using PRESS sequence by 
placing a 2x2x2 mm3 voxel on the slice containing either the liver or the leg muscle of the 
mouse with parameters: TR 10s, TE 9ms, 64 averages and SW 2800 Hz. The images 
obtained from whole body MRI were used to position the voxels on liver and muscle. Figure 
2.4 shows the images of liver (a) and muscle (b). 
 
 
Figure 2.4. Voxel localization of liver and muscle. 
(a) shows a slice through the liver and the 2x2x2 mm3 voxel used to perform the MRS on. (b) 
Shows a slice through the legs of the mouse. The voxel is placed on the right leg muscle of 
the mouse. Attention was paid to place the voxels around the same locations each time. 
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Spectra were analysed using MestRe-C (Santiago de Compostela, SPAIN). 1.5Hz of 
exponential line broadening, followed by phase and baseline correction were applied. The 
water peak was referenced at 4.7 ppm and the integral of water and lipid peak (about 1.3 
ppm) was taken. The integral value of the lipid peak represents the lipid as a percentage of 
the water peak. Figure 2.5 represents an analysed spectrum. 
The percentage of adiposity was calculated using eqn. 2.2 and the integrals of the water and 
lipid the peaks from the spectroscopy data (Mystkowski et al., 2000a). 
                                 % adiposity=
100×lipid integral
lipid integral+water integral+0.38 water integral
          (eqn. 2.2) 
 
 
Figure 2.5. Whole body spectrum of a mouse. 
The figure shows a whole body spectrum of a mouse obtained using the MestRe-C software. 
The water peak is at 4.7ppm and the lipid peak is at 1.3ppm. The integrals of the water and 
lipid peaks are also shown. Lipid content is 43% of the water content for this mouse. The 
percent whole body adiposity for this mouse is 23.76% obtained by substituting 0.43 into 
eqn. 2.2. 
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2.1.1.4 MEMRI 
 On the 9th week of feeding, animals underwent MEMRI scanning in order to assess the 
effects of different diets on neuronal activity in appetite regulating centres of the 
hypothalamus. Mice were anesthetised at 2-2% isoflurane-oxygen mix and the tail vein was 
cannulated using a 27G butterfly cannula and connected by a tube line to a syringe 
containing 100mM manganese chloride solution. The head was placed into a quadrature 
birdcage coil and scanned using a 9.4T Unity Inova MR scanner (Varian Inc, USA). During 
the scan, the animal breathing rate and body temperature was monitored, and the 
temperature was maintained at 370C.  Oxygen was maintained at 2% and isoflurane was 
arranged according to the breathing rate of the animal, always keeping it below 1. Animal set 
up is shown in figure 2.6. 
 
 
Figure 2.6. Animal setup for 9.4T MEMRI scans. 
During the 9.4T scan animals were kept anaesthetized by a face mask at 1-2% isofluorane-
oxygen mix. A respiration pad was used to monitor breathing. Temperature was monitored 
by a rectal probe and maintained at 370C. For manganese infusion, the tail vein was 
cannulated by a butterfly cannula. The head of the animal was placed in the RF coil. 
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A two dimensional (2D) fast SE multi-slice sequence was used to acquire transverse slices 
of the brain, in an array of 66 repetitions, with parameters: TR 1.8s, TE 10ms, FOV 25 x 25 
mm2, matrix size 192x192, 1 average, slice thickness 0.4mm, 46 slices per array and 1s time 
gap between acquisitions. At the end of the third acquisition, MnCl2 infusion was started 
using an infusion pump (Harvard Apparatus) at a rate of 9.34µl per g of lean body mass per 
hour and dose of 0.58mmol/g of lean body mass (volume of 5.83µl/g of lean body mass). 
Lean body mass was calculated using the integral of the lipid peak from the whole body 
MRS by using equations 2.2 (Mystkowski et al., 2000a) in section 2.1.1.3 and 2.3. 
                                           lean mass= 100-% adiposity ×0.01×body weight                        (eqn. 2.3) 
 
Motion correction was applied to acquired images using SPM5 (The FIL Methods Group, 
2005) and registered to a brain atlas (Dorr et al., 2008) by using tools from AFNI (Medical 
College of Wisconsin) and FSL (FMRIB, UK). Both individual Mn+2 uptake analysis for each 
mouse and group analysis were performed using the FEAT tool of FSL with thresholds z>2.3 
and p<0.05 which provided images showing the neuronal activation for individual mice and 
the difference in neuronal activation between groups. 
In addition, signal intensities (SI) within individual hypothalamic nuclei, ARC, VMH and PVN, 
were measured for the array of 66 acquisitions. SI was baseline corrected by using the first 3 
images and normalised to the anterior pituitary gland (AP). The AP lies outside the blood 
brain barrier and therefore acts as a suitable control for the different rates at which MnCl2 
arrives at the brain. SI in the 4th ventricle was used to check if the Mn+2 had successfully 
entered the brain and to see circulation differences between animals. The hypothalamic 
centres together with AP and the 4th ventricle are shown on Figure 2.7. 
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Figure 2.7. Brain slices acquired through MEMRI showing various hypothalamic 
nuclei. 
(a), (b), (c) and (d) are various slices through the mouse brain obtained with MEMRI. (i) is 
part of image (a) enlarged showing the approximate location of PVN. (ii) is part of image (b) 
enlarged showing the approximate locations of ARC and VMH. (iii) is part of image (c) 
enlarged showing the approximate location of AP.  (iv) is part of image (d) enlarged showing 
approximate location of 4th ventricle.  
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2.1.1.5 Statistical Analysis 
All data are presented as mean +/- standard error of mean (SEM). One-way ANOVA with the 
Tukey‟s correction using GraphPad Prism (GraphPad Software, USA) was performed where 
applicable on food intake, body weight and adiposity data. Where one-way ANOVA was not 
applicable either Kruskal-Wallis test with the Dunnett‟s correction using GraphPad Prism or 
Kendall‟s test using SPSS 16 (SPSS Inc., Chicago) were performed. 
Generalized estimating equations (GEE) and t tests were used to evaluate SI differences in 
hypothalamic appetite centres between different groups using Stata10 (StataCorp Lp, USA). 
GEE was also used to analyse the cumulative weight gain over the 8 weeks feeding period. 
In all cases, values of p<0.05 were considered statistically significant. 
GEE was first developed in 1986 by Liang and Zeger. It is used to analyze longitudinal data. 
Simple models are used for within subject correlation and a working correlation matrix is 
used to explain these correlations, giving GEE. It uses regression analysis and the equations 
that are employed are an extension of quasi-likelihood methods. As quasi-likelihood 
methods does not require the distribution of the result to be provided, GEE is applicable for a 
wide range of longitudinal data (Zeger and Liang, 1986).  
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2.1.2 Results 
2.1.2.1 Food Intake and Body Weight 
No significant differences in food intake were observed between the control and IN group 
(12.33±0.15 and 11.56±0.18g/day/cage respectively). Animals in the IM7.5_LS(12.5) group 
had the lowest daily food intake (10.91±0.13g/day/cage) followed by IM20_NS(0) 
(11.72±0.38g/day/cage) (figure 2.8). 
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Figure 2.8. Average daily food intake per cage. 
Daily food intake per cage (per 4 mice) averaged over 8 week feeding period is shown on 
the graph. The data are represented as mean±SEM. N=12/group. The significant differences 
are shown on the graph; ***: p<0.001 and *: p<0.05. Data were analysed by Kruskal-Wallis 
analysis. 
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There was no significant difference in overall weight gain between control and inulin diet (IN) 
animals, although animals on inulin diet showed reduced weight gain from day 20 to 45 
compared with those on the control diet. 1-way ANOVA analysis revealed a significant 
difference between IM7.5_LS(12.5) and IM7.5_HS(20) (9.75±0.37g, p<0.05) and 
IM20_HS(20) (10.04±0.76g, p<0.05) but none of the groups showed significant difference 
compared with the control group, see figure 2.9.  
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Figure 2.9. The effect of dietary supplementation with Isomaltulose on overall weight 
gain over the 8 week feeding period.  
Average overall weight gain of animals at the end of the 8 week feeding period is shown. 
The data is shown as mean±SEM. Significant differences are shown on the graph. *: p<0.05, 
ns: p>0.05, n= 12/group. 
 
 
The cumulative weight gain graph following 8 weeks of dietary supplementation is shown in 
Figure 2.10. Again, no significant differences were observed between control and the groups 
on supplements.  
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Figure 2.10. Cumulative weight gain over time. 
Average weight gain of animals over the 8 week feeding period is shown in the figure. Each 
graph shows a comparison of the control diet with the different diets used in this study. Refer 
to Table 2.1 for diet ingredients. The data shown as mean±SEM, n=12/group. 
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Comparisons of IN versus IM7.5_HS(20) and IM20_HS(20) showed significant 
difference, where IN was significantly lower than both with p values 0.0033 and 
0.0039, respectively.  IM7.5_LS(12.5) was also significantly lower than IM7.5_HS(20) 
and IM20_HS(20) with p values 0.0096 and 0.0056, respectively (see Figure 2.11).
0 10 20 30 40 50 60
-1
0
1
2
3
4
5
6
7
8
9
10
11
IM7.5_HS(20)
IM20_HS(20)** **
IN
Time (days)
W
e
ig
h
t 
G
a
in
 (
g
)
0 10 20 30 40 50 60
-1
0
1
2
3
4
5
6
7
8
9
10
11
IM7.5_LS(12.5)
IM7.5_HS(20)
IM20_HS(20)
** **
Time (days)
W
e
ig
h
t 
G
a
in
 (
g
)
a b
n=12/group
 
Figure 2.11. Significant differences in cumulative weight gain over time. 
Average weight gains of animals over the 8 week feeding period which have significant 
difference are shown. GEE analysis showed that IN was significantly different from 
IM7.5_HS(20) and IM20_HS(20) (a) and that IM7.5_LS(12.5) was significantly different from 
IM7.5_HS(20) and IM20_HS(20) (b). n=12/group, **: p<0.01. 
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2.1.2.2 Whole Body, Localized Liver and Muscle 1H MRS 
1-way ANOVA analysis showed no significant reduction in the fasted body weights and 
whole body adiposity between IN and Control group, although a significant difference was 
observed between IM7.5_LS(12.5) and IM7.5_HS(20) groups, (p <0.05, Figure 2.12 (a)) 
where IM7.5_LS(12.5) was lower. Whole body adiposity was the lowest for group 
IM7.5_LS(12.5) (12.58±1.76%) and was significantly different from IM20_NS(0) 
(23.20±1.80%, p< 0.01) and IM20_HS(20) (22.64±2.70, p< 0.01) (Figure 2.12 (b)).  
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Figure 2.12. Fasted body weight and whole body adiposity. 
For adiposity scans, animals were fasted overnight. (a) shows fasted body weights of all 
groups before adiposity scans. The percentage of whole body adiposities were obtained by 
substituting the results of MRS analysis into equation 2.2. The data shown as mean±SEM. 
Statistical analysis carried out by 1-way Anova. Significant differences are displayed on the 
graphs. *: p<0.05 and **: p<0.01, ns: p>0.05, n= 11/12 per group. 
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Figure 2.13 (a) and (b) shows the lipid content of liver and muscle, respectively. There was 
no significant differences in liver fat between Control (8.46±1.32%), and IM7.5_LS(12.5) 
(5.59±0.66%), IN (10.09±1.13%) and IM20_HS(20) (13.86±2.87%) mice. Liver lipid content 
of IM7.5_LS(12.5) group (5.59±0.66%) was significantly lower than IM20_NS(0) 
(13.43±1.76%, p< 0.01) and IM7.5_HS(20) (10.58±1.10%, p< 0.05).  
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Figure 2.13. Lipid content of liver and muscle. 
Lipid concentrations in liver (a) and muscle (b) obtained by MRS are shown. The data are 
displayed as mean±SEM. Statistical analysis was performed by Kendall‟s test; *: p<0.05, **: 
p<0.01, ns: p>0.05, n=11/12 per group.  
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2.1.2.3 Whole Body Fat Distribution 
No differences in body fat distribution were observed between control and supplemented 
groups. IM7.5_LS(12.5) group had the lowest internal (2.00±0.21g), subcutaneous 
(3.12±0.22g) and total (5.16±0.42g) adipose tissue content but this did not reach 
significance. Again, a significant difference was observed between the subcutaneous 
adipose tissue content of IM7.5_LS(12.5) and IM20_HS(20) (4.14±0.30g) where 
IM7.5_LS(12.5)  was lower than IM20_HS(20) (Figure 2.14).  
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Figure 2.14. Adipose tissue content in grams and ratio of subcutaneous and internal 
fat obtained by segmentation of the whole body MRI images. 
The three graphs show the internal (a), subcutaneous (b) and total (c) AT mass of each diet 
group, obtained by segmenting the whole body images. The ratio of subcutaneous to internal 
AT is also shown (d). All data are represented as mean± SEM. Statistical analysis performed 
by 1-way ANOVA, *: p<0.05, ns: p>0.05. n=11/12/group. 
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2.1.2.4 MEMRI of Brain 
Signal intensity in the ARC, VMH, PVN and PE hypothalamic nuclei was analysed by GEE 
analysis for Control (n=9), IN (n=9), IM7.5_LS(12.5) (n=6) IM20_NS(0) (n=7), IM7.5_HS(20) 
(n=9) and IM20_HS(20) (n=5). Figure 2.15 shows normalized percentage enhancement 
measurements in the ARC through the 66 acquisitions for all diet groups. 
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Figure 2.15. Normalized percentage enhancement in the ARC for all diet groups. 
Each graph shows the normalized percentage enhancement for an isomaltulose diet 
together with the control and inulin diets in the ARC. The arrows show the acquisition at 
which the manganese infusion was started and the bars show the duration of the infusion. 
The data for control (n=9), IN (n=9), IM7.5_LS(12.5) (n=6), IM20_HS(20) (n=5), IM20_NS(0) 
(n=7) and IM7.5_HS(20) (n=9) are shown as mean±SEM.  
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Figure 2.16 shows the groups with significant difference. SI of Control was significantly 
higher than IN (p=0.0044) (2.16.a), IM7.5_LS(12.5) (p=0.0071) (2.16.b) and IM20_HS(20) 
(p=0.0017) (2.16.c) and IM7.5_HS(20) was significantly higher than IM20_HS(20) (0.00273) 
(2.16.d). The control was also marginally different from IM7.5_HS(20) (p=0.0522) (individual 
graph not shown). 
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Figure 2.16. Normalized percentage enhancement in the ARC for groups with 
significant differences. 
Each graph shows the normalized percentage enhancement of ARC of significantly different 
groups. The arrows show at which acquisition the manganese infusion started and the bars 
show the duration of the infusion. (a) shows Control (n=9) and IN (n=9), (b) shows Control 
(n=9) and IM7.5_LS(12.5) (n=6), (c) shows Control (n=9) and IM20_HS(20) (n=5)  and (d) 
shows IM7.5_HS(20) (n=9) and IM20_HS(20). All data are shown as mean±SEM. GEE 
analysis was used for statistical analysis; *: p<0.05, **: p<0.01.  
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Figure 2.17 shows normalized percentage enhancement measurements in the VMH through 
the 66 acquisitions for all diet groups. 
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Figure 2.17. Normalized percentage enhancement measurement in VMH for all diet 
groups. 
Each graph shows the normalized percentage enhancement for an isomaltulose diet 
together with control (n=9) and inulin (IN, n=9) diets in VMH. The arrows show the 
acquisition at which the manganese infusion was started and the bars show the duration of 
the infusion. IM7.5_LS(12.5) (n=6) is shown in (a), IM20_NS(0) (n=7) is shown in (b),  
IM7.5_HS(20) (n=9) is shown in (c) and IM20_HS(20) (n=5) is shown in (d). All data are 
shown as mean±SEM. 
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Comparison of normalized percentage enhancement measurements in the VMH (displayed 
in Figure 2.18) showed that; Control was significantly higher than IN (p=0.0293) (2.18.a), 
IM7.5_LS(12.5) (p<0.0001) (2.18.b) and IM20_HS(20) (p=0.0003) (2.18.c), IM7.5_LS(12.5) 
was significantly lower than IM20_NS(0) (p=0.0356) (2.18.d) and IM7.5_HS(20) (p=0.0204) 
(2.18.e). IM7.5_HS(20) was also marginally different from IM20_HS(20) (p=0.0569). 
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Figure 2.18. Significant differences between different diet groups in VMH. 
Each graph shows the normalized percentage enhancement of VMH of significantly different 
groups. The arrows show at which acquisition the manganese infusion has started and the 
bars show the duration of the infusion. Control (n= 9) is significantly different from IN (n= 9) 
(a) (from acquisition 42 and onward), IM7.5_LS(12.5) (n= 6) (b) (from acquisition 7 and 
onwards) and IM20_HS(20) (n= 5) (c) (from acquisition 12 and onwards). IM7.5_LS(12.5) 
was also different from IM20_NS(0) (n= 7) (d) and IM7.5_HS(20) (n= 9) (e). All data are 
shown as mean±SEM. GEE analysis was used for statistical analysis; *: p<0.05 and ***: 
p<0.001.  
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Figure 2.19 shows normalized percentage enhancement measurements in the PVN through 
the 66 acquisitions for all diet groups. 
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Figure 2.19. Normalized percentage enhancement measurement in PVN for all diet 
groups. 
Each graph shows the normalized percentage enhancement for an isomaltulose diet 
together with control (n=9) and inulin (n=9) diets in the PVN. The arrows show the 
acquisition at which the manganese infusion was started and the bars show the duration of 
the infusion. IM7.5_LS(12.5) (n=6) is shown in (a), IM20_NS(0) (n=7) is shown in (b), 
IM7.5_HS(20) (n=9) is shown in (c) and IM20_HS(20) (n=5) is shown in (d). All data are 
shown as mean±SEM. 
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Comparison between diet groups also showed differences in the percentage enhancement 
of the PVN (figure 2.20). IM7.5_LS(12.5) was significantly lower than Control (2.20.a), 
IM20_NS(0) (p=0.0462) (2.20.b) and IM7.5_HS(20) (p=0.0042) (2.20.c) and the 
enhancement in IM7.5_HS(20) was significantly higher than IM20_HS(20) (p=0.0487) 
(2.20.d). 
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Figure 2.20. Significant differences between different diet groups in PVN. 
Each graph shows the normalized percentage enhancement of PVN of significantly different 
groups. The arrows show at which acquisition the manganese infusion has started and the 
bars show the duration of the infusion. IM7.5_LS(12.5) (n= 6) was significantly different from 
Control (n= 9) (a), IM20_NS(0) (n= 7) (b) and IM7.5_HS(20) (n= 9) (c). IM7.5_HS(20) and 
IM20_HS(20) (n= 5) (d) are also significantly different. All data are shown as mean±SEM. 
GEE analysis was used for statistical analysis; *: p<0.05 and **: p<0.01.  
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2.1.3 Discussion 
In the current study inulin supplementation did not lead to changes in body composition, 
despite the significant changes in brain activity and despite 8 weeks of dietary intervention. 
Previous studies have shown that mice fed on inulin based diets show a reduced food intake 
and weight gain (Cani et al., 2005, Cani et al., 2006). Furthermore in an earlier study in our 
laboratory, inulin was shown to significantly reduce body adiposity, as well as modulate 
appetite (Anastasovska et al., 2012). It is unclear as to the mechanisms underlying this 
discrepancy, but it may be related to alterations in the composition of the inulin diet used. It 
transpired, through the course of the data analysis, that the manufacturer to maintain 
isocaloric content of the feeds had increased the corn starch content of the inulin feed. 
Addition of corn-starch is known to increase the GI of a diet, which in turn can increase 
insulin concentrations and facilitate the storage of fat (Brand-Miller et al., 2002). In a recent 
study (Isken et al., 2009), it was shown that long term feeding of animals with high fat diet 
supplemented with a soluble fibre did not reduce body weight or fat mass compared with 
same diet supplemented with an insoluble fibre. The higher production of short chain fatty 
acids might increase available energy therefore counterbalancing positive short term effects.  
It is possible that in the presence of high corn-starch the positive effects of inulin on fat 
composition of mice may be significantly dampened, even though the effects on the appetite 
centre remained unaltered. This would suggest that the effects of high GI may affect 
peripheral metabolism independent of CNS control, allowing increased fat deposition in the 
presence of decreased hypothalamic activity. Further work is required to assess the potential 
mechanism underlying this metabolic process both at CNS and peripheral level.  
This study did however show some interesting phenotypic changes. The average daily food 
intake was shown to be the lowest for IM7.5_LS(12.5) group. Food intake for IM20_HS(20) 
and Control groups was similar and higher than that of all other groups. IM20_HS(20) and 
IM7.5_HS(20) groups put on more weight than the others and IM7.5_LS(12.5) was the group 
with the lowest weight gain. Whole body and liver adiposities were the lowest for 
92 
 
IM7.5_LS(12.5) group again and IM20_NS(0) and IM20_HS(20) had the highest values. 
Total fat mass obtained from the whole body imaging were similar to spectroscopy results, 
IM7.5_LS(12.5) was the group with lowest total fat mass. Internal and subcutaneous fat 
mass of IM7.5_LS(12.5) was also the lowest. MEMRI results showed two distinct 
polarizations of the groups. Control, IM20_NS(0) and IM7.5_HS(20) had higher signal 
enhancement than IN, IM7.5_LS(12.5) and IM20_HS(20). Fasting mice have been shown to 
increase the enhancement in ARC, PVN, PE and VMH, due probably to their increased 
appetite (Kuo et al., 2006).  
 
2.1.3.1 Subgroup Reanalyzed 
To explore the potential reasons for the apparent discrepancy between brain activity and 
body compositon in the the IM20_HS(20) IN and IM7.5_LS(12.5) groups, the former showed 
similar MEMRI acitivity, but food intake and whole body adiposity were different, the data 
were re-analysed to only include in the comparison animals that had both MEMRI and boy-
MRI studies done on the same session. This would help to remove any confounders arising 
from possible contribution to the overall effect by time differences or lack of full data set, 
which happened with a number of animals, which due to technical reason did not have brain 
scans. Thus, food intake and adiposity results were reanalysed excluding all animals whose 
MEMRI scans were not performed. The number of animals in Control, IN and IM7.5_HS(20) 
groups was 9, 6 for IM7.5_LS(12.5) group, 7 for IM20_NS(0) and 5 for IM20_HS(20). 
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The average daily food intake per cage for Control animals was significantly higher than the 
IN, IM7.5_LS(12.5) and IM20_NS(0) groups. IM20_HS(20) food intake was  also significantly 
higher when compared with IN, IM7.5_LS(12.5), IM20_NS(0) and IM7.5_HS(20) groups. A 
summary of these findings is shown in Figure 2.21.  
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Figure 2.21. Average daily food intake per cage in animals used in MEMRI scans. 
Average daily food intake per 4 mice is shown. Only animals which had MEMRI scans were 
used in this analysis. The data for Control group (n=9), IN, (n=9), IM7.5_LS(12.5) (n=6), 
IM20_NS(0) (n=7), IM7.5_HS(20) and IM20_HS(20) (n=5) are shown as mean±SEM. 
Statistical analysis was performed by 1-way ANOVA and is represented on the graph; *: 
p<0.05, **: p<0.01, ***: p<0.001. 
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No significant differences in the average overall weight gain were observed between the 
Control and any of the other groups (Figure 2.22). 
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Figure 2.22. Average weight gain per mouse following 8 week feeding period in the 
animals used in MEMRI scans. 
Average of total weight gains of the animals at the end of the feeding period are shown on 
the scatter plot. Only animals which had MEMRI scans were used. N=9 for Control, IN, 
IM7.5_HS(20), n=6 for IM7.5_LS(12.5), n=7 for IM20_NS(0) and n=5 for IM20_HS(20). 
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No significant differences in adiposity (Figure 2.23) and ectopic fat (Figure 2.24) were 
observed. As can be seen in the scatter plots more clearly, the results within each group 
were varied. 
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Figure 2.23. Percentage of whole body adiposity using animals used in MEMRI scans.  
Both of the graphs show the percentage of whole body adiposity, obtained by MRS of the 
animals whose MEMRI scans were completed. The data on (a) is represented by 
mean±SEM. In (b) the same data using a scatter plot is shown. 
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Figure 2.24. Fat content of liver and muscle using animals used in MEMRI scans. 
Scatter plots of percentage of adiposities of liver (a) and muscle (b) obtained by MRS where 
only the animals whose MEMRI scans were completed are used.  
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Clearly the reduction in food intake in the IN group, compared with Control, may partly help 
to explain the drop in hypothalamic SI observed by MEMRI in the former group. However, 
the reanalysis results also showed that the IM20_HS(20) group, which although had similar 
food intake to Controls, had similar SI in the MEMRI experiment to the IN and 
IM7.5_LS(12.5) groups. Once again the reasons for this apparent discrepancy is unknown 
but clearly the interaction between food components, hypothalamic activity, and behaviour 
are highly dynamic and complex (Holsen et al., 2011), suggesting further work is required to 
understand the relationship between the effects seen by in vivo MEMRI, food components 
and phenotypic outcome. 
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2.2 Diet Preference Study 
A taste preference study was carried out to answer a number of questions arising from the 
above results. Firstly, to try to understand the possible reason as to why the inulin study did 
not manage to reproduce the previous inulin study carried out in our laboratory. Second, why 
the suppressed signal enhancement in appetite centres for the IM20_HS(20)  group was not 
accompanied by lowered food intake.   
 
2.2.1 Methods 
The taste preference of Control, IN, IM7.5_LS(12.5) and IM20_HS(20) diets from Table 2.1 
and the inulin diet from the previous study done by our group were compared. All diets were 
isocaloric. IM20_HS(20) was compared with Control and IM7.5_LS(12.5) diets, and the inulin 
diet (IN) was compared with the previously used inulin diet. The main differences in the 
constituents of the IN diet and the previously used inulin diet are shown on Table 2.3. 
Ingredient Old Inulin IN 
raw corn starch - 2.5 
sucrose ~34 20 
maltodextrin 7.5 20 
Inulin 7.5 7.5 
 
Table 2.3. Changes in ingredient percentages of different inulin diets. 
The two inulin diets used for the taste preference study were isocaloric, 21% fat and had the 
same amount of inulin in them. IN was used in the Isomaltulose feeding study to compare 
the results of isomaltulose to inulin. Old inulin was a diet that has been used at our 
laboratory in previous studies. The IN diet has 2.5% corn starch whereas the Old Inulin diet 
did not have any. IN diet had 20% of sucrose and maltodextrin, Old Inulin diet has 
approximately 34% of sucrose and 7.5% maltodextrin.  
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Adult male C57BL/6 mice were housed in IVC cages, 4 animals per cage. After an 
acclimatization period, the food hopper was divided and two separate diets were placed for 
equal availability ad libitum for five days. Food content was measured daily.  
One cage was provided with IM20_HS(20) and Control, another received IM20_HS(20) and 
IM7.5_LS(12.5) and one had IN and the inulin used in our previous study (see Table 2.4).  
 
 Cage 1 Cage 2 Cage 3 
Control X   
IN   X 
IM7.5_LS(12.5)  X  
IM20_HS(20) X X  
Old Inulin   X 
 
Table 2.4. Diets provided in each cage for the taste preference study. 
The table shows the combinations of the two diets provided in each cage. Control was the 
high fat control diet, IN (IN) was the inulin high fat diet with 7.5% inulin. IM7.5_LS(12.5) was 
the isomaltulose diet with 7.5% isomaltulose, IM20_HS(20) is the isomaltulose diet with 20% 
isomaltulose and old inulin was the inulin diet used in previous studies by our group. Mice in 
all three cages had equal access to the two diets provided. 
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2.2.2 Results 
The daily food intake per cage is shown in Figure 2.25. Mice consummed more 
IM20_HS(20) compared with the IM7.5_LS(12.5) and Control groups. Similarly, when the 
inulin-new diet used in this study (IN) was compared with the Old Inulin, animals preferred 
the former. 
 
 
Figure 2.25. Diet preference study results. 
Each graph shows the daily food intake per cage a period of for four days. Each cage was 
provided with two different diets, IM20_HS(20) and IM7.5_LS(12.5) (a), IM20_HS(20) and 
control (b) and IN and old inulin diet (an inulin supplemented high fat diet previously used by 
our group which showed significant differences in adiposity) (c).  
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2.2.3 Discussion  
The results from this study suggest a potential mechanism for why mice on IM20_HS(20) 
diet, although they had the same suppression in appetite centres similar to the  
IM7.5_LS(12.5) group  consumed higher amounts of food. This may be in part due to 
differences in the taste.  Food intake has been shown to not only be determined by 
hypothalamic activity related to hunger and satiety, but also by the reward effects of foods, 
including taste and texture (Grabenhorst et al., 2010, Mitra et al., 2011). Rewards centre in 
the brain can clearly override satiety factors leading to increase/decrease food consumption 
disassociated from hypothalamic activity (Vucetic et al., 2012).  Another potential 
explanation is that the effects observed by MEMRI in the hypothalamic area do not solely 
reflect hunger related activity and the signal may correspond to a more complex interaction 
of neuronal activity related to hunger, reward and energy homeostasis (Morton et al., 2006). 
Similarly, the lack of effect with the inulin diet may again be related to taste. This might mean 
that although there was appetite suppression by the fermentation of IN, the taste of the diet 
was so appealing that the animals continued eating. The presence of corn starch in the IN 
diet might also have increased the palatability of the feed making animals increase food 
intake well beyond their normal hypothalamic controlled concentrations. Clearly further work 
is required to determine the different control processes associated with food intake, 
preference, satiety and reward.  
  
101 
 
2.3 Conclusion 
This study failed to reproduce previously reported results with inulin supplementation, except 
for the change in hypothalamic activity. The results point to the importance of potential 
confounders, including food preference, associated with dietary manipulation in murine 
models. It can also be concluded that the best form of isomaltulose based diet is 
IM7.5_LS(12.5) where the reductions in food intake, weight gain and adiposities were 
observed together with reduced signal enhancements in the hypothalamic nuclei analysed, 
indicating a reduced appetite.  
Although IM7.5_LS(12.5) and IM7.5_HS(20) had the same amounts of isomaltulose, they 
showed almost opposite results. They differed in sucrose and maltodextrin content. If 
sucrose concentrations were compared between all groups, it can be observed that addition 
of Isomaltulose to high fat, high sucrose diet increases the body weight and whole body 
adiposity. Similarly, if isomaltulose was substituted for sucrose in a high fat diet, the same 
effect would be observed. However, if a low level of Isomaltulose is added to a high fat diet 
in addition to a low level of sucrose, both the weight gain and adiposity decreases.  
IN and IM7.5_LS(12.5) groups had lower SI in the hypothalamic centres which correlates 
with reduced food intake for both groups compared with control found in subgroup analysis. 
The reason why signal intensity is lowered in hypothalamic appetite centres for IM20_HS(20) 
remains unclear. Investigating the activation in the brainstem might be useful to see if there 
are interfering signals from the appetite centres in the brainstem that are increasing the food 
intake. 
An alternative explanation for why there was a signal intensity reduction in appetite centres 
for IM20_HS(20) fed animals but no other effects, relates to the diet preference study 
results. In this study it is clearly shown that mice had a preference for eating IM20_HS(20) 
compared with the IM7.5_LS(12.5) or control diets. When IM20_HS(20) and control diets 
were put in the same cage animals ate almost nothing from the control diet. During the 
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original feeding study the average daily intake of control and IM20_HS(20) diets were 
approximately the same. The signal suppression in appetite centres was greater in 
IM20_HS(20) fed animals than the control fed animals. This might mean that during 8 week 
feeding study the appetite of IM20_HS(20) fed animals were reduced but its highly palatable 
nature, resulted in similar intake to that of the control fed animals. During the diet preference 
study, the amount of IM7.5_LS(12.5) diet eaten decreased as the amount of IM20_HS(20) 
diet eaten increased. During the 8 week Isomaltulose feeding study, average daily food 
intake was higher for IM20_HS(20) than the IM7.5_LS(12.5). IM7.5_LS(12.5) and 
IM20_HS(20) are isocaloric and generate similar signal suppressions in appetite centres, 
however animals ate more of the IM20_HS(20) diet, suggesting the palatability of the diets 
may have been a confounding factor. Future work will examine neuronal activation in reward 
pathways in association with these animal models of dietary manipulation in order to try and 
determine the reason for this difference in food intake. Indeed, a recent MEMRI study has 
successfully examined the connectivity of ventral tegmental regions and forebrain structures 
involved in brain reward pathways (Li et al., 2009).  
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CHAPTER 3. BIODISTRIBUTION AND NOVEL DELIVERY 
SYSTEM OF ACETATE 
3.1 Introduction 
Acetate is the main SCFA produced by colonic fermentation of fermentable carbohydrates. 
After the ingestion of fermentable carbohydrates such as inulin these carbohydrates are 
passed to the colon undigested where they get digested by microbiota (Ballard, 1972). Two 
of the SCFAs produced, butyrate and propionate, get absorbed mostly in the colon whereas 
acetate gets in the blood stream and is transferred to the liver and other tissues (Wong et al., 
2006). Feeding of fermentable carbohydrates (Beylot, 2005) and acetate (Fushimi et al., 
2006, Kondo et al., 2009) has been shown to have positive effects on obesity, decreasing 
food intake and adiposity. 
 
3.1.1 Hypothesis 
My working hypothesis is that the positive effects of fermentable carbohydrates arise from 
the increased production of SCFAs in the colon and therefore increased availability of SCFA 
to the liver. To investigate this hypothesis 2 studies were performed: PET 11C-acetate study 
to investigate biodistribution, and the use of encapsulated acetate to enhance delivery and 
metabolism. 
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3.1.2 Aims and Objectives of Studies 
The aims of this chapter were: 
1. To investigate the biodistribution of acetate under different routes of administration 
and physiological conditions. 
2. To determine the concentrations of acetate reaching different organs after colonic 
administration of acetate at physiological concentrations and to determine changes in 
metabolites formed in various organs.  
3. To find an alternative and effective delivery method to deliver high dose of acetate to 
the liver.  
4. To investigate the effects of short term chronic administration of acetate on different 
markers of obesity. 
The objectives were: 
1. To investigate the biodistribution of acetate by using PET in conjunction with 11C-
acetate  
2. To investigate the metabolism by administering 13C-acetate through colon. 
3. To develop a liposomal nanoparticle that was used as a delivery method. 
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3.2 Biodistribution of Acetate 
Acetate is an example of a short chain fatty acid produced by the fermentation of resistant 
carbohydrates in the colon. Administration of acetate to rodents has been shown to reduce 
body weight and adiposity of the animals (Yamashita et al., 2007, Kondo et al., 2009). 
Despite the extensive work on SCFA, their biodistribution has not been fully assessed.  In 
this study, I have therefore used PET techniques to investigate the biodistribution of acetate 
in a murine model. I have also determined the possible effects of route of administration and 
physiological status (fed vs fasted) on its biodistribution. 
 
3.2.1 Methods 
3.2.1.1 Animals 
All animal procedures were conducted in accordance with the UK Animals (Scientific 
Procedures) Act, 1986. Adult male C57BL6 mice (Harlan, UK) were acclimatised for at least 
a week before any procedures were carried out on them. 
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3.2.1.2 Experimental Procedures 
3.2.1.2.1 The Metabolic Fate of Acetate in Fed and Fasted State 
Fasted_i.v. (n=3) group of animals were food deprived overnight but had free access to 
water. Fed_i.v. (n=4) group of animals had ad libitum access to food and water. The scans 
were carried out as described in section 3.2.1.3. 11C-acetate (~20MBq) was bolus injected 
(~10 seconds) to the tail vein at the start of the PET scan. At the end of the scan animals 
were sacrificed by a schedule 1 method. 
 
 
3.2.1.2.2 The Metabolic Fate of Acetate Following Different Route of Administration 
Animals (n=4) were food deprived overnight but had free access to water. The scans were 
carried out as described in section 3.2.1.3. Instead of tail vein administration, 11C-acetate 
(~20MBq) was bolus injected to the colon at the start of the PET scan by using a tube that 
was inserted 1cm into the rectum of the animals (infusion time ~10 seconds). At the end of 
the scan animals were sacrificed by a schedule 1 method. 
 
3.2.1.2.3 Potential “Receptor” Occupancy 
Animals (n=3) were food deprived overnight but had free access to water. The scans were 
carried out as described in section 3.2.1.3. The tail vein was cannulated. A cannula was also 
placed into the peritoneal cavity and fixed to the abdomen of the animals. After the first CT 
scan, animals were injected with sodium acetate (500mg/kg of animal body weight) 
intraperitoneally (i.p.) through the previously fitted cannula. 10 minutes after the i.p. injection, 
11C-acetate (~20MBq) was bolus injected into the tail vein and the PET scan was started. 
The animal setup is shown in figure 3.1. At the end of the scan animals were sacrificed by a 
schedule 1 method. 
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Figure 3.1. PET/CT animal setup for cold acetate study. 
Animals were placed on the bed, anaesthetisia was maintained using a mask at 1-2% 
isoflurane-oxygen mix. Breathing was monitored with a breathing pad placed on the bed. For 
the cold acetate study where animals received an i.p. unlabelled (cold) acetate before i.v. 
11C-acetate injection, the i.p. cannula was fixed to the abdomen and the tail vein was 
cannulated with a butterfly cannula both with lines coming out of the bed for later injection.  
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3.2.1.3 Scan Procedure and Parameters 
At the time of the scan, animals were anesthetized with a 2-2% isoflurane-oxygen mix. The 
tail vein was cannulated using a 27G butterfly cannula (used for 11C-acetate and/or CT 
contrast infusions). After the animals were placed in the scanner, a CT scan without contrast 
was performed, followed by the PET scan where 11C-acetate (~20MBq) was administered at 
the start of the PET scan. The PET scan was then followed by a CT scan where contrast 
was infused. Both of the CT scans lasted 10 minutes and the PET scan was about 1 hour 
long. During the scan animals were maintained at 1-2% isoflurane-oxygen mix and body 
temperature of 370C. 
A micro PET/CT (Siemens) scanner was used for this experiment. The CT had an X-ray 
source of 80kVp and 500µA with exposure time 200ms and isotropic resolution of 103µm. 
The scan consisted of 3 bed positions with a 20% overlap. When a CT contrast was 
acquired, Ultravist 370 (Bayer, AG, Germany) was administered i.v. through the tail vein to 
the animals. The CT scan was used for anatomical data and attenuation correction 
purposes. 
The PET system consisted of 64 lutetium oxyothosilicate (LSO) based detectors blocks 
arranged in 4 contiguous rings, with a crystal ring diameter of 16.1cm and an axial extent of 
12.7cm. Each detector block was composed of a 20x20 array of LSO crystals coupled to a 
position sensitive photomultiplier tube via a light guide. Each crystal was 10 mm long and 
had a cross sectional area of 1.51x 1.51mm. The crystal pitch was 1.59 mm in both axial and 
transverse directions.  
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3.2.1.4 Analysis 
Inveon Research Workplace (IRW) Version 3 which was provided by the supplier of the 
machine was used for data analysis; reconstruction of PET images, CT PET registration and 
region of interest (ROI) measurements. The data acquired from PET were list-mode data. 
This was then sorted into 3D sinograms with a span of 3 and ring difference of 79. These 
were then converted into 2D sinograms by Fourier rebinning. Images with matrix size 
12x128, pixel size 0.776mm2 and slice thickness 0.796mm were reconstructed from the 2D 
sinogram by 2D filtered backprojection using a ramp filter with a nyquist frequency of 0.5. 
Dynamic framing was used in reconstruction with 20 3s frames, 8 30s frames, 5 60s frames 
and 10 300s frames. Attenuation correction (obtained from the CT scan) was also used to 
correct the image for attenuation. 
Reconstructed PET images were then registered onto the CT images. ROIs were drawn on 
the desired organs using the CT images. PET signals on the desired ROI were obtained 
over the scan period. Using Microsoft Excel percentage injected dose (%ID/g) was 
calculated by using the following two formulas.  
 
                                                                 % ID/g = 𝐶𝑃𝐸𝑇 𝐼𝐷 × 100                                                  (eqn. 3.1) 
                                                                      𝐼𝑡 = 𝐼0𝑒
−𝜆𝑡                                                                        (eqn. 3.2) 
Where;  𝜆 = 0.693 𝑇1
2 
 , T1/2 is the half-life of the radionuclide, It is activity at a given time 
where I0 is the starting activity and t is the time passed, CPET is the contrast of the image and 
ID is the activity of the injected acetate. 0.693 is ln2. 
 
Activity of 11C-acetate was measured before and after injection by using equation 3.2 and ID 
was calculated by subtracting activity left after injection from activity before injection. 
Calculated %ID was displayed using the Graphad Prism software as mean±SEM. GEE 
analysis was carried out to investigate differences. 
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3.2.2 Results 
Figure 3.2 shows typical murine images obtained by CT and PET. CT images were acquired 
to provide the anatomical data for PET registration, which is poor in anatomical information. 
In figure 3.3 CT images show typical ROIs for the brain, blood pool and liver used to 
determine the 11C-acetate signal. ROIs together with images were saved so that the same 
ROIs could be placed to a similar position in each animal. 
Figure 3.4 shows representative images at different frames from the 4 different groups. The 
first image in each row corresponds to a PET/CT image, where the sum of frames 0-2 
minutes was used for reconstruction of the PET image. The second image corresponds to 
the same CT image with the PET image reconstructed from frames 2 to 10 minutes. The 
third image corresponds to the same CT image with the PET image reconstructed from 
frames 10 to 30 minutes and the last image corresponds to the PET image from frames 30 
minutes till the end of the scan. The first row of images (a) were obtained for a mouse from 
the fasted group receiving an i.v. injection of 11C-acetate, the second row (b) for a mouse 
which was fasted and received a colonic injection of labelled acetate and the third row (c) for 
a mouse from the fed group receiving an i.v. injection of 11C-acetate. The images in the last 
row (d) are from an animal which was fasted and received i.p. cold acetate prior to the 
injection of i.v. labelled acetate. 
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Figure 3.2. PET/CT images. 
The figure shows the same frame of CT, PET and registered images for sum of first 60 
minutes of a fed mouse that received i.v. acetate. (a) 3D CT images, (b) PET image, (c) the 
PET/CT registered images.  
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Figure 3.3. Example ROIs used in the PET experiment. 
CT images are shown in the figure. Blue areas in (a) show the ROI for the brain, red areas in 
(b) show the ROI for the blood pool and yellow areas in (c) show the ROI for the liver. 
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Figure 3.4. Sum of PET images at different time points. 
Sum of activity PET images from start to 2 minutes, from 2 till 10 minutes, 10 to 30 minutes 
and 30 minutes till the end of the scan, reconstructed onto the same CT image are shown in 
each row (from left to right). (a) the images obtained for a fasted animal. (b) images of an 
animal which received 11C-acetate through colon. (c) a fed animal. (d) an animal which 
received i.p. cold acetate prior to the injection of i.v. labelled acetate. 
114 
 
3.2.2.1 Biodistribution  
Figure 3.5 shows the percent injected dose calculated for two different ROIs drawn on the 
liver for fasted mice which received i.v. 11C-acetate.  
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Figure 3.5. Average percent injected dose in liver. 
Average percent injected dose measured on two different ROIs on liver for fasted animals 
which received i.v. 11C-acetate (approximately 20mBq) are shown. Percent injected dose for 
each animal was calculated using the equations in section 3.2.1. The data are shown as 
mean±SEM. 
 
 
The percent injected dose calculated for different tissues are shown in Figure 3.6 shows; 
brain (a), heart (b), fat (c), brown adipose tissue (BAT) (d), colon (e) and muscle (f).  
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Figure 3.6. Average percent injected dose measured in various organs. 
Average percent injected dose of brain (a), heart (b), fat (c), BAT (d), colon (e) and muscle 
(f) for fasted animals which received i.v. 11C-acetate (approximately 20MBq) are shown. 
Percent injected dose for each animal was calculated using the equations in section 3.2.1. 
The data are shown as mean±SEM. 
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Figure 3.7 shows percent injected dose calculated for kidneys (a) and bladder (b).  
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Figure 3.7. Percent injected dose of kidney and bladder. 
Average percent injected dose measured in the kidneys (a) and bladder (b) for fasted 
animals which received i.v. 11C-acetate (approximately 20mBq) is shown. Percent injected 
dose for each animal was calculated using the equations in section 3.2.1. The data are 
shown as mean±SEM. 
 
 
 
 
 
 
 
 
 
 
117 
 
Figure 3.8 shows percent injected dose calculated at the blood pool inside the heart cavity.  
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Figure 3.8. Blood pool percent injected dose. 
Average percent injected dose of blood pool for fasted animals which received i.v. 11C-
acetate (approximately 20mBq) are shown. Percent injected dose for each animal was 
calculated using the equations in section 3.2.1. The data are shown as mean±SEM. 
 
 
 
The highest uptake was observed at heart followed by the liver. It was shown that when 
administered acetate does reach to the brain and as it is observed in the first couple of 
minutes of injection this more likely acetate than any of its metabolites. The peak uptakes 
are observed during the first 10 minutes of injection in the tissues after which it starts to be 
excreted, building in the bladder. 
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3.2.2.2 Route of Administration 
In this section animals which received i.v. 11C-acetate are compared with those receiving 
colonic 11C-acetate. Animals in both groups were fasted overnight before the scans. 
Figure 3.9 shows the percent injected dose calculated for two different ROIs drawn on the 
liver. GEE analysis was carried out on the data. The group which received i.v. 11C-acetate 
(Fasted_i.v.) was compared with the group which received labelled acetate through the 
colon (Fasted_Colonic). The colonic administration group showed a significant difference in 
percent injected dose compared with the i.v. group, in the liver. Colonic administration took 
longer to reach to the liver. 
 
1 2 3 4 5 6 7 8 910
0
2
4
6
8
10
Fasted_i.v.
Fasted_Colonic
20 30 40 50 60 70
Time (minutes)
A
v
e
r
a
g
e
 P
e
r
c
e
n
t
In
je
c
t
e
d
 D
o
s
e
1 2 3 4 5 6 7 8 910-0.5
1.5
3.5
5.5
7.5
9.5
11.5
Fasted_i.v.
Fasted_Colonic
20 30 40 50 60 70
Time (minutes)
A
v
e
r
a
g
e
 P
e
r
c
e
n
t
In
je
c
t
e
d
 D
o
s
e
a b
n=3/4 per group
*** ***
 
Figure 3.9. Average percent injected dose in liver. 
Average percent injected dose measured on two different ROIs on liver for Fasted_i.v. 
(black) and Fasted_Colonic (green) animals are shown. Fasted_i.v. animals received i.v. 
11C-acetate. Fasted_Colonic animals were administered 11C-acetate to their colons. All 
animals received approximately 20mBq of labelled acetate. Percent injected dose for each 
animal was calculated using the equations in section 3.2.1. The data are shown as 
mean±SEM.   ***: p<0.001. 
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Figure 3.10 shows percent injected dose calculated for different tissues; brain (a), heart (b), 
fat (c), BAT (d), colon (e) and muscle (f). Animals which received 11C-acetate through colon 
were significantly different from i.v. animals in the brain, heart and BAT with a p value of 
zero, in muscle with a p value of less than 0.01 and in colon with a p value less than 0.001. 
Moreover, there was trend in fat with a p value of 0.067. The main difference between i.v. 
and colonic administration was during the first 10 minutes where it took longer for acetate to 
reach to the organs in colonic administered mice than the i.v. 
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Figure 3.10. Average percent injected dose measured in various organs. 
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Average percent injected dose of Fasted_i.v. and Fasted_Colonic groups are shown on each 
graph for organs, brain (a), heart (b), fat (c), BAT (d), colon (e) and muscle (f). Fasted_i.v. 
animals received i.v. 11C-acetate. Fasted_Colonic animals were administered 11C-acetate to 
their colons. All animals received approximately 20mBq of labelled acetate. Percent injected 
dose for each animal was calculated using the equations in section 3.2.1. The data are 
shown as mean±SEM. **:p<0.01 and ***:p<0.001. 
Figure 3.11 shows percent injected dose calculated for kidneys (a) and bladder (b). GEE 
analysis revealed no differences in the bladder. In the kidney animals which received 11C-
acetate through colon were significantly different from i.v. animals with a p value of less than 
0.0001. 
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Figure 3.11. Percent injected dose of kidney and bladder. 
Average percent injected dose measured kidneys (a) and bladder (b) for Fasted_i.v. and 
Fasted_Colonic animals are shown. Fasted_i.v. animals received i.v. 11C-acetate. 
Fasted_Colonic animals were administered 11C-acetate to their colons. All animals received 
approximately 20mBq of labelled acetate. Percent injected dose for each animal was 
calculated using the equations in section 3.2.1. The data are shown as mean±SEM.          
***: p<0.001. 
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Figure 3.12 shows percent injected dose calculated for the blood pool inside the heart cavity. 
Animals that received 11C-acetate through colon were significantly different from animals that 
received i.v. 11C-acetate (p<0.0001). The results for all the comparisons are summarized in 
table 3.1. 
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Figure 3.12. Blood pool percent injected dose. 
Average percent injected dose of blood pool for Fasted_i.v. and Fasted_Colonic animals are 
shown. Fasted_i.v. animals received i.v. 11C-acetate. Fasted_Colonic animals were 
administered 11C-acetate to their colons. All animals received approximately 20mBq of 
labelled acetate. Percent injected dose for each animal was calculated using the equations 
in section 3.2.1. The data are shown as mean±SEM. ***: p<0.001 
 
 
The main difference caused by the colonic injection was the slower uptake time of 11C-
acetate to the tissues. This might be caused by acetate taking longer time to reach to the 
123 
 
circulation as can be observed by blood pool graph. At steady state the dose of 11C-acetate 
observed at all the tissues except for muscle are similar. 
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3.2.2.3 Feeding State 
In this section animals which were fasted overnight were compared with fed animals. Both 
groups received i.v. 11C-acetate. 
Figure 3.13 shows the percent injected dose calculated for two different ROIs drawn on the 
liver. The fasted group (Fasted_i.v.) was compared with the fed group (Fed_i.v.). GEE 
analysis was carried out on the data which showed no significant difference. 
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Figure 3.13. Average percent injected dose in liver. 
Average percent injected dose measured on two different ROIs on liver for Fasted_i.v. 
(black) and Fed_i.v. (blue) animals are shown. All animals received i.v. 11C-acetate 
(approximately 20mBq). Percent injected dose for each animal was calculated using the 
equations in section 3.2.1. The data are shown as mean±SEM. 
 
 
Figure 3.14 shows percent injected dose calculated for different tissues; brain (a), heart (b), 
fat (c), BAT (d), colon (e) and muscle (f). No significant differences were observed as a 
result of feeding state. 
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Figure 3.14. Average percent injected dose measured in various organs. 
Average percent injected dose of fasted and fed groups are shown on each graph for 
organs, brain (a), heart (b), fat (c), BAT (d), colon (e) and muscle (f). All animals received i.v. 
11C-acetate (approximately 20mBq). Percent injected dose for each animal was calculated 
using the equations in section 3.2.1. The data are shown as mean±SEM. 
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Figure 3.15 shows percent injected dose calculated for kidneys (a) and bladder (b). GEE 
analysis revealed no differences in the bladder and kidney due to feeding state.  
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Figure 3.15. Percent injected dose of kidney and bladder. 
Average percent injected dose measured kidneys (a) and bladder (b) for fasted and fed 
animals are shown. All animals received i.v. 11C-acetate (approximately 20mBq). Percent 
injected dose for each animal was calculated using the equations in section 3.2.1. The data 
are shown as mean±SEM. 
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Figure 3.16 shows percent injected dose calculated for the blood pool inside the heart cavity. 
No significant difference was observed between the groups. The results for all the 
comparisons are summarized on table 3.1. 
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Figure 3.16. Blood pool percent injected dose. 
Average percent injected dose of blood pool for fasted and fed animals are shown. All 
animals received i.v. 11C-acetate (approximately 20mBq). Percent injected dose for each 
animal was calculated using the equations in section 3.2.1. The data are shown as 
mean±SEM. 
 
 
 
Feeding state of the animals did not cause any significant change (summarised in table 3.1). 
The peak uptake values were lower in fat, BAT and muscle and higher in colon, bladder, 
kidney and blood pool in fed animals see table 3.2. 
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3.2.2.4 Saturable State 
In this section animals which received i.p. unlabelled acetate prior to i.v. 11C-acetate (CA) 
were compared with those that did not received unlabelled acetate (Fasted_i.v.). All animals 
were fasted overnight and received i.v. 11C-acetate the only difference being the “cold 
acetate” administration in the CA group. 
Figure 3.17 shows the percent injected dose calculated for two different ROIs drawn on the 
liver. GEE analysis was carried out on the data. The fasted group (Fasted_i.v.) was 
compared with the group which received cold acetate (i.p.) prior to labeled acetate injection 
(i.v.) (CA). No significant difference was observed. 
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Figure 3.17. Average percent injected dose in liver. 
Average percent injected dose measured on two different ROIs on liver for Fasted_i.v. 
(black), and cold acetate (purple) animals are shown. CA animals received i.p. unlabelled 
acetate (500mg/kg) prior to 11C-acetate injection. Animals in both groups were fasted and 
received i.v. 11C-acetate, approximately 20mBq. Percent injected dose for each animal was 
calculated using the equations in section 3.2.1. The data are shown as mean±SEM. 
 
 
Figure 3.18 shows percent injected dose calculated for different tissues; brain (a), heart (b), 
fat (c), BAT (d), colon (e) and muscle (f). Uptake of acetate in CA animals was significantly 
lower than Fasted_i.v. animals in fat and muscle with a p value of less than 0.05. Uptake 
was similar in colon for the two groups and for the rest of tissues, there was trend towards 
higher uptake in CA group than i.v. group, although this did not reach significance. 
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Figure 3.18. Average percent injected dose measured in various organs. 
Average percent injected dose for organs, brain (a), heart (b), fat (c), BAT (d), colon (e) and 
muscle (f) are shown. Cold acetate (CA) animals received i.p. unlabelled acetate (500mg/kg) 
prior to 11C-acetate injection. Animals in both groups were fasted and received i.v. 11C-
acetate, approximately 20mBq. Percent injected dose for each animal was calculated using 
the equations in section 3.2.1. The data are shown as mean±SEM. *:p<0.05. 
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Figure 3.19 shows percent injected dose calculated for kidneys (a) and bladder (b). GEE 
analysis revealed no difference in the bladder. Recent injected dose of kidney were 
significantly different (p<0.0001).  
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Figure 3.19. Percent injected dose of kidney and bladder. 
Average percent injected dose measured kidneys (a) and bladder (b) for Fasted_i.v. and 
cold acetate animals are shown. CA animals received i.p. unlabelled acetate (500mg/kg) 
prior to 11C-acetate injection. Animals from both groups were fasted and received i.v. 11C-
acetate, approximately 20mBq. Percent injected dose for each animal was calculated using 
the equations in section 3.2.1. The data are shown as mean±SEM. ***: p<0.001 
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Figure 3.20 shows percent injected dose calculated at the blood pool inside the heart cavity. 
Cold acetate animals had a trend towards higher acetate uptake than Fasted_i.v. animals 
but did not reach to significance (p value of 0.1968). The results for all the comparisons are 
summarized on table 3.1. 
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Figure 3.20. Blood pool percent injected dose. 
Average percent injected dose of blood pool for Fasted_i.v. and cold acetate animals are 
shown. CA animals received i.p. unlabelled acetate (500mg/kg) prior to 11C-acetate injection. 
Animals from both groups were fasted and received i.v. 11C-acetate, approximately 20mBq. 
Percent injected dose for each animal was calculated using the equations in section 3.2.1. 
The data are shown as mean±SEM. 
 
 
 
 
Although injection of cold acetate prior to 11C-acetate injection did not cause any significant 
change except for fat and kidney trends toward higher uptake in liver, brain, heart, BAT and 
blood pool and lower uptake in the muscle was observed. 
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Table 3.1 summarizes the differences in biodistribution under different conditions. Route of 
administration caused significant differences in most of the tissues, feeding state did not 
cause any difference and the administration of unlabelled acetate prior to 11C-acetate 
caused some differences.  
             Comparisons 
   ROIs 
Route of 
administration 
(i.v.-colon) 
Feeding state 
(fed-fasted) 
Saturable state 
(with-without CA) 
Liver_ROI_1 p<0.0001 p=0.4597 p=0.2432 
Liver_ROI_2 p<0.0001 p=0.9913 p=0.1393 
Brain p<0.0001 p=0.153 p=0.1133 
Heart p<0.0001 p=0.684 p=0.1956 
Fat p=0.0673 p=0.1957 p=0.0215 
BAT p<0.0001 p=0.733 p=0.2027 
Colon p=0.0042 p=0.1149 p=0.7244 
Muscle p=0.0001 p=0.3 p=0.0279 
Bladder p=0.1904 p=0.1252 p=0.6892 
Kidney p<0.0001 p=0.2795 p<0.0001 
Blood Pool p<0.0001 p=0.321 p=0.1968 
 
Table 3.1. Summary of comparisons between all the groups for the PET study. 
GEE analysis carried out on test groups are summarized in the table. Feeding state 
comparison is shown as fasted vs. fed. Route of administration is shown as i.v. vs. colonic 
which compares i.v. injection with colonic. Lastly, the effect of unlabelled acetate is shown as 
with vs. without CA (cold acetate). N=3/4 per group.  
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Table 3.2 shows the peak uptake of labelled acetate observed in tissue investigated. It 
shows that peak uptake was not affected greatly by feeding state, colonic infusion has 
reduced peak uptake in most tissues and cold acetate injection prior to labelled acetate has 
decreased peak uptake in fat, muscle and kidneys and increased in brain, heart and blood 
pool.  
             Peak 
%ID 
   ROIs 
Fasted_i.v. Fed_i.v. Fasted_Colonic Cold acetate 
Liver_ROI_1 7.78 7.63 4.51 13.69 
Liver_ROI_2 9.68 8.83 4.05 7.60 
Brain 2.9 3.03 2.22 4.17 
Heart 20.29 21.6 3.34 48.18 
Fat 2.85 1.79 1.92 1.41 
BAT 3.58 2.79 2.19 4.16 
Colon 4.19 6.02 39.8 3.55 
Muscle 1.96 1.42 1.48 1.07 
Bladder 3.95 5.63 10.88 3.71 
Kidney 18.47 24.62 3.65 7.29 
Blood Pool 24.49 28.73 3.71 31.4 
 
Table 3.2. Summary of peak uptake by tissues investigated. 
Peak uptake (%ID) of 11C-acetate observed for the tissues investigated. 
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Table 3.3 shows the coefficient of variation measured for the percent injected dose of 
different ROIs investigated for the Fasted_i.v. group which is high as the n number is low. 
 Coefficient of variation (%) 
ROIs %ID graph Peak %ID 
Liver_ROI_1 32.41 12.50 
Liver_ROI_2 39.41 10.11 
Brain 30.46 13.23 
Heart 69.85 32.49 
Fat 35.28 37.75 
BAT 37.18 0.84 
Colon 35.28 31.31 
Muscle 45.57 11.80 
Bladder 67.08 33.09 
Kidney 65.74 12.39 
Blood Pool 74.51 19.84 
 
Table 3.3. Coefficient of variation for Fasted_i.v. group. 
This table shows the coefficient of variation (%) for %ID graphs and peak %ID of Fasted_i.v. 
animals, measured for the different ROIs investigated. 
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3.2.3 Discussion 
This set of experiments measured the biodistribution of 11C-acetate following various routes 
of administration and under different physiological conditions. This is the first study that has 
looked at biodistribution of 11C-acetate following different routes of administration on normal 
mice without any lesions. All other papers concentrated on tumour uptake in different cancer 
models (Zhao et al., 2009, Jonson and Welch, 2002).  
Although the results given in this study are not absolute values because of the lack of an 
input function, it gives an overall picture of the distribution of acetate. An input function gives 
the concentration of tracer activity in blood. This is usually possible through blood sampling 
at various intervals during the scan which is an impractical and difficult method in mouse 
models. Tissue uptake of tracer is then corrected by the input function. Although there are 
alternatives suggested (Kim et al., 2006, Herrero et al., 2006) to estimate input function, use 
of these methods does not give accurate values in mouse models because of the low 
resolution of PET images acquired.  
Authier et al, investigated the biodistribution of 11C-acetate by sacrificing mice with different 
tumour types at different time intervals after its administration (Authier et al., 2008). They 
measured the radioactivity in different organs dissected, using a gamma camera. Their 
values of percent injected dose are comparable to the values obtained in this thesis for the 
fed and fasted animals. 
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3.2.3.1 Biodistribution 
The biodistribution of 11C-acetate in fasted animals showed that the highest uptake was in 
heart followed by liver. The uptake of the other tissues investigated were at least half of 
liver‟s uptake. After liver the highest uptake was in colon followed by BAT, brain and adipose 
tissue respectively. The lowest uptake was observed in muscle. Bladder and kidneys show 
the excretion process, which was high during the first couple of minutes for the kidneys and 
then starts to decrease whereas it builds up in the bladder. Activity in heart pool was 
measured to get an estimate of 11C-acetate in circulation, which was very high at first but 
decreased with time as acetate was taken up by the tissues. It should be noted that due to 
the nature of the heart muscle and its movement, the activity measured for the ROI drawn 
here will be affected by the heart pool. Another point that should be raised is that the labelled 
carbon atom is traced by this technique and not the acetate per se. As acetate gets 
metabolised the labelled carbon will be passed on. It has been previously shown that when 
administered to animals the acetate concentration in plasma reached a peak value at 15 min 
and thereafter started to decrease. In an hour it had dropped to pre-administration 
concentrations (Ge et al., 2008). The peak uptake in my study is seen in couple of minutes 
of its administration for all tissues during which time we are still tracing acetate. 15 minutes 
after administration of acetate till the end of the scan, metabolites start to form and are also 
traced together with not yet metabolised acetate. 
 
3.2.3.2 Route of Administration 
Route of administration caused a significant difference in almost all tissues examined and 
this was mostly during the first 10 minutes of injection, when acetate was being taken up by 
the tissues. From the blood pool graph it can be seen that with the colonic injection it took 
longer for the acetate to reach circulation and this is reflected in the uptake of tissues. Also 
the %ID graph of animals that received tracer colonic resembled an uptake curve more than 
a decay curve as in animals which received i.v. tracer. As the tracer reached the organs 
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later, a one hour long scan might not have been enough to image the wash out or use of the 
entire tracer from the tissue.  
 
3.2.3.3 Feeding State 
No difference was observed in the tissues investigated due to feeding state. As acetate can 
be used as a fuel under energy deprived conditions, a lower uptake was hypothesised for 
fed animals. The fact that animals were anesthetised and not active might be the reason why 
this was not observed. 
 
3.2.3.4 Saturable State 
And lastly the animals which received unlabelled i.p. acetate prior to i.v. 11C-acetate injection 
(CA) and the animals which did not receive unlabelled acetate (Fasted_i.v.) were compared. 
Fat and muscle uptake of labelled acetate were significantly different in cold acetate animals 
than in Fasted_i.v. animals. The uptake of labelled acetate was delayed in fat and muscle in 
animals that received cold acetate. Uptake of labelled acetate in other tissues, although not 
significant, was higher in the cold acetate animals than in the Fasted_i.v. animals. Cold 
acetate injected animals were compared with those that did not receive this injection to 
investigate the effect of GPR43 receptors on the biodistribution of acetate. Hong et al have 
shown previously that GPR41 and GPR43 receptors are found predominantly in adipose 
tissue but also in the muscle as well (Hong et al., 2005). Delayed uptake of labelled acetate 
in animals which received unlabelled acetate might be due to saturation of GPR43 receptors. 
I hypothesize that less uptake of labelled acetate by these tissues (muscle and fat) caused 
longer circulation of 11C-acetate in the blood and higher uptake by the other tissues. 
Although not significant the activity in blood pool is higher in mice which received unlabelled 
acetate, indicating that acetate is circulating longer.  
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3.3 Acetate Metabolism 
The aim of the study was: 
1. To explore the possibility of assessing acetate metabolism in a murine model 
following its administration in a physiologically relevant concentration and route. 
The objective of the study was: 
1. To administer 13C enriched acetate into the colon in a physiologically relevant dose.  
2. To employ NMR spectroscopy to observe the changes in concentration of acetate 
and its metabolites. 
 
3.3.1 Methods 
3.3.1.1  Animals and Treatments 
3.3.1.1.1 Animal and Administration 
Adult male C57BL6 mice (Harlan, UK) were allowed to acclimatize for 3 days before the 
experiment. Animals were treated by colonic infusion as it is more physiologically relevant 
way of administering acetate as it is produced in the colon. The treatments were either with 
2-13C acetic acid or with water. The colonic treatment was administered using an 18 gauge 
oral gauge. Before the colonic administration, animals were anesthetized with 3-4% and 
maintained at 2-2% oxygen isoflurane mix. The oral gauge was placed 1cm into the rectum 
and acetic acid or water was administered. Then depending on the time point, animals were 
either recovered or cardiac puncture was performed immediately to collect blood (for time 0). 
The time points used were 0, 15 min, 30min, 1h, 2h, 6h, 12h and 24h. After these times the 
animals were anesthetized again and cardiac puncture was carried out. Then animals were 
culled and dissected. Dissected organs were weighted and put into aluminium foil. A freeze 
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clamp which consists of two metal disks was chilled in liquid nitrogen. This was then used to 
freeze and crush the organ wrapped with the foil by pressing the two disks together.  
 
3.3.1.1.2 Dose 
Animals received 2-13C acetic acid diluted in water (20mM, 6.105 mg/kg) using a 
physiologically relevant dose (Ballard, 1972, Yamashita et al., 2007) of 5ml/kg of animal 
body weight, or with water using the same volume. 
 
3.3.1.2 Sample Preparation for NMR 
For tissue extraction from the organs collected by dissection, the following steps were 
followed: 
1. A styrofoam container was filled with enough liquid Nitrogen to cover the bottom of 
the container.  
2. The mortar was placed into the Styrofoam container with the liquid Nitrogen and 
allowed to reach freezing temperature. 
3. The frozen tissue was placed into the mortar grinded with the pestle until in powder 
form. 
4. 5ml/g of tissue of 6% perchloric acid (PCA) was added to the frozen sample and 
grinded and then allowed to thaw. 
5. PCA tissue suspension was transferred to an eppendorf tube and centrifuged. 
6. The supernatant was removed and neutralized with potassium hydroxide until 
reaches a pH of 7.0 (adjust pH with KOH and PCA). 
7. The sample was spun down and precipitate discarded. 
8. The supernatant was poured into a universal tube that had been frozen to -80ºC. 
9. Samples were then freeze-dried overnight. 
10. Samples were re-hydrated with 1 ml of deuterium oxide (D2O). 
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11. Samples were spun down to remove salts and 600µl was retained for NMR. 
 
3.3.1.3 NMR Scan Parameters 
13C NMR spectra were acquired on a Bruker scanner with a 5 mm normal mode BBO probe 
at 125 MHz, sweep width 210 ppm (26455 Hz), data points 32 k, acquisition time 0.619 s, 
relaxation delay 2 s (overall recycle delay 2.62 s), pulse width 6 µs (corresponding to a 45 
degree pulse), composite pulse decoupling of 1H using waltz 16, number of averages 
>10000 and temperature of 298K. 
1H NMR spectra were also acquired on a Bruker scanner with a 5 mm inverse mode BBI 
probe at 500.13 MHz, sweep width 12 ppm (6009 Hz), data points 32 k, acquisition time 
2.726 s, relaxation delay 3 s (overall recycle delay 5.726 s), pulse width 6 µs (corresponding 
to a 55 degree pulse), 64 averages and temperature of 298K. 
 
3.3.1.4 Analysis 
MestRe-C software was used for the analysis of both 1H and 13C spectra. The FID signal 
was apodized to reduce noise and fourier transformed. Baseline correction was carried out 
using a spline function. Peaks were then integrated for relative quantification. 
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3.3.2 Results 
3.3.2.1 Serum 
A typical serum spectrum of an acetate administered animal is shown in figure 3.21. Peak 
assignments of different metabolites found in the 1H NMR spectrum of serum are also 
displayed in this figure. Typical 1H NMR spectra of serum samples from treatment and 
control mice are shown in figures 3.22 and 3.23. The peaks marked with green lines are 
assigned to arising from acetate representing the natural abundance of this SCFA found in 
plasma. The spectra and subsequent quantification suggest that colonic infusion of acetate 
had no effects on the overall concentration of serum acetate. The concentration of acetate 
varied with time but this change was random. Same level of acetate peaks was observed 
both in water and acetate administered mice. 
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Figure 3.21. 1H NMR spectrum of serum from an animal 15 min after acetate 
administration. 
Various metabolites can be identified in an 1H NMR spectrum of serum. These are shown in 
the figure. OH But: β hydroxy butyrate, Ala: alanine, Lac: Lactate, Ac: acetate, Cr: cretanine, 
Glc: glucose, NAc: N-acetyl, Glutamine, Glutamate and citrate are shown in the figure. 1 is 
the expanded version of identified region. 
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Figure 3.22. 1H NMR serum spectra of acetate administered animals. 
Mice that received acetic through colon were culled at 0, 15, 30 minutes, 1, 2, 6, 12 and 24 
hours after administration. 1H NMR spectra were carried out on the serum samples obtained 
by cardiac puncture. The green lines show the peaks for acetate and the blue lines show the 
peaks for lactate. 
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Figure 3.23. 1H NMR serum spectra of water administered animals. 
Control mice which received water through colon were culled at 0, 15, 30 minutes, 1, 2, 6, 12 
and 24 hours after administration. 1H NMR spectra were carried out on the serum samples 
obtained by cardiac puncture. The green lines show the peaks for acetate and the blue lines 
show the peaks for lactate. 
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3.3.2.2 Liver 
Spectra of PCA extraction of livers from control and treated mice were also analyzed. A 
typical 13C-NMR liver spectrum is shown in figure 3.24 together with assigned peaks.   
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Figure 3.24. 13C NMR spectrum of liver from a mouse 30 min after acetate 
administration. 
Various metabolites can be identified in a 13C NMR spectrum of liver extract. These are 
shown in the figure. Ala: alanine, Lac: Lactate, Glu: Glutamate, Gln: Glutamine, Asp: 
Aspartate and OH But: β hydroxyl-butyrate are shown in the figure. 1 is the expanded 
version of identified region. 
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Figure 3.25 shows the ex-vivo liver 13C-NMR spectra from Control (a) and acetate treated (b) 
mice. a1 and b1 are expansions of spectra from 26 to 19 ppm. The acetate peak is normally 
found at 24ppm in a typical 13C-NMR spectrum, however no peaks for acetate were found. 
 
 
Figure 3.25. Ex-vivo liver 13C NMR spectra of water and acetate administered animals. 
Liver 13C NMR spectra of Control (a) and 13C-acetate (b) mice are shown. The expanded 
regions show the spectra from 26-19ppm.  
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Figure 3.26 shows ex-vivo 13C-NMR spectra for acetate administered animals culled at 
different time points; 15 minute (a), 1 hour (b) and 24 hours (c). Again, no signal that can be 
assigned to acetate peak was observed at any of the time points studied. 
 
 
Figure 3.26. Ex-vivo 13C NMR spectra of mouse livers acquired at different times. 
Liver 13C NMR spectra of 13C-acetate administered animals obtained 15 minutes (a), 1 hour 
(b) and 12 hours (c) after administration are shown in the figure. The expanded regions 
show the spectra from 26-19ppm.  
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3.3.3 Discussion 
This study was carried out to assess the possibility of determining the metabolic fate of 
acetate in various organs following colonic administration of physiologically relevant 
concentrations of acetate. Acetate was infused through colon because this is the most 
physiologically relevant route as acetate is normally produced in the colon. The 
concentration of infused acetate (6.105 mg/kg) was chosen from published data, as a 
physiological dose normally found in rodents and which has been shown to have positive 
effects on obesity when administered chronically (Ballard, 1972, Yamashita et al., 2001). 
Indeed, this concentration has been shown to lead to reduced lipid concentration in the liver 
and decreasing lipid accumulation in adipose tissue (Yamashita et al., 2009, Yamashita et 
al., 2007). 
The current study has however failed to provide any positive or conclusive results, as no 
changes in metabolites or acetate concentrations were observed following acetate 
administration. The main reasons may be related to the relatively low amount of acetate 
administered and possibly the low sensitivity of the NMR technique. The detection limit of 1H 
NMR is around 10µM for 500MHz and the limit of 13C NMR is 100µM (Bell, 1992, Malet-
Martino and Martino, 1992). From the PET study carried out, it is known that after colonic 
administration of acetate, liver is the second tissue with the highest uptake. The fact that no 
significant change was seen in either the acetate concentrations or the metabolites in liver 
and serum samples suggests that the changes were too subtle for the dose administered or 
that acetate is rapidly oxidised in the liver into 13CO2 and excreted, thus avoiding detection in 
the liver extracts. 
Other groups have shown acetate and its metabolites in rat liver and brain extracts and 
plasma after 2-13C acetate infusion (Deelchand et al., 2009, Chateil et al., 2001, Kalderon et 
al., 1987). However the concentrations of 2-13C acetate infused in these studies were 100 
times higher than the concentration used in this thesis and therefore of little physiological 
relevance as clearly concentration of ~1g/kg, even if administered via a physiologically 
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relevant route, will inevitably lead to metabolic consequences which are well outside the 
metabolic parameters normally encountered by a tissue with unforeseen metabolic effects 
and outcomes. Clearly there is a need for more sensitive techniques, including mass-
spectroscopy, to be utilised to assess acetate metabolism at physiologically relevant 
concentrations, both in murine models and in human subjects. 
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3.4 Encapsulated Acetate 
A number of approaches have been investigated in order to increase the concentrations of 
circulating SCFAs in the blood stream in rodent models and human subject. These 
unfortunately have not been very successful, as administration of large concentrations of 
acetate, orally, rectally or as an infusion, can cause significant harmful side effects (Pound, 
1968, Martínez et al., 1999). Clearly an efficient and safe delivery method of acetate delivery 
to tissue of interest would be of major benefit for researchers and possibly for the public at 
large. The aim of this study was to develop and implement a method for the acute and 
chronic delivery of acetate to a murine model of obesity.   
 
3.4.1 Methods 
3.4.1.1 Liposome Formulation and Formation 
3.4.1.1.1 Liposome Preparation 
The stock solutions of lipids were prepared in chloroform as, 2mg/ml DSPC (1,2-Distearoyl-
sn-glycero-3-phosphocholine, C44H88NO8P), 5mg/ml CDAN (N1-cholesteryloxycarbonyl-3-7-
diazanonane-1,9-diamine, C35H64N4O2), 10mg/ml Cholesterol (C27H46O), 1mg/ml DOPE-
Rhodamine (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B 
sulfonyl) C68H109N4O14PS2), 5mg/ml Gd.DOTA.DSA (Tri-tert-butyl 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetate.4,4-Dimethyl-4-silapentane-1-ammonium 
trifluoroacetate, C55H109N6O8Gd) and 25mg/ml DSPE_PEG_2000 (1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000],  C133H267N2O55P), see 
figure 3.27.  
152 
 
 
Figure 3.27. Lipids used in liposome formulations. 
Lipids used in liposome formulations are shown in the figure. (a) DSPC, (b) CDAN, (c) 
Cholesterol, (d) DSPE_PEG_2000, (e) DOPE-Rhodamine and (f) is Gd.DOTA.DSA. 
 
 
Three different liposome formulations were used which are summarized in table 3.4. For 
histology experiments, liposomes with rhodamine lipid were used, for MRI experiments 
liposomes with gadolinium lipid were used and for everything else liposomes without 
rhodamine and gadolinium lipids were used, liposome formulations 2, 3 and 1 respectively 
on table 3.4.  
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 DSPC 
(mol%) 
CDAN 
(mol%) 
Cholesterol 
(mol%) 
DSPE_PEG_2000 
(mol%) 
DOPE_Rhodamine 
(mol%) 
Gd.DOTA.DSA 
(mol%) 
1 32 32 35 1 - - 
2 32 32 34 1 1 - 
3 32 32 34 1 - 1 
 
Table 3.4. Liposome formulations used. 
Three different liposome formulations were used in this study. 1st one which does not have 
any contrast agent in was used in chronic studies. 2nd one which has 1% DOPE_Rhodamine 
which is a fluorescent lipid was used in histology studies. 3rd one was used in MRI T1 
measurement studies and has 1% Gd.DOTA.DSA. 
 
 
Liposomes were prepared as described below. 
1. The appropriate volume of each lipid was added to a round bottom flask and was 
evaporated to produce a film.  
2. 1M Acetate buffer at pH 4 and 4mM HEPES buffer were made up. 
3. The lipid film was hydrated with 1 ml of the Acetate buffer and was sonicated for 1 h 
at 300C.  
4. The pH of the liposomes was raised to 7 using sodium hydroxide (NaOH, pH 12) and 
hydrochloric acid (HCL, pH 2) to adjust. 
5. To filter out any buffer solution that is not encapsulated in the liposomes, float-a-lyzer 
dialysis membranes were prepared following manufacturer‟s instructions and the 
liposome solution was added to the inside of the membrane and floated in a reservoir 
containing distilled water for 24 hours. Water was changed 2 times during this time. 
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Figure 3.28. Diagrammatic representation of acetate encapsulated liposomes. 
A schematic diagram of a liposome, showing the hydrophilic head groups (blue) and the 
hydrophobic tails (yellow) that self assemble to form a spherical bilayer with an aqueous 
core containing acetate. Lipid bilayer is modified by using fluorescent (DOPE-Rhodamine), 
paramagnetic (Gd.DOTA.DSA), charged (CDAN) or neutral (PEG) for the purpose of the 
liposomes. Modified from (Kamaly et al., 2009). 
 
 
After preparation liposomes were sized using Zetasizer Nano ZS (Malvern, UK). Zetasizer 
provides an intensity distribution curve of the sizes of molecules found in volume provided. 
Figure 3.28 shows a schematic diagram of liposomes formed. 
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3.4.1.1.2 NMR 
1H NMR was employed to prove the encapsulation of acetate in the liposomes and to 
determine its concentration. For scanning parameters see section 3.3.1.3. 
3.4.1.1.2.1 Acetate Encapsulation 
To prove encapsulation of acetate by liposomes were prepared as described above using 
formulation 1.  
After filtering liposomes were scanned on an NMR scanner. Albumin was then added to the 
scanned liposome solution. Albumin is a large molecule which has a tendency to react with 
acetate. Being a large molecule, it should not be able to enter into the liposomes and should 
react with any acetate that is in solution but not encapsulated in the liposomes. After the 
addition of albumin and good shake, the new sample was scanned by NMR spectroscopy. 
 
3.4.1.1.2.2 Concentration of Encapsulated Acetate 
To investigate the amount of acetate encapsulated in the liposomes, they were prepared 
again with the previously mentioned protocol and formulation 1. A known amount of lactate 
(5.2mg) was added to 200µl of liposomes. This solution was freeze dried and resuspended 
in D2O and was then analysed by NMR spectroscopy. 
The obtained spectra were baseline corrected, referenced and integrated using the MestRe-
C software. 
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3.4.1.2 Liposome Delivery 
3.4.1.2.1 Histology 
3.4.1.2.1.1 Animals and Treatment 
Adult male C57BL6 mice (Harlan, UK) were used for this study. The first aim of the study 
was to find the highest concentration of acetate that can be used which will not have any 
adverse effect on the animals as well as to show the delivery of the liposomes to various 
organs.  
4 different concentrations of acetate; 1M, 10mM, 1mM and 100µM and control liposomes 
were prepared by using formulation 2. Animals received the liposome injection either i.p. or 
i.v. 2 hours after the injection, animals were culled and liver, spleen, kidneys and heart were 
dissected and frozen in dry ice. These were then kept at -800C. Histology was carried out on 
the collected organ samples. 4 animals per concentration and injection type were used. 
 
3.4.1.2.1.2 Rhodamine Liposomes and Histology 
A cryostat was used to slice up the organs with a slice thickness 7µm. Organs were placed 
on a chuck using OCT tissue embedding medium and allowed to reach -400C which is the 
temperature of the cryostat machine. Samples were sliced and each slice was placed on a 
microscope slide. 10µl of 4',6-diamidino-2-phenylindole (DAPI) which is a fluorescent stain 
that binds to DNA was put on top and was covered with a cover slip. To ensure the cover 
slip did not move, nail polish was used to fix it in the corners.  
 A microscope (IX71, Olympus) with 3 different filters was used to see if liposomes were 
present. A red filter would show liposomes if present as red because of the rhodamine 
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present in the liposomes. The green filter shows the background. Liposomes identified in the 
red filter should not be seen in this filter. The blue filter is used to demonstrate the presence 
of cells. DAPI binds to DNA and in UV light is excited showing the nuclei of the cells. 
 
3.4.1.2.2 Gadolinium Liposomes and T1 Measurements 
2 sets of acetate liposomes were prepared according to the protocol described in 3.4.1.2.1 
one with formulation 2 and the other with formulation 3. Gd is an MRI contrast agent which 
when taken up by the tissues decreases the relaxation time of the tissue therefore increasing 
the signal from the tissue. 
Animals were anesthetized with 4-3% isoflurane oxygen mix, placed in a birdcage coil and 
maintained at 2-2%. A breathing pad was used to monitor the breathing rate and a rectal 
probe for the body temperature which was maintained at 370C.  
Following shimming on the water signal of the whole mouse, a scout image was obtained. 
This was used to plan the axial slices covering the whole animal. An array of a fast spin echo 
sequence with TR 8500msec, TEeff 20msec, ETL 8, k zero at 2, FOV 50x50 mm
2, matrix 
256x256, one average, 40 slices of 2mm thickness, with TI 50, 100, 500, 1000 and 
5000msecs was obtained. Each array of 5 TI image volumes was 22 minutes with the total 
scan time per animal about 30 min. 
After the scan was finished animals received 200µl of acetate liposomes either with or 
without Gd, intraperitoneally. Animals were then recovered in a heating box. 2, 16, 24 and 48 
hours after the injection, the scan was repeated.  
For each time point and each TI signal intensities were measured in ROIs placed in the 
following organs, liver, brain, heart, fat and kidney using Image J. These were fitted into the 
equation 3.3 to determine the T1 values using Graphad Prism. 
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                                                                𝑌 = 𝑎𝑏𝑠  M0 ×  1+e
8500
T1 -2e-
TI
T1                                        (eqn. 3.3) 
 
T1 values were averaged as mean±SEM. Unpaired t-test was carried out for statistical 
analysis. 
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3.4.1.3 Chronic Administration of Acetate-Liposomes to Murine Model 
This study was performed to investigate if chronic administration of liposomes causes any 
adverse effects on mice and to assess the metabolic effects of acetate on liver metabolism 
in mice on control diets. The final aim of the study was to assess the metabolic effects of 
acetate on liver metabolism on mice on high fat diet.  
 
3.4.1.3.1 Animals and Treatments 
The experimental procedures for the two different experiments carried out are shown in 
figures 3.29 and 3.30 for animals on control and high fat diets respectively.  
 
 
Figure 3.29. Chronic acetate liposome treatment.  
After their arrival, animals were acclimatised at least for 72 hours and adiposity scans were 
carried out. At the start of week one, animals started acetate or hepes encapsulated 
liposome treatments (3 times per week). During the 3rd week of treatment, adiposity scans 
were repeated. During the fourth week, fasted glucose tolerance test (GTT) were performed. 
In the fifth week, animals were sacrificed and blood and tissue samples collected. 
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Figure 3.30. Chronic acetate liposome treatment on high fat fed animals. 
After their arrivals, animals were acclimatised for at least for 72 hours and adiposity scans 
were carried out. At the start of week one, animals were started to high fat diet and 
randomised to acetate or hepes encapsulated liposome treatments (3 times per week). 
During 3rd week of treatment, adiposity scans were repeated. During the fourth week, fasted 
glucose tolerance test were performed. During the fifth week, animals were sacrificed and 
blood and tissue samples were collected. 
 
  
Adult male mice were housed 4 per cage. Each cage was assigned to a treatment group 
randomly. After a week of acclimatisation, mice were fasted overnight and MRI scans were 
performed to assess whole body and liver fat content before treatment. Mice were allowed to 
recover and after 2 days treatment was started. Animals on the normal fat study, only 
received injections during the treatment period. Animals on high fat diet, for the obesity 
prevention study, were given a high fat diet on the first day of treatment and remained on 
this diet throughout the study. All animals received 3 i.p. injections of assigned liposomes 
per week for 4 weeks. During this time, animal weight and food intake were recorded weekly. 
During the fourth week, whole body and liver adiposity scans were repeated on animals 
following an overnight fast.  
A glucose tolerance test was performed on animals fasted overnight on a separate date. 
During the 5th and 6th week animals were culled and organ samples were collected.  
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3.4.1.3.2 Liposomal Treatments 
Mice in each cage were assigned either to acetate or Hepes encapsulated liposomes 
injections. Liposomes were prepared according to the procedure described earlier in section 
3.4.1.1.1 with formulation 1. 
 
3.4.1.3.3 Diets 
For the animals on the normal diet chow diet RM3 (Special Diet Services, Essex, UK) was 
used. For the animals on the high fat diet, 60% kCal fat diet (EF D12402) was used. The 
ingredients of these diets are shown in the table 3.5.  
 
Ingredient Chow High Fat 
Protein 22.39 24.1 
Fat 4.25 34 
Fibre 4.21 20 
Starch 33.92 2.2 
Sugar 5.75 22.4 
 
Table 3.5. Ingredients of diets used in the chronic studies. 
The percentages of ingredients of diets used in chronic studies are shown in the figure. RM3 
is normal chow diet that was used in normal fat chronic study. EF D12402 is the high fat diet 
used in the high fat chronic study. 
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3.4.1.3.4 MRI and MRS Scanning Procedures and Parameters 
MRI and MRS scans were performed to assess whole body and liver fat content before and 
at the end of the treatment. Overnight fasted animals were anaesthetised with 3-2% oxygen- 
isoflurane mix and placed into a whole body birdcage coil, and scanned in a 4.7T Unity Inova 
MR scanner (Varian Inc, USA). Respiration and body temperature were monitored during the 
scan. 
Whole body 1H MRS was carried out using the SPULS sequence with TR 10s, Pulse angle 
45°, 4 averages and spectral width (SW) 20,000Hz.  
A scout image was then obtained which was used to place axial slices over the liver. A fast 
spin echo image with TR 2600msec, TE 20msec, FOV 40x40 mm2, matrix size 128x128, 1 
average and 10 2mm slices was performed. This image was then used to locate the liver. 
Localized 1H MRS of the liver was performed using PRESS sequence by placing a 2x2x2 
mm3 voxel on the localised liver with parameters: TR 10s, TE 9ms, 64 averages and SW 
2800 Hz.  
 
3.4.1.3.5 Glucose Tolerance Test 
Mice were fasted overnight for glucose tolerance test. Prior to treatment with glucose, the tail 
tip was cut and the glucose test was done with a commercially available glucose meter 
(Boots, UK). 15, 30, 60 and 120 minutes after administration of the glucose (20%, i.p.), tests 
were repeated by bleeding the tail again. 
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3.4.1.3.6 Organ Sample Collection 
Mice were anesthetised using a 4-3% isoflurane oxygen mix and terminal cardiac puncture 
was carried out to collect blood sample. Animal was then culled and dissected. Brain, liver, 
heart, kidneys, spleen, pancreas, leg muscles, subcutaneous, epididymal, retroperitoneal 
and mesenteric adipose tissues were collected. 
 
3.4.1.3.7 Adipocyte Isolation and Counting 
Samples from the epididymal and subcutaneous fat depots collected were used to isolate 
and measure adipocyte numbers and size. Dulbecco's Modified Eagle Medium (DMEM) 
solution (glucose 1g/ml) was prepared with 4% albumin. Collagenase solution was made up 
by adding 1mg/ml of collagenase to the DMEM solution with 4% albumin. Wash buffer 
solution was prepared with trypsin inhibitor 1mg/ml of 4% albumin DMEM solution. The 
tissue was rinsed in DMEM solution 4% albumin and then added to a bijou tube along with 
1ml of prepared collagenase solution per 0.5g of tissue. The tissue was finely minced with 
scissors and kept in a vibrating water bath at 140cycles/min and 37°C for 75-90 minutes. 
The cell suspension was then filtered through a polypropylene mesh (250μm) in order to 
separate the adipocytes from undigested tissue into a clean bijou tube. To stop any further 
digestion separated adipocytes were washed thoroughly with wash buffer. The tube was left 
out of the water bath till a cell suspension was formed. Then using a blunt needle, the wash 
buffer was sucked up from underneath the cells. More wash buffer was added to the tubes 
and left until the cell suspension was formed again. 
After the second wash, the wash buffer was removed and the cells were transferred to a 
universal tube. 5mls of DMEM solution (glucose 1g/ml) with 4% albumin was added to the 
universal tube and this was left in the water bath at 120 cycles/min and 37°C for 30-60 
minutes. 
The adipocytes were then sized using Multisizer™ 4 COULTER COUNTER® (Beckman 
Coulter, USA). 
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3.4.1.3.8 Serum Analysis 
Blood collected from animals was treated in two ways. Blood from half of the animals was 
treated with 10% Aprotinin (100000KIU) at the collection time, allowed to clot on a rocker for 
at least 30 minutes and then centrifuged at 4000rpm for 10 minutes. Serum was removed 
and kept at -800C until used. These samples were used for analysis of creatinin, ALT, AST, 
alkaline phosphate, cholesterol, triglycerides, HDL and LDL, albumin, free fatty acids, beta 
hydroxy butyrate, ghrelin, GLP-1 and adiponectin. Ghrelin, total GLP-1 and adiponectin were 
measured using 2-site electrochemical luminescence immunoassays from MesoScale 
Discovery (Gaithersburg, Maryland, USA). Free fatty acids were measured using the Non-
Esterified Free Fatty Acid kit (Roche). 3-OH butyrate was measured using a Liquicolour Beta 
Hydroxybutyrate kit (Stanbio, Texas, USA). Creatinine, ALT, AST, alkaline phosphate, 
triglyceride, HDL and cholesterol were measured on the Dimension RXL autoanalyser 
(Siemens Healthcare). LDL was calculated from the cholesterol, HDL and triglyceride results 
using the Friedwald formula. 
The other half of the blood samples collected were treated with 10 µl DPPIV inhibitor (for 
GLP-1 measurement), 10 µl of Protease Inhibitor cocktail (for Amylin measurement), and 
100 µl of Serine protease inhibitor (for active ghrelin measurement) at the time of collection 
and were allowed to clot for at least 30 minutes. They were then centrifuged at 4000rpm for 
10 minutes and serum was removed and stored at -800C. The Mouse Metabolic Assay 
(Millipore) was carried and concentrations of C-Peptide, ghrelin, GIP, GLP-1, interleukin-6, 
glucagon, insulin, leptin, MCP-1, PP, PYY, resistin and TNF-α were measured by Millipore 
MAGPIX (Millipore, UK). 
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3.4.1.3.9 Liver Histology 
Two sections were cut from the large lobe of the livers extracted from the animals. One 
section was frozen in dry ice and kept at -800C until Oil Red O staining was performed. 
The other section of the liver was placed in 10% formalin solution (Sigma). They were then 
paraffin waxed, sectioned and H&E stained. H&E staining was carried out as follow: 
1. Sections were taken to water 
2. Stained in Harris's haematoxylin for 10 minutes 
3. Washed in tap water 
4. Differentiated in 1% acid alcohol for 10 seconds controlling microscopically 
5. Washed in water 
6. Blued in Scott's tap water substitute for 30 seconds 
7. Washed in tap water. 
8. Stained in 1% eosin for 5 minutes. 
9. Washed to differentiate in water for a few seconds. 
10. Dehydrated, cleared and mounted 
Oil Red O staining was carried as follow: 
1. 2 slices were cut from the frozen liver section. 
2. Fixed in 10% formal calcium. 
3. Washed in water. 
4. Rinsed in 60% T.E.P. (triethyl phosphate). 
5. Stained in filtered oil red O for 10-15 minutes. 
6. Rinsed in 60% T.E.P. 
7. Rinsed in water. 
8. Nuclei were stained with Mayer‟s haematoxylin for 1 minute.  
9. Blued in tap water. 
10. Mounted in aqueous mountant (glycerin jelly). 
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3.4.1.4 Statistical Analysis 
All results are shown as mean±SEM. GEE analysis was carried on time line graphs. 1-way, 
2-way ANOVA, unpaired t-test or unpaired t-test with Welch‟s correction were used to 
analyse data where appropriate. 
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3.4.2 Results 
3.4.2.1 Liposome Formulation and Formation 
The prepared liposomes were sized using Zetasizer Nano (Malvern, UK). Figure 3.31 shows 
typical size distribution examples of (a) hepes and (b) acetate encapsulated liposomes. The 
average size of hepes encapsulated liposomes was 95.85±8.9 nm and the average size of 
acetate encapsulated liposomes were 102.3±7.54 nm with coefficient of variation 20.76% 
and 23.30% for each respectively (p=0.6). 
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Figure 3.31. Hepes and acetate encapsulated liposomes sized after preparation. 
The size distribution graphs of hepes (a) and acetate (b) encapsulated liposomes. x-axis is 
the size in nm and y-axis represents number in %. The z-average size of hepes 
encapsulated liposomes were 82.13 nm (PDI: 0.175) and the z-average size of acetate 
encapsulated liposomes were 159.7 nm (PDI: 0.475). 
a 
b 
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3.4.2.1.1 Acetate Encapsulation 
To show that acetate is indeed encapsulated within the liposomes a binding experiment was 
designed and implemented. Acetate is known to interact with a number of proteins, including 
albumin, which would make it NMR “invisible”. Thus, liposomes were prepared and analysed 
using NMR spectroscopy in the presence or absence of increasing concentrations of 
albumin. Two different amounts of albumin (2g and 4g) were added to liposome 
encapsulated acetate solution and scanned (figure 3.32.) before and after the addition of the 
protein. The 1H NMR peak arising from acetate can be normally observed at 2.03ppm. 
Addition of albumin had no significant effects on the signal intensity arising from acetate. 
However, when the same experiment was repeated with a solution containing similar 
concentration of free acetate (no liposomal particle present), the NMR signal from acetate 
was completed suppressed, demonstrating that it had “interacted” (bound) to the albumin 
macrostructure and thus become NMR invisible (Figure 3.33). Thus, the fact that in the 
former experiment albumin had no effect on the NMR signal from acetate, clearly indicates 
that the acetate molecules must be within the liposomal structure and unavailable to interact 
with this protein. 
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Figure 3.32. 1H NMR spectra of acetate encapsulated liposomes with added albumin. 
1H NMR spectra of acetate encapsulated liposomes with added albumin (~2g) (a) and same 
liposomes with more albumin (~2g more, therefore ~4g in total) (b) is shown. 0ppm is 
trimethylsilyl propionate (TSP) which is used as a reference and 2ppm is the peak for 
acetate. The green boxes on each spectrum are expanded parts of the whole spectra from 
4.5 to -0.5 ppm. 
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Figure 3.33. 1H NMR spectra of acetate with added albumin. 
1H NMR spectra of acetate only (a) and acetate with added albumin (b) is shown. 2ppm is 
the peak for acetate. The green boxes on each spectrum are the expanded parts of the 
whole spectra from 4.5 to -0.5 pmm. 
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3.4.2.1.2 Concentration of Encapsulated Acetate 
To determine the actual concentration of acetate encapsulated within the liposomes 
nanoparticles, a liposomes formulation containing acetate was prepared and immediately 
freeze-dried (in order to release the encapsulated acetate) and re-disolved in a solution 
containing a known concentration of lactate, which served as a standard for quantitation 
(5.2mg of sodium lactate was added to 200µl of liposomes). 1H-NMR spectra of the 
subsequent solution were then obtained. Figure 3.34 shows 1H spectra of freeze dried 
acetate-liposomes formulation with: (a) no added lactate and (b) acetate with added lactate 
(b). The lactate peak is at 1.3ppm and the acetate peak is at 2ppm. Integrating the acetate 
peak in reference to the lactate (figure 3.35), the acetate concentration is 1.9 percent that of 
lactate. From the known amount of lactate, the concentration of acetate in 200µl was found 
to be 52.9µg (4.41mM). Since 1 ml of liposomes formulation is known to contain 1011 
nanoparticles (personal communications with Prof. A Miller). Each liposomal particle 
contains 4.41×10−14mmol of acetate. 
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Figure 3.34. 1H NMR spectra of acetate liposomes with and without added lactate. 
1H NMR spectra of freeze dried acetate encapsulated liposomes without added lactate (a) 
and with added lactate (b) are shown. Peak at zero is the reference peak, peak at 1.3ppm is 
lactate and peak at 2ppm is acetate. 
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Figure 3.35. 1H NMR spectrum of acetate liposomes with added lactate. 
1H NMR spectra of  freeze dried acetate encapsulated liposomes with added lactate (5.2mg)  
Peak at zero is the reference peak, peak at 1.3ppm is lactate and peak at 2ppm is acetate. 
Values underneath the peaks (in red) are the integrals of the peaks, acetate is integrated in 
reference to lactate. 
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3.4.2.2 Liposome Delivery 
To track the bio-distribution of the liposomal particles, two different imaging methods were 
employed.  Fluorescence liposomes prepared with rhodamine lipid were used to investigate 
their biodistribution ex-vivo. Liposomal formulation was also prepared using a gadolinium-
lipid, previously used by our group as a MRI a contrast agent, in order to image delivery of 
liposome to tissues in vivo. 
 
3.4.2.2.1 Rhodamine Liposomes and Histology 
Biodistribution of liposomes were investigated ex-vivo.  For the liposomes to be visible with 
microscopy, rhodamine was placed in the lipid bilayer of during formulation. Distribution of 
liposomes in different tissues with varying concentrations of acetate encapsulated in 
liposomes and with different administration routes (i.v. and i.p.) were investigated. The 
results are shown in the table 3.6. 
 
Organs 
Control 1mM 10mM 1M 
i.v. i.p. iv i.p. i.v. i.p. i.v. i.p. 
Liver         
Spleen         
Kidneys         
Heart -     - -  
Lungs -        
 
Table 3.6. Histology 2 hours after injection of liposomes. 
The table shows in which tissue samples liposomes were observed by histology, 2 hours 
after their administration.  4 different acetate concentrations were used and liposomes were 
administered either i.v. or i.p. Liver, spleen, kidneys, heart and lungs were investigated. 
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For all concentrations and injection methods, no adverse effects were observed on the 
animals. The highest concentration of liposomes was observed in the spleen and liver. Much 
lower concentrations were observed in the kidneys, brain and heart. No detectable signal 
from liposome was observed in skeletal muscle and lungs. Some example images are 
shown in the figures 3.36-3.40. In the top image of each figure liposomes appear in red due 
to the fluorescent rhodamine lipid. The second image serves as a control, obtained through 
a filter with different wavelength. In the bottom image any cell present in the slide can be 
observed. 
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Figure 3.36. Histology images of spleen. 
Images obtained from the spleen of an animal which received i.v. liposomes (prepared with 
10mM acetate) are shown. In (a) liposomes are seen in red because of the fluorescent 
rhodamine lipid. (b) is a control image. (c) shows the cells present in the slide.  
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Figure 3.37. Histology images of liver. 
Images obtained from the liver of an animal which received i.p. liposomes (prepared with 1M 
acetate) are shown. In (a) liposomes are seen in red because of the fluorescent rhodamine 
lipid. (b) is a control image. (c) shows the cells present in the slide. 
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Figure 3.38. Histology images of lung. 
Images obtained from the lungs of an animal which received i.p. liposomes (prepared with 
1mM acetate) are shown. In (a) liposomes are seen in red because of the fluorescent 
rhodamine lipid. (b) is a control image. (c) shows the cells present in the slide.  
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Figure 3.39. Histology images of heart. 
Images obtained from the heart of an animal which received i.p. liposomes (prepared with 
1M acetate) are shown. In (a) liposomes are seen in red because of the fluorescent 
rhodamine lipid. (b) is a control image. (c) shows the cells present in the slide.  
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Figure 3.40. Histology images of kidneys. 
Images obtained from the kidneys of an animal which received i.p. liposomes (prepared with 
10mM acetate) are shown. In (a) liposomes are seen in red because of the fluorescent 
rhodamine lipid. (b) is a control image. (c) shows the cells present in the slide. 
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In the second histological study, animals were assessed at different time points to 
understand the time course of liposome delivery. Animals were dissected at 16, 24 and 48 
hours after the injection (i.p.) of liposomes. Table 3.7 shows where and at which time points 
liposomes were observed. In addition to the organs examined in the previous study, brain, 
muscle and pancreas samples were also investigated. As in the first histology study, 
liposomes were found in liver, spleen and kidneys. They were also found in the brain and 
pancreas. It was difficult to detect any liposomes in the heart, lungs and muscle. 
 
          Organ 
Time 
Liver Spleen Kidneys Lungs Heart Brain Muscle Pancreas 
16h    -   -  
24h    - -  -  
48h   - - -  - - 
 
Table 3.7. Histology at different time points after liposome injection. 
Table shows the times at which liposomes were observed at different tissues after its 
administration. Liver, spleen, kidneys, lungs, heart, brain, muscle and pancreas were 
investigated, 16, 24 and 48 hours after the i.p. injection of acetate encapsulated liposomes. 
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3.4.2.2.2 Gd Liposomes and T1 Measurements 
This experiment was carried out to assess liposome delivery to tissues in vivo. Two sets of 
liposomes were prepared and administered, with and without Gd lipid. Gd is an MR contrast 
agent, which when taken up by a tissue decreases the T1 time of the water within that tissue 
and it was placed in the lipid bilayer during preparation of the liposomes. 
The organs investigated were; liver (a), fat (b), brain (c) and kidneys (d) and results are 
shown in the figure 3.41. In the liver T1 at 24 and 48 hours after the administration of Gd 
liposomes was significantly decreased (495.90±37.36 and 502.80±65.89 msec, respectively) 
compared with the T1 pre-administration (807.80±76.59msec, p<0.05). Also at 24h the T1 
values of the liver from mice administered with Gd-liposomes were significantly different from 
mice administered control liposomes (804.10±81.81msec, p: <0.05). 
For the other tissues analysed no changes were observed in the T1 value. T1 of fat before 
liposomes were injected was similar for Gd and control liposomes (432.30±16.61 and 
446.20±36.09 msec, respectively). Administration of Gd liposomes did not change the T1 
value of fat tissue 2, 16, 24 and 48 hours after administration (422.00±32.26, 442.90±17.32, 
451.90±38.55 and 454.90±38.75 msec, respectively). T1 values of the hypothalamus were 
similar pre-injection of Gd and liposomes without Gd (905.70±49.12 and 941.00±69.98 
msec, respectively) and these were not reduced following injection of Gd liposomes 2, 16, 24 
and 48 hours after administration of Gd liposomes (886.60±68.42, 884.80±77.33, 
860.40±44.04 and 890.10±98.50, respectively). T1 values of kidney for Gd and liposome 
without Gd groups were 796.50±52.88 and 902.60±106.60 msec pre-injection and 2, 16, 24 
and 48 hours post-administration of the Gd liposomes T1 values were 873.50±86.73, 
884.20±37.69, 814.40±78.34 and 930.00±136.00 msec, respectively.  
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Figure 3.41. T1 measurements at different time points after administration of Gd or 
liposomes without Gd. 
Graphs show the T1 values of liver (a), fat (b), brain (c) and kidney (d) in animals injected 
with Gd liposomes or liposomes without Gd lipid. x-axis shows the time points T1 values 
were measured at which were; before liposome injection, 2, 16, 24 and 48 hours after the i.p. 
injection of liposomes. Results are displayed as mean±SEM. 1-way ANOVA was used to 
analyze T1 change over time for Gd or no Gd treatments. T-test was used to compare T1 
values at each time point for Gd and no Gd. N=4 for both groups, *: p<0.05. 
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3.4.2.3 Chronic Administration of Acetate-Liposomes to a Murine Model Fed on 
Normal Fat Diet 
Following the testing of the efficacy of the liposomal formulation and its delivery to the target 
organs, a study was performed to investigate if chronic administration of liposomes (non-
acetate containing nanoparticles) cause adverse effects on mice and to assess the 
metabolic effects of liposome delivered acetate on liver metabolism on mice on normal fat 
diet.  
 
3.4.2.3.1 Food Intake 
During the 3 weeks of treatment, food intake and body weights of the animals were 
measured. Figure 3.42 shows average daily food intake per week. Before treatment average 
daily food intake for control animals was 13.84±0.43g and for acetate animals 14.90±1.42g. 
During week 1 of the treatment, daily food intake was 12.64±0.43g and 13.50±0.99g for 
control and acetate treated animals, respectively. During week 2, it was 12.26±0.38g and 
13.45±0.82g and during the 3rd week 13.03±1.16g and 13.54±0.96g for control and acetate 
treated animals, respectively. No significant difference was observed between the groups. 
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Figure 3.42. Average daily food intake per mouse per week. 
Average daily food intake (g) is shown until the end of 3rd week of acetate and control 
treated animals. Acetate animals received acetate encapsulated liposomes 3 times per week 
and control animals received hepes encapsulated liposomes. Data analysed with 2-way 
ANOVA which revealed no difference (n=12/group). 
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3.4.2.3.2 Weight Gain 
Cumulative weight gain of the animals is shown in figure 3.43. There was no significant 
difference between acetate and the control group (p>0.05). 
 
Be
fo
re
 tr
ea
tm
en
t
1s
t w
ee
k
2n
d w
ee
k
3r
d w
ee
k
2
3
4
5
Acetate
Control
W
e
ig
h
t 
g
a
in
 (
g
)
 
Figure 3.43. Cumulative weight gain of animals before and during the treatment 
duration. 
Weight gain (g) of animals from 1 week before till the end of 3rd week of treatment period is 
shown. Black line is control (hepes liposomes injected) animals and green line is acetate 
(acetate liposomes injected) animals. GEE analysis was carried on data which revealed no 
difference, n=12/group. 
 
 
 
 
 
 
 
188 
 
3.4.2.3.3 Body Composition 
3.4.2.3.3.1 Body Fat 
The effect of liposome delivered acetate on whole body adiposity was determined by in vivo 
MRS. 
Whole body adiposities of control and acetate treated animals were similar both before and 
after treatment (figure 3.44). Before treatment, whole body adiposity relative to water content 
was 0.0776±0.0071 and 0.0864±0.0054 for control and acetate treated groups, respectively. 
Following treatment the whole body adiposity increased to 0.1421±0.0120 for control 
liposome and 0.1420±0.0188 for the acetate liposome treated group. 
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Figure 3.44. Whole body adiposity before and after the treatment. 
Whole body adiposity of control and acetate animals is shown in the graph. y-axis represents 
the whole body lipid content in reference to water. Unpaired t-test was carried out on data to 
compare control and acetate groups, before treatment and after treatment. N=11/12 per 
group. 
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At the end of the study, different organs and tissue were collected. Figure 3.45.a shows total 
white adipose tissue which was calculated by summing subcutaneous, epididymal, 
retroperitoneal and mesenteric adipose tissues, for the control (1.50±0.05g) and acetate 
(1.36±0.07g) treated animals (p=0.12). Figure 3.45.b shows the weight of adipose tissue 
depots including, subcutaneous (0.63±0.03 and 0.61±0.04 g for control and acetate 
respectively, p=0.61), epididymal (0.52±0.03 and 0.45±0.03 g for control and acetate 
respectively, p=0.09), retroperitoneal (0.15±0.01 and 0.13±0.01 g for control and acetate 
respectively, p=0.12), mesenteric (0.19±0.004 and 0.16±0.01 g for control and acetate 
respectively, p=0.05) and BAT (0.14±0.01 and 0.14±0.01 g for control and acetate 
respectively, p=0.68). Total internal fat which was calculated by adding epididymal, 
retroperitoneal and mesenteric fat masses was significantly reduced in acetate liposome 
treated animals compared with control animals (p=0.04) and it was 0.87±0.03 and 0.75±0.04 
for control and acetate liposome treated animals, respectively (c). (d) on figure 3.45 shows 
the ratio of internal and subcutaneous fat which was 1.38±0.07 and 1.26±0.07 for control 
and acetate liposome treated animals respectively. No significant difference was observed 
on this ratio (p=0.24). 
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Figure 3.45. Weight of fat depots dissected. 
Animals were dissected at the end of the study and different fat depots were weighed. White 
adipose tissue depots (subcutaneous, epididymal, retroperitoneal and mesenteric) were 
summed and are shown for the control and acetate treated animals on graph (a). Weights of 
subcutaneous, epididymal, retroperitoneal, mesenteric and BAT are shown on graph (b). 
Total internal fat is shown together with subcutaneous fat on (c). (d) shows the ratio of 
internal to subcutaneous fat. Data are shown as mean±SEM, unpaired t-test was used was 
to compare all data except for mesenteric fat which was compared with unpaired t-test with 
Welch‟s correction. N=11/12 per group, *: p<0.05 
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The whole body adiposity measured by MRS and total white fat calculated by the sum of 
subcutaneous, epididymal, retroperitoneal and mesenteric fat depots is significantly 
correlated (p=0.01) shown in figure 3.46.  
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Figure 3.46. Correlation of fat measured by dissection and MRS. 
Total fat mass dissected from animals were correlated with the % whole body adiposity 
measured by 1H-MRS. This correlation was significant with a p value of 0.01 and pearson r 
value 0.52. 
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Results from the adipocyte isolation from control and acetate treated animals are shown in 
figure 3.47. The mean number of cells (a), mean number of cells per ml (b), mean volume of 
cells (c) and mean surface area of cells (d) are shown. Although there was no significant 
difference, there is a trend that acetate treated animals have a smaller number of cells in 
epididymal fat (1054±112.4 and 776.9±144.1 control vs. acetate treated groups, 
respectively; p=0.17) and a greater number of cells in subcutaneous fat depots than control 
animals (976.3±128.3 and 1189±238.1 control and acetate treated groups, respectively; 
p=0.48).  
Epididimal Subcutaneous
0
500
1000
1500
Control
Acetate
a
Adipose tissue
N
u
m
b
e
r
Epididimal Subcutaneous
0
1100 5
2100 5
3100 5
Control
Acetate
b
Adipose tissue
N
u
m
b
e
r/
m
l
Epididimal Subcutaneous
0
1.0107
2.0107
3.0107
4.0107
5.0107
6.0107
7.0107
8.0107
9.0107
1.0108
1.1108
Control
Acetate
c
Adipose tissue
V
o
lu
m
e
 (

m
3
)
Epididimal Subcutaneous
0
1.0106
2.0106
3.0106
4.0106
5.0106
6.0106
7.0106
8.0106
9.0106
1.0107
1.1107
Control
Acetate
d
Adipose tissue
S
u
rf
a
c
e
 A
re
a
 (

m
2
)
n=10/group
 
Figure 3.47. Adipocyte isolation. 
Adipocytes were isolated from epididymal and subcutaneous fat depots. Mean number (a), 
number per ml (b), volume (c) and surface area (d) are displayed. Data are shown as 
mean±SEM. Unpaired t-test was used for comparisons. N=10/group. 
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3.4.2.3.3.2 Liver Fat 
The effect of liposome delivered acetate on liver morphology was investigated using H&E 
and Oil Red O staining. 
H&E staining showed that both treated and control animals had normal liver architecture, 
normal portal tracts and no parenchymal inflammation. Acetate treated animals had minimal 
cytoplasmic microvacuolation whereas half of the control animals had midzonal cytoplasmic 
microvacuolation. Animals in both groups showed no macro-vesicular change. Typical 
examples are shown in figure 3.48.  
  
Figure 3.48. H&E stained liver samples. 
H&E stained liver slides with 20 times magnification for control (a) and acetate treated 
animals (b) are shown. 
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Oil Red O staining showed that, animals treated with acetate had fewer and smaller 
cytoplasmic globules in cells. Typical examples are shown on figure 3.49. 
 
 
Figure 3.49. ORO stained liver samples. 
Oil red O stained samples with 40 times magnification shown for control (a) and acetate (b) 
treated animals. 
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No significant difference between groups was observed in liver fat concentrations (IHCL) at 
baseline (0.0535±0.0106 and 0.0779±0.0106 for control and acetate groups respectively, 
figure 3.50a). At the end of the treatment, the acetate group had lower liver lipid content 
although this did not reach significance (0.1023±0.0138 vs. 0.0662±0.0232, respectively; 
p=0.2). When change in IHCL during the treatment period was calculated, the acetate 
treated group showed a decrease whereas the control showed an increase in IHCL 
(0.0487±0.0147 and -0.0118±0.0240, respectively; p<0.05) (figure 3.50.b). 
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Figure 3.50. Liver lipid content and change in liver lipid content. 
Liver lipid content before the start of the experiment for control and acetate groups are 
shown in graph (a). Lipid content of liver in reference to water content of liver is the y-axis. 
Graph (b) shows change in IHCL during the treatment for control and acetate animals 
(calculated from data on (a)). N=11/12 per group, unpaired t-test was carried on liver 
adiposity before treatment, after treatment and change in adiposity, *:p<0.05 
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3.4.2.3.4 Metabolism 
A glucose tolerance test carried out in the 4th week of treatment showed no differences 
between the control and acetate groups. Figure 3.51.a shows blood glucose concentrations 
at time points measured and figure 3.51.b shows the area under the curve for each time 
curve. 
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Figure 3.51. Glucose tolerance test results. 
Fasted animals were injected (i.p.) with glucose and blood glucose concentrations (mmol/L, 
y-axis) were measured before the injection, 15, 30, 60 and 120 minutes after injection. Black 
line represents control animals and the green line represents the acetate animals (a). (b) 
shows area under curve calculate from (a) for control and acetate graphs. GEE analysis was 
carried on blood glucose concentrations and AUC was compared with unpaired t-test. 
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The analysed serum samples (collected at the end of the study) showed a significant 
reduction in triglyceride concentrations of acetate treated animals (0.80±0.04 mmol/L) 
compared with controls (1.03±0.11 mmol/L, p=0.05). There were no differences in total 
cholesterol and HDL, see figure 3.52.a. No change was observed in FFA, 3-OH butyrate and 
creatinine in figure 3.52.b. Adiponectin concentrations were not affected by acetate 
treatment either. ALT, AST and alkaline phosphate although not significant showed a trend 
for decreased concentrations in acetate liposome treated animals (figure 3.52.d). The results 
are summarized in table 3.8. 
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Figure 3.52. Serum analysis results.  
On the serum samples collected at the end of the study the concentration of cholesterol, 
triglycerides, HDL and LDL (shown on (a)), free fatty acids, 3-OH Butyrate, creatinine 
(shown on (b)), adiponectin (shown on (c)) and ALT, AST and alkaline phosphate (shown on 
(d)) were tested. Data was analysed with unpaired t-test except cholesterol and HDL data 
which are analysed with unpaired t-test with Welch‟s correction. N=4 for control animals and 
n=6 for acetate animals. *: p<0.05. 
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Serum samples from animals were also used to investigate mouse metabolic markers of 
obesity. Serum concentration of leptin (p<0.05) was reduced in acetate treated animals 
compared with controls. For control and acetate liposome treated animals serum 
concentrations of C-peptide, ghrelin, GIP, IL-6, insulin, MCP-1 and resistin were not changed 
significantly (See figure 3.53). Serum concentrations of amylin, GLP-1, glucagon, PP and 
TNF-α could not be obtained. The results are summarized in table 3.8. 
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Figure 3.53. Serum analysis results. 
Second set of serum samples were used in measurement of concentrations (pg/ml) of c-
peptide, ghrelin, GIP, interleukin-6, insulin, leptin, MCP-1, PYY and resistin. Data 
represented as mean± standard error. Statistical analysis was carried out with unpaired t-
test. N=6/group, *: p<0.05. 
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 Control 
(Mean±SEM) 
Acetate 
(Mean±SEM) 
P 
value 
Cholesterol (mmol/L) 2.78±0.22 3.03±0.05 0.34 
Triglycerides (mmol/L) 0.80±0.04 1.03±0.11 0.05 
HDL (mmol/L) 1.60±0.13 1.77±0.01 0.24 
LDL (mmol/L) 0.83±0.08 0.78±0.06 0.62 
FFA (µmol/L) 800.00±12.42 820.20±36.20 0.72 
3-OH But. (µmol/L) 268.30±41.44 318.4±40.62 0.42 
Creatinine (µmol/L) 25.25±1.49 24.40±2.16 0.77 
Adiponectin (ng/ml) 13710.00±831.5 12940.00±988.2 0.59 
ALT (U/L) 34.00±6.46 27.20±2.87 0.33 
AST (U/L) 127.00±28.00 105.00±19.99 0.54 
Alk. Phos. (U/L) 83.00±4.02 78.17±3.55 0.40 
C-Peptide (pg/ml) 808.30±241.90 831.60±119.90 0.93 
GIP (pg/ml) 19.84±2.33 14.87±3.83 0.29 
Insulin (pg/ml) 349.60±94.22 244.00±96.90 0.45 
Ghrelin (pg/ml) 11.79±4.84 23.59±8.14 0.24 
PYY (pg/ml) 111.90±15.92 48.21±4.16 0.06 
Leptin (pg/ml) 2214±324.30 1398±193.80 0.05 
Resistin (pg/ml) 5496±1106 5664±711.40 0.90 
Inteleukin-6 (pg/ml) 31.76±8.91 32.03±8.55 0.98 
MCP-1 (pg/ml) 20.97±6.30 26.16±6.61 0.59 
Table 3.8. Serum analysis results. 
Results obtained for control and acetate liposome treated groups are summarized in the 
table. Data shown as mean±SEM. T-tests were carried out to compare the two groups, p 
values given. 
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3.4.2.4 Chronic Administration of Acetate-Liposomes to a High Fat Diet Fed Murine 
Model 
The aim of this study was to assess the metabolic effects of liposome delivered acetate on 
liver metabolism on mice on high fat diet.  
 
3.4.2.4.1 Food Intake 
During 3 weeks of the treatment, food intake and body weights of the animals were 
measured. Figure 3.54 shows the average daily food intake by week. Before treatment the 
average daily food intake was 11.92±0.35g and 11.88±0.31g for control and acetate treated 
animals, respectively. During week 1 of the treatment, daily food intake was 10.33±0.16g 
and 10.35±0.20g for control and acetate treated animals. During the 2nd week, it was 
8.74±0.08g and 8.91±0.41g and during the 3rd week it was 9.25±0.15g and 8.99±0.41g for 
control and acetate treated animals. No significant difference was observed between the 
groups. 
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Figure 3.54. Average daily food intake of high fat fed animals. 
Average daily food intake (g) is shown until the end of 3rd week of acetate and control 
treated animals on high fat diet. Acetate animals received acetate encapsulated liposomes 3 
times per week and control animals received hepes encapsulated liposomes. Data analysed 
with 2-way ANOVA which revealed no differences, n=12/group. 
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3.4.2.4.2 Weight Gain 
The cumulative weight gain of animals is shown in figure 3.55.a. There was no significant 
difference between the control and acetate groups. But when overall weight gain during the 
treatment period was investigated (b), the acetate treated group (2.12±0.18 g) was 
significantly lower than the control group (2.96±0.31 g, p=0.024). 
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Figure 3.55. Weight gain of high fat fed animals. 
Cumulative weight gain (g) of animals from 1 week before till the end of 3rd week of 
treatment period is shown on graph (a). The black line represents the control (hepes 
liposomes injected) animals and green line represents the acetate treated (acetate 
liposomes injected) animals. Graph (b) shows the overall weight gained during the treatment 
period of control and acetate animals. GEE analysis was carried on cumulative weight gain 
data, unpaired t-test was performed on overall weight gain data. n=12/group, *: p<0.05. 
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3.4.2.4.3 Body Composition 
3.4.2.4.3.1 Body Fat 
The effect of acetate liposome treatment on whole body adiposity was determined by in vivo 
MRS. Figure 3.56 shows the change in whole body adiposity relative to water content. The 
change in whole body adiposity of control and acetate treated animals were 0.29±0.03 and 
0.21±0.03 respectively, p=0.07. 
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Figure 3.56. Change in whole body adiposity of high fat fed animals. 
Whole body adiposity was measured before the start and at the end of the experiment. 
Change in whole body adiposity for control and acetate groups during the treatment are 
shown in graph. N=11/12 per group, unpaired t-test was carried on data, p values are shown 
on the graphs. 
 
 
The weight of total white fat dissected which is the sum of subcutaneous, epididymal, 
retroperitoneal and mesenteric fat was not different between the two groups (p=0.84) (figure 
3.57). The weight of subcutaneous fat was 1.42±0.12 and 1.32±0.08 grams, the weight of 
epididymal fat was 1.04±0.09 and 1.00±0.06 grams, the weight of retroperitoneal fat was 
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0.28±0.03 and 0.26±0.01grams, the weight of mesenteric fat was 0.31±0.03 and 0.28±0.01 
grams and the weight of BAT was 0.15±0.01 and 0.23±0.08 grams for control and acetate 
treated animals. Total internal fat was calculated by adding epididymal, retroperitoneal and 
mesenteric fat masses and it was 1.63±0.14 and 1.55±0.07 for control and acetate liposome 
treated animals (c). (d) on figure 3.57 shows the ratio of internal and subcutaneous fat which 
was 1.15±0.04 and 1.20±0.06 for control and acetate liposome treated animals respectively. 
No significant difference was observed on this ratio.     
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Figure 3.57. Mass of different fat depots dissected of high fat fed animals. 
Animals were dissected at the end of the study and different fat depots were weighed. 
Weights of total white adipose tissue (sum of subcutaneous, epididymal, retroperitoneal and 
mesenteric) are shown in (a). Weights of subcutaneous, epididymal, retroperitoneal, 
mesenteric and BAT are shown on (b). Total internal fat is shown together with 
subcutaneous fat on (c) and the ratio of internal fat to subcutaneous fat is shown on (d). 
Data are shown as mean±SEM, unpaired t-test was used was to compare all data. N=12 per 
group. 
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The whole body adiposity measured by MRS and total white fat calculated by the sum of 
subcutaneous, epididymal, retroperitoneal and mesenteric fat depots dissected is correlated 
with a p value of 0.004 (figure 3.58). 
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Figure 3.58. Correlation of fat measured by dissection and MRS. 
Total fat mass dissected from animals were correlated with the % whole body adiposity 
measured by 1H-MRS. This correlation was significant with a p value of 0.004 and pearson r 
value 0.57. 
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Results from the adipocyte isolation of the dissected fat depots of control and acetate treated 
animals are shown in figure 3.59. The mean number of cells (a), mean number of cells per 
ml (b), mean volume of cells (c) and mean surface area of cells (d), are shown. No 
difference was observed neither in the epididymal nor the subcutaneous fat cells between 
the two groups.  
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Figure 3.59. Isolated adipocytes for high fat study. 
Adipocytes were isolated from epididymal and subcutaneous fat depots. Mean number (a), 
number per ml (b), volume (c) and surface area (d) are displayed. Data are shown as 
mean±SEM. Unpaired t-test was used in comparisons of adipocytes of epididymal fat and 
unpaired t-test with Welch‟s correction was used in comparisons of adipocytes of 
subcutaneous fat. N=8/group. 
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3.4.2.4.3.2 Liver Fat 
The effects of acetate treatment on liver morphology were investigated using H&E and Oil 
Red O staining. Figure 3.60 shows the typical examples of H&E stained liver samples for 
control (a) and acetate (b) treated animals. Oil red O stained liver samples are shown on 
figure 3.61 for control (a) and acetate (b) treated animals. 
 
 
Figure 3.60. H&E stained liver samples of high fat fed animals. 
H&E stained liver slides with 20 times magnification for control (a) and acetate (b) treated 
animals are shown. 
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Figure 3.61. Oil red O stained liver samples of high fat fed animals. 
Oil red O stained liver slides with 20 times magnification for control (a) and acetate (b) 
treated animals are shown. 
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Change in liver fat content during the treatment was assessed by in vivo MRS (Figure 3.62). 
Change in liver lipid content of control and acetate treated animals were 0.01±0.01 and 
−0.03±0.02 respectively (p=0.06). 
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Figure 3.62. Change in liver lipid content of high fat fed animals. 
IHCL was measured before the start and at the end of the experiment. Change in IHCL for 
control and acetate groups are shown in graph. N=11/12 per group, unpaired t-test was 
carried on data, p value is shown on the graphs. 
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3.4.2.4.4 Metabolism 
The results of the glucose tolerance test that was carried out during the 4th week of 
treatment are shown in figure 3.63, showing blood glucose concentrations at the time points 
measured (a) and the area under the curve for each time curve (b). Blood glucose 
concentrations analysed with GEE analysis showed borderline difference between the 
control and acetate treated groups (p: 0.0687). The t-test carried out at each time point 
showed a significant difference at time zero, fasted glucose level, (p<0.05), and at 30 
minutes (p<0.05). The area under the curve showed no differences between the two groups, 
1984±164.7mmol/L/min and 2253±83.27mmol/L/min for control and acetate treated groups, 
respectively.  
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Figure 3.63. Glucose tolerance test results of high fat fed animals. 
Fasted animals were injected (i.p.) with glucose and blood glucose concentrations (mmol/L, 
in y-axis) were measured before the injection, 15, 30, 60 and 120 minutes after injection. 
The black line represents the control animals and the green line represents the acetate 
treated animals (a). (b) shows area under curve calculate from (a) for control and acetate 
graphs. GEE analysis was carried on blood glucose concentrations and AUC was compared 
with unpaired t-test. 
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Serum samples collected at the end of the study showed no difference of total cholesterol, 
triglyceride and HDL concentrations, see figure 3.64.a. No significant change was observed 
in creatinine but FFA had trend towards lower concentrations in acetate liposome treated 
animals compared with control animals (p=0.0597) and 3-OH butyrate level was significantly 
elevated in acetate liposome treated animals compared with control animals (p=0.04), figure 
3.64.b. Adiponectin concentrations were not affected by acetate treatment, figure 3.64.c.  
AST (p<0.01) and alkaline phosphate (p<0.02) were reduced significantly in acetate 
liposome treated group compared with control group. ALT concentrations were also 
decreased in acetate treated animals although this was not significant (p=0.22) (graph (d) on 
figure 3.64). The results are summarized in table 3.9. 
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Figure 3.64. Serum results of high fat fed animals. 
On the serum samples collected at the end of the study the concentration of cholesterol, 
triglycerides, HDL and LDL (shown on (a), n=11/group), free fatty acids, 3-OH Butyrate, 
creatinine (shown on (b), n=10/group), ALT, AST and alkaline phosphate (shown on (c), 
n=11/group) and adiponectin (shown on (d), n=6/group) were tested. Data are analysed with 
unpaired t-test or unpaired t-test with Welch‟s correction. *: p<0.05. 
 
 
The serum samples from animals were also used to investigate metabolic markers of 
obesity. Control and acetate liposome treated animals had serum concentrations of amylin 
and PP increased and C-peptide, GIP, glucagon and insulin reduced (not significant), shown 
in figure 3.65.a. Serum concentrations of the gut hormones ghrelin (p=0.13) and GLP-1 
(p=0.07) were reduced in acetate liposome treated animals and PYY concentration was not 
changed, figure 3.65.b. The concentrations of leptin and resistin were similar for control and 
acetate liposome treated animals (figure 3.65.c). The serum concentrations for IL-6 were 
(p=0.15) and TNF-α (p=0.2) had trend of reduced concentrations for acetate liposome 
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treated animals. MCP-1 concentrations were not affected, figure 3.65.d. The results are 
summarized in table 3.9. 
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Figure 3.65. Serum analysis of high fat fed animals. 
The second set of serum samples were used in measurement of concentrations (pg/ml) of 
amylin, c-peptide, ghrelin, GIP, GLP-1, glucagon, interleukin-6, insulin, leptin, MCP-1, PP, 
PYY, resistin and TNF-α. Data presented as mean±SEM. Statistical analysis was done with 
unpaired t-test. Unpaired t-test with Welch‟s correction was carried out on amylin and PP. 
N=6/group. 
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 Control  
(Mean±SEM) 
Acetate  
(Mean±SEM) 
P  
value 
Cholesterol (mmol/L) 4.54±0.23 4.36±0.31 0.66 
Triglycerides (mmol/L) 1.21±0.11 1.17±0.12 0.83 
HDL (mmol/L) 3.50±0.15 3.36±0.20 0.59 
LDL (mmol/L) 0.51±0.11 0.46±0.12 0.79 
FFA (µmol/L) 750.70±52.29 631.30±23.76 0.06 
3-OH But. (µmol/L) 179.0±10.74 285.80±44.71 0.04 
Creatinine (µmol/L) 17.82±1.54 18.86±2.37 0.70 
Adiponectin (ng/ml) 20940±1725 19490±2279 0.62 
ALT (U/L) 39.91±13.58 21.90±2.91 0.22 
AST (U/L) 175.4±19.16 106.10±9.83 0.01 
Alk. Phos. (U/L) 76.91±6.02 57.45±4.22 0.02 
Amylin (pg/ml) 37.83±0.87 47.90±6.49 0.20 
C-Peptide (pg/ml) 702.80±223.30 378.80±110.80 0.25 
GIP (pg/ml) 516.4±140.1 313±77.02 0.26 
Glucagon (pg/ml) 47.75±5.50 37.20±6.66 0.25 
Insulin (pg/ml) 338.70±101.90 170.30±48.07 0.17 
PP (pg/ml) 48.17±4.10 62.40±12.22 0.33 
Ghrelin (pg/ml) 59.08±9.24 40.30±4.87 0.13 
GLP-1 (pg/ml) 17.83±1.68 25±3.33 0.07 
PYY (pg/ml) 85.67±4.98 93.50±8.81 0.44 
Leptin (pg/ml) 3753±489 3535±345.60 0.73 
Resistin (pg/ml) 6034±768.70 5936±516.60 0.92 
Inteleukin-6 (pg/ml) 41.17±10.27 21.60±5.96 0.15 
MCP-1 (pg/ml) 19.50±3.25 18±5.59 0.81 
TNF-α (pg/ml) 18±2.45 14±1.14 0.20 
Table 3.9. Serum analysis results for high fat fed animals. 
Results obtained for control and acetate liposome treated groups are summarized in the 
table. Data shown as mean±SEM. T-tests were carried out to compare the two groups, p 
values given. 
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3.4.3 Discussion 
To provide continuous and targeted delivery of SCFA to the liver, acetate was encapsulated 
in liposomal nanoparticles. Liposomes are formed of lipid bilayers. The membrane of a 
liposome can be modified by different lipids used in formulation specific for their purpose. In 
this study, liposomes that are ~100nm were used with PEG and cholesterol lipid to increase 
their circulation in the body and reduce the possibility of being engulfed by macrophages. By 
using 13C NMR spectroscopy, it was shown that acetate is indeed encapsulated in the 
liposomes. This was achieved by the use of albumin. Albumin is a relatively large molecule 
that has been shown to bind anionic molecules, including acetate (Boyer et al., 1947). This 
binding causes a reduction in the NMR signal of the compound (Chatham and Forder, 1999). 
Addition of albumin to a liposome free acetate solution had a significant effect on the NMR 
signal intensity of the latter, reducing its presence in the spectra significantly. No such effect 
was observed with the liposomes encapsulated acetate solution. These data indicate that 
acetate is being encapsulated within the confines of the nanoparticle to which albumin does 
not have access. 
The concentration of acetate encapsulated in liposomes was determined using 1H NMR 
spectroscopy. A known amount of lactate was added to formed acetate encapsulated 
liposomes and freeze dried. By using the ratio between the lactate and acetate peak the 
concentration of acetate used in a single dose of treatment was calculated as 52.9µg/200µl.  
After the formation of liposomes was confirmed, histology and MRI T1 measurements were 
employed to demonstrate they reach the organ of interest. For histology rhodamine which is 
a fluorescent lipid was used. Liposomes were accumulated in liver and spleen more 
commonly than other organs investigated. For T1 measurements a gadolinium lipid (a lipid 
containing Gd, which is a paramagnetic ion that increases the signal in the tissue it is 
absorbed into) was used. Although histology has confirmed the presence of liposomes in 
organs such as brain and kidneys, T1 change was only observed in the liver. This is more 
probably related to lower accumulation of liposomes in these tissues compared with liver. A 
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significant T1 reduction was observed in the liver, 16 and 24 hours after the injection of Gd 
liposomes. Nazila et al have also seen T1 reduction in tumour 16 and 24 hours post injection 
of Gd liposomes  (Kamaly et al., 2007). 
After the formation of acetate liposomes and their ability to reach the organ of interest were 
demonstrated, these nanoparticles were used in two studies; one in normal mice and the 
other in combination with a high fat diet treatment. In both studies, animals were treated for 4 
weeks with either acetate or control liposomes, 3 times per week. During the course of the 
study, mice were fed with either a normal fat or high fat diet. During and after the 
experiment, animals underwent various procedures and tests to understand how effective 
acetate liposomes were in overcoming early signs of the metabolic syndrome.  
In both sets of experiments, chronic injections of liposomes did not seem to cause ant side 
effects and overall animal behaviour appeared normal. In normal fat fed animals, acetate 
and control liposome treated groups had no difference in weight, food intake and whole body 
adiposity at the end of the study. Acetate liposome treated animals showed reduced liver fat 
compared with control treated animals which displayed increased liver fat. Increased liver fat 
in control treated animals shows an age related increase and the reduction in liver fat of 
acetate liposome treated animals shows that this age related increase can be prevented by 
this treatment. Glucose tolerance tests gave similar results for both groups. The fat depots 
dissected were similar in amount and adipocytes isolated from the subcutaneous and 
epididymal fats were not significantly different. Tests done on serum samples revealed 
decreased triglyceride concentrations in acetate treated animals. Although serum markers of 
liver disease were not significantly different, they had a trend of being lower in acetate 
liposome treated animals. Leptin concentrations were reduced significantly and PYY had a 
trend towards reduction in acetate liposome treated animals. This suggests reduced appetite 
but was not observed in the study. The treatment was for 4 weeks, on a longer treatment 
period a reduced appetite might have been observed. 
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In a study involving acetic acid supplementation, Yamashita et al fed rats with normal diet for 
6 months. After the 5th week of the experiment they observed decreased food intake and 
body weight gain. The acetate treated group had lower serum concentrations of glucose, 
triglycerides, cholesterol, insulin and leptin (Yamashita et al., 2007). In this thesis the 
treatment period was only 4 weeks during which no differences were observed in body 
weight gain or food intake. Leptin and triglycerol concentrations were decreased 
significantly. This is most likely due to the duration of experiment. Since they observed 
weight differences after 5 weeks, it is possible that an incubation period is required before 
the effects of acetate supplementation can be seen. Decreased concentrations of 
triglycerides and lower lipid content in the liver, suggest increased fatty acid oxidation. 
Increased fat accumulation in the liver is implemented in the development of insulin 
resistance. Triglycerides concentrations in serum and the fat content of the liver were higher 
in control liposome injected animals, because they were fed with normal diet they are still 
lean animals. Any increased lipid level is likely due to age related reasons but at the end of 
this experiment the animals were 12 weeks old, at the end this is unlikely. Decreased liver 
lipid concentrations in the acetate treated group show an improved condition and suggest 
acetate treatment may be helpful in treatment or prevention of age related symptoms of 
metabolic syndrome. 
In the study where high fat diet fed animals were treated with acetate or hepes liposomes,  
animals did not have significant difference in food intake but overall weight gain during the 
treatment period was significantly lower in the acetate liposome treated animals. Change in 
whole body and liver adiposity had a strong trend towards a difference in the two groups; 
acetate liposome treated animals being lower than the control treated animals. Glucose 
tolerance tests did not show any significant differences but the blood glucose concentration 
of fasted animals was significantly different. The dissected fat masses were similar for the 
two groups and the average number and size of isolated adipocytes from epididymal and 
subcutaneous fat masses were similar as well. AST and alkaline phosphate concentration in 
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serum were significantly lower in acetate liposome treated animals and ALT had a trend of 
being lower in the acetate liposome treated animals compared with control animals. Serum 
concentration of lipids, ketones and free fatty acids were all similar. Also the serum 
concentration of inflammatory markers and hormones associated with metabolic syndrome 
were not different except from GLP-1 which had a trend towards an increased level in 
acetate liposome treated animals.  
When these results are compared with the previous studies done at our lab with fermentable 
carbohydrate inulin (Anastasovska et al., 2012) similarities such as reduced weight gain, 
whole body adiposity and liver fat content are observed with acetate treatment but the 
reduced food intake observed with inulin supplementation is not observed with acetate 
treatment. Reduced TG concentrations observed with inulin or oligofructose supplementation 
by others was not observed with acetate treatment (Cani et al., 2004, Kok et al., 1998). 
The results obtained with the high fat diet study in this thesis are similar to the results of 
Kondo et al (Kondo et al., 2009). They reported a decreased body weight in acetate 
treatment despite no difference in food intake. Their acetate treated groups had lower fat 
mass and there was no difference in triglyceride concentrations. In the high fat study of this 
thesis, there was no difference in food intake of control and acetate liposome treated groups 
but the acetate group put on less weight during the treatment period. Serum lipid 
concentrations were not different in the two groups. In this study, a change in fat mass was 
not observed but whole body and liver adiposity was lower after acetate treatment. Since 
with MRS all lipid molecules are observed, this might suggest fat in and around the tissues 
are decreased with acetate liposome treatment.  
In this thesis, serum level of 3-hydroxybutyrate was higher in the acetate treated group than 
the control (p=0.04) accompanied by a lower level of free fatty acids (p=0.0597) which 
suggests that fat oxidation was higher in acetate treated animals (Choi et al., 2007, Orellana-
Gavaldà et al., 2011). This is confirmed with the lower level of lipid by MRS in the same 
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group. Insulin concentrations in control animals had a trend of being higher than in acetate 
treated animals. Other studies have shown the relation between the insulin, fatty acid 
concentrations and fat mass (An et al., 2004). IL-6 and TNF-α had a trend toward decreased 
concentrations in acetate liposome treated animals which suggests reduced inflammation in 
the adipose tissue of these animals. Elevated concentrations of FFAs and inflammatory 
factors IL-6 (p=0.15) and TNF-α (p=0.2) are precursors of liver disease. 
This study also showed for the first time that serum markers of liver disease were lowered 
with acetate treatment. A study done with mice to investigate the effect of high fat diet and 
exercise on liver function found that only AST was influenced from both dieting and exercise, 
ALT was only influenced by exercising and alkaline phosphate only by dieting (Marques et 
al., 2010). In this thesis, only four weeks of treatment with acetate liposomes caused a 
significant reduction in AST and alkaline phosphate, and a trend for reduction in ALT.   
Although there were trends in the serum results obtained, most of them did not reach 
significance. Because of different tests done and the limited volume that can be obtained 
from each mouse not all tests could be carried out in every sample collected which had an 
effect on the n numbers. Increasing the number of animals might make these tests more 
significant. 
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CHAPTER 4. SUMMARY AND CONCLUSIONS 
4.1 Overall Conclusion and Discussion 
The increasing worldwide prevalence of obesity and its comorbidities, including insulin 
resistance, type II diabetes, CVD, NAFLD and cancer, is a growing concern. At the present 
time there is no public health solution to weight gain in adults.  A number of epidemiological 
studies have suggested that dietary fibre may play a role in prevention of weight gain 
(Besrastrollo, 2006, Liu et al., 2003).  Recent evidence from both animal (Cani et al., 2004, 
Kok et al., 1996) and human (Cani et al., 2006) studies have suggested that the fermentable 
component of dietary fibre may be responsible to limiting weight gain and having effects on 
body composition, such as reducing liver lipid content.  The hypothesis for this thesis was to 
assess the metabolic effect of the fermentable carbohydrates and specifically the SCFA 
acetate on energy homeostasis and lipid metabolism in the liver.  
To demonstrate the effects of fermentable products on body weight, appetite regulation and 
body composition the effects of inulin compared with a positive control of isomaltulose were 
investigated.  In previous studies the absorbable disaccharide isomaltulose has been shown 
to decrease body weight, lower whole body and liver lipid content and reduced plasma 
insulin and glucose concentrations (Fujiwara et al., 2007, Sato et al., 2007, Arai et al., 2004). 
The hypothesis was that inulin and isomaltulose would have similar effects on body weight 
but via different effect on central appetite regulation. Surprisingly the inulin diet did not show 
the predicted results of reducing the fat content of liver.  This is contrary to current published 
work of others and our own lab (Dewulf et al., 2011, Cani et al., 2004). Other people have 
also failed to observe this effect by fermentable carbohydrate supplementation (Isken et al., 
2009) and increased microbiota population (Bäckhed et al., 2004). Also some studies done 
with healthy man failed to show effects on lipid metabolism (Luo et al., 2000). Isken et al 
suggests that increased production of SCFAs by the gut microbiota may increase energy 
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availability. As SCFAs can be used as a fuel for cells (Yamashita et al., 2001), energy 
imbalance is formed promoting fat storage. Inulin has been shown to increase the population 
of beneficiary gut microbiota (Anastasovska et al., 2012) which ferments the indigestible 
fibre into SCFAs and other products . Studies by Bäckhed et al failed to observe any 
decrease in fat accumulation or weight gain by microbiota „implants‟. On the contrary they 
observed increase in fat accumulation. Animals with microbiota „implants‟ showed reduced 
food intake and higher metabolic rate compared with the control animals but their fat 
synthesis genes were more active together with LPL (Bäckhed et al., 2004). Although it is 
hard to explain, these contradictory results may arise from potential differences in 
constituents of the diets used. To explore this, the diet preference study was carried out 
which showed that the palatability of a diet plays an important role in its consumption. The 
palatability may have been affected by the sucrose in the diets. I hypothesise that the taste 
of diets is an important factor that can suppress the positive effects of dietary supplements, 
highlighting the fact that aspects of rodent diets outside of the nutritional content are 
important.  
Given the potential organoleptic effects of the diets in this study coupled with the consistent 
results from our group and others, that fermentable carbohydrates play a role in body weight, 
adiposity and liver fat, investigation of the effects of the SCFA acetate was carried out. The 
hypothesis tested was that the effects of fermentable carbohydrate such as inulin are caused 
by increased production of SCFAs therefore the third chapter focused on acetate, the SCFA 
produced in greatest concentration in the colon and which has the highest peripheral 
circulating concentration. The first step was to visualize the uptake of acetate in normal 
animals, which was carried out by using 11C labelled acetate and micro PET/CT scanner. 
Biodistribution in fasted animals showed that the liver was the most favoured organ after 
heart, in the uptake of acetate. The brain was also shown to take up to 3% of administered 
acetate which is similar to that observed in a human study (Song et al., 2009). Visualizing 
biodistribution in fed and fasted state is important as it is thought that there may be 
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differences due to acetate being used as a primary fuel in the fasted state (Yamashita et al., 
2001). No difference was observed in the tissues investigated due to feeding state. This 
needs further investigation as the potential effects of anaesthesia cannot be ruled out. 
Colonic administration of acetate, which gives a more physiological model, was also 
assessed. In this case significant differences in almost all tissues investigated were 
observed. There was a lag time of about 10 minutes when acetate is being taken up by the 
tissues. Lastly, to better understand the involvement of a receptor system in the distribution 
of acetate, unlabelled acetate was administered prior to labelled acetate. A very high dose of 
unlabelled acetate was used to potentially saturate GPR41/43 receptors. Injecting unlabelled 
acetate increased the uptake of labelled acetate by all tissues which I hypothesize to be a 
consequence of saturation of SCFA receptors, namely GPR41/43 receptors. Unlabelled 
acetate taken up by the receptors predominantly found in fat and also in muscle increased 
the amount of circulating labelled acetate and thus as a result its availability to be taken up 
by other tissues. This study is important as it shows that liver is the most favoured tissue for 
acetate uptake but that it is also taken up by tissues including brain, fat and muscle. It 
suggests the existence of peripheral “saturable” acetate receptors. This study may also 
benefit those using 11C-acetate as a tracer in tumour imaging, both in preclinical and clinical 
studies. Injecting unlabelled acetate as it saturates the receptors can reduce the amount of 
labelled acetate needed to be administered to subjects, which in return reduce overall cost 
and of course the dose administered to patients.  
To understand the metabolic fate of acetate taken up by the liver, 13C-acetate study was 
carried out. For this experiment, colonic administration of acetate was chosen it better 
mimics the in vivo availability of the SCFA following fermentable carbohydrate ingestion. 
Furthermore a physiological level of 13C labelled acetate was given to avoid potential 
confounding factors associated with pharmacological administration of the metabolite. In vivo 
NMR was used to study its metabolites. This study failed to give any conclusive evidence. 
No difference or pattern was observed in either the serum or liver tissue extracts. Other 
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groups have used pharmacological concentrations of acetate and observed changes in 
acetate metabolism (Chateil et al., 2001, Deelchand et al., 2009) but using the doses used in 
these studies would have caused unrealistic metabolic effects which would undermine the 
validity of any findings. 
To assess the potential beneficial effects of acetate on adiposity, a novel way of 
administering this SCFA to mice by means of a nanoparticle which carries large quantities of 
acetate was developed. The aim was to achieve targeted and prolonged delivery of acetate 
to the liver. I demonstrated that this novel delivery of acetate had positive effects on obesity 
and liver metabolism. Even in lean animals fed on control diet, liver adiposity was 
significantly decreased together with triglyceride and serum markers of liver disease. In 
animals fed a high fat diet, body weight and whole body adiposity was significantly reduced, 
liver adiposity, serum concentrations of free fatty acids and liver enzymes were also 
reduced. In addition, ketone concentrations were significantly increased; suggesting fatty 
acid oxidation was increased by acetate delivered by these nanoparticles.  
McGarry has hypothesized that the relationship between FA metabolism and insulin 
resistance is a two step process (McGarry, 2002). FFA coming to the liver through the blood 
stream is converted to fatty acyl-CoA by acyl-CoA synthetase. These then either converted 
into TG together with glycerol or combined with carnitine by CPT1 and through the action of 
carnitine translocase transferred into the mitochondria. In mitochondria acyl-CoA is formed 
back from acyl carnitine by CPT2 and enters into the TCA cycle. Citrate formed in the TCA 
cycle is transferred out of the mitochondria, converted into acetyl-CoA and this is then 
metabolised into malonyl-CoA by ACC, and then to fatty acid by FAS. Acyl-CoA synthetase 
turns fatty acids into fatty acyl-CoA which can be stored as TG or go into TCA cycle. When 
the level of malonyl-CoA increases as under high carbohydrate feeding, malonyl-CoA 
inhibits CPT1 which causes reduction in β-oxidation and increased concentrations of fatty 
acyl-CoA. This is the first step where the rate of β-oxidation is reduced. Increased level of 
fatty acyl CoA is hypothesised to be the reason for insulin resistance. Under normal 
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conditions insulin phosphorylates (insulin receptor) IRS1. IRS1 then activates 
phosphatidylinositol 3-kinase (PI3K) which translocates Glut2 receptor to move to the cell 
surface to get glucose into the cell. When fatty acyl CoA concentrations are high 
diacylglycerol is generated which activates protein kinase C (PCKθ). PCKθ phosphorylates 
IRS receptors decreasing cells sensitivity to insulin. In the second step very high 
concentrations of fatty acyl CoA induces β-oxidation by activating CPT1 (McGarry, 2002).  
My hypothesis is summarised in figure 4.1. When acetate delivered by liposomes reaches 
the liver, it is converted into acetyl CoA by ACS1 by using ATP. As a result AMP:ATP ratio 
increases and AMPK is phosphorylated. AMPK increases the activation of PPARα which 
activates CPT1 and ACO. CPT1 combines fatty acyl-CoA with carnitine. Thus step 1 of the 
process which causes increased level of fatty acyl-CoA in the liver, and subsequently results 
in insulin resistance, is therefore prevented. Fatty acyl-CoA concentrations never increase 
enough to cause insulin resistance and TG is not stored in the liver. Insulin concentrations in 
acetate liposome treated animals were reduced suggesting better sensitivity to insulin than 
control animals. In addition reduced concentrations of FFAs and increased concentrations of 
ketones in acetate liposome treated animals suggests increased rates of β-oxidation.  
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Figure 4.1. Acetate mechanism. 
The hypothesised effect of increased delivery of acetate to the liver is summarized in figure. 
Acetate uses ATP to be converted into acetyl CoA by ACS1 causing AMP:ATP ratio to 
increase which causes phosphorylation of AMPK. AMPK increases the activity of PPARα 
and PPARα increases the activity of CPT1. Activated CPT1 restores the β-oxidation rate 
which was reduced due to inhibition of CPT1 by malonyl CoA because of high 
concentrations of malonyl CoA. 
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NAFLD is caused by excessive storage of lipids in the liver and its incidence has been 
increasing (Smith and Adams, 2011, Williams et al., 2011). As people with NAFLD are at 
higher risk of developing more conditions such as cirrhosis and HCC (Hashimoto and 
Tokushige, 2011), it is important to prevent ectopic fat accumulation in liver.  
Excessive FFAs causes an increase in the intranuclear nuclear factor-kB (NF-kB) binding 
activity and an increase in the expression of proinflammatory factors and ROS generation 
(Khandekar et al., 2011). In this study, FFA concentrations were reduced and there was a 
trend toward decreased concentrations of pro-inflammatory factors, IL-6 and TNF-α in the 
acetate liposome treated group. This suggests that the reduction of FFAs in acetate 
liposome treated group in high fat diet study was enough to cause this change. It is 
important to decrease the inflammation as these factors activate the signal transducer and 
activator of transcription 3 (STAT3) which causes metathesis and anti-apoptosis leading to 
HCC (Khandekar et al., 2011, Sun and Karin, 2011).  
Another important factor in the development of HCC is insulin resistance. As the tissues get 
insensitive to insulin, the pancreas produces more insulin to compensate. Increased 
concentrations of insulin cause more production of insulin-like growth factor 1 (IGF1) which 
together with insulin increase cell proliferation (Khandekar et al., 2011). Administration of 
acetate encapsulated liposomes caused a decrease in the serum insulin concentration 
compared with the control animals in the high fat chronic study. 
Administration of encapsulated acetate showed positive effects on lowering total and liver 
lipid content. On the other hand the hypothesized effects of inulin on lowering adiposity were 
not observed in this study. This implies that increasing the availability of SCFAs through 
ingestion of fermentable carbohydrates might not always give the desired results because of 
the palatability of the diet. Whereas administration of acetate encapsulated with liposomal 
nanoparticles provide direct delivery of acetate to the liver in desired concentration giving 
consistent results also avoiding the side effects of acid injection. 
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In conclusion, delivery of acetate to the liver by the nanoparticles lead to a metabolic 
reprogramming of the hepatocytes, leading to increased β-oxidation and improved 
mitochondrial function. 
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4.2 Discussion of Methods Used 
In chapter 2, MRI and MRS methods were used to assess adiposity. Total fat mass 
calculated using MRI was higher than the adiposity calculated by MRS. Using MRS only 
gives the lipid content of the whole animal as biochemical molecules are detected with MRS 
(Mukherji, 1998). Using MRI, mass of adipose tissue can be calculated (Thomas et al., 
1998), including the connective tissue surrounding the adipocytes, which might explain the 
higher mass of adipose tissue calculated by MRI. With MRI only the visible fat depots can be 
identified but with MRS intracellular lipid content which is not visible to MRI can be 
quantified. Therefore MRS was used to assess intrahepatocellular and intramuscular lipid 
content. An advantage of MRI is that it can be used to investigate different fat depots and it 
was used to distinguish internal and subcutaneous fat depots. 
In chapter 3, MRS and dissection of fat depots were employed to assess adiposity. As in 
MRI with dissection only visible fat depots can be dissected but MRS allows us to detect lipid 
molecules including the lipid in tissues other than the adipose tissue. Adipose tissue does 
not only consist of lipids but connective tissue as well. This is not taken into account by MRS 
but measured with dissected fat depots. As can be seen in figures 3.46 and 3.58 these two 
methods are significantly correlated. This correlation was also shown by Mystkowski at al 
previously (Mystkowski et al., 2000b). The main advantage of using MRS in this study was 
that it allowed measurements of adiposity before and after the treatment which would not be 
possible by dissection method. On the other hand, fat depots dissected gave the opportunity 
to be able to differentiate between different fat depots which could not be done by MRS. 
Therefore the two methods are complementary to each other and are both essential parts of 
this study. 
In chapter 2, MEMRI was used to assess the hypothalamic activation. Although the results 
were compared with the study of (Kuo et al., 2006) where decreased appetite is followed by 
suppressed activity, it should be noted that there are two sets of appetite regulating neurons 
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in the hypothalamus as explained in section 1.3.1. The activation of the hypothalamic 
appetite centres might mean activation of NPY and AgRP (increasing appetite) or activation 
of POMC and CART (reducing appetite) or vice versa (Parkinson et al., 2009b).  
In chapter 3.1, PET was employed to image the biodistribution of 11C-acetate. Although no 
input function was used because of the animal model used, the results obtained give the 
overall picture of biodistribution. 
NMR of tissue extracts failed to give any conclusive results. This was due to both the low 
dose of acetate administered to the animals and the low sensitivity of 13C NMR (Bell, 1992). 
A more sensitive method such as mass spectrometry may be desirable. 
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4.3 Limitations of the Studies 
In the isomaltulose and inulin feeding study only low isomaltulose and low sucrose group 
(IM7.5_LS(12.5)) group showed a reduced food intake together with reduced hypothalamic 
activity. High isomaltulose high sucrose (IM20_HS(20)) and  inulin (IN) groups although 
showing reduced hypothalamic activity showed no difference in food intake compared with 
control. A proposed reason for this is the taste of diets, shown in the diet preference study. 
Therefore the reduced food intake and associated effects may be related to the palatability 
rather than the action of isomaltulose. 
 With MEMRI only the hypothalamic centres can be imaged. Because the hypothalamus is 
very close to the blood brain barrier, manganese can pass through the incomplete BBB and 
get taken up by the active regions (Kuo et al., 2006). However, appetite is not only controlled 
through the hypothalamus. Appetite centres in the brainstem play an important role as well 
(Parkinson et al., 2009a, Goldstone et al., 2000). Furthermore the reward centres have been 
shown to play a key role in food consumption (Goldstone et al., 2009) and therefore need to 
be assesst in future studies with SCFA and fermentable carbohydrates. 
In the study to investigate biodistribution of normal animals the main shortcoming of the 
study was the numbers of animals. Because of limited production of 11C-acetate obtained, 
the number of animals per group was limited to 4. Another limitation of this study was the 
use of the mouse model. In mice, repeated measurements of blood activity during the scan 
cannot be carried out due to limited amount of blood that can be obtained from the animals. 
The last limitation of the study is that, not acetate but 11C is actually imaged by PET. As 
acetate is metabolised, 11C is passed to its metabolites. With PET imaging, it is not possible 
to differentiate, the labelled acetate from the metabolites that are produced. 
Statistical analysis of longitudinal data in this thesis was performed by GEE analysis. This is 
a good method for analysing these types of data (Alencar et al., 2012) as the data does not 
have to be linear and have Gaussian distribution because the analysis is based on the 
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similarities within a group (Zeger and Liang, 1986). It has been used by our group previously 
in analysing any kind of longitudinal data (Parkinson et al., 2008, Kuo et al., 2007, 
Anastasovska et al., 2012) as we are interested in the mean effect of a treatment caused to 
a group of animals rather than  the effect on individual animals where other methods based 
on random effects analysis would have been more appropriate (Locascio and Atri, 2011). It 
should still be noted that with small sample numbers the data might be biased but it has 
been reported that statistical power of GEE with small sample size (Locascio and Atri, 2011) 
but increased repeated measurements is higher than the statistical power of repeated 
measures ANOVA (Ma et al., 2012). 
Colonic administration of low dose 13C acetic acid which was performed to study the 
metabolites in various organs and serum failed to give any conclusive results. The main 
reason for this may have been the use low of the concentration of 13C acetic acid. Although it 
may cause some changes in the metabolism NMR is not sensitive enough to detect minute 
changes. 
A number of interesting results were obtained by the preliminary study with acetate 
encapsulated in liposomal nanoparticles. The results could have been enhanced with a 
prolonged treatment period. The serum collected from animals was used for a number of 
tests, affecting the statistical power. Although the results obtained from these studies give a 
good idea about the positive effects of acetate, the mechanism by which it causes these 
effects are not fully elucidated, although preliminary hypothesis has been put forward.  
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4.4 Future Studies 
As mentioned in the above section, currently the MEMRI technique only provides information 
on hypothalamic brain activity. However in regulation of appetite, brainstem and reward 
centres are also involved. Recently it was suggested that doing multiple injections of 
manganese over a few days before the actual MRI scan makes it possible to image higher 
brain areas (Tambalo et al., 2009, Grünecker et al., 2010). We have tested this method 
doing either 2 or 8 fractionated injections of manganese chloride (2µmol/g). Areas such as 
ventral tegmental area, prefrontal cortex, nucleus accumbus and amygdale were examined. 
No signal difference could be detected as a result of cocaine or for high fat diet (unpublished 
data). We are now carrying out C-FOS studies to explore the reasons for this.  
If the metabolism of acetate after colonic administration is to be repeated, a recovery rate 
experiment should be carried out. This will give information on how much labelled acetate 
should be used in order detect it under NMR. 
Epigenetic changes are thought to be important in the effects of SCFA. Epigenetics can be 
defined by Bird as “the structural adaptation of chromosomal regions so as to register, signal 
or perpetuate altered activity states” (Bird, 2007), these adaptations are chromosomal marks 
which are caused by environmental factors (Bird, 2007, Stöger, 2008). Yamashita et al 
investigated mRNA expression of lipogenic enzymes. The transcription of lipogenic enzymes 
ACC, ME, G6PD, L-PK and FAS were reduced in acetate administered animals and lipolysis 
enzymes LCACD, 3KACT and SREBP-1 were similar to the control group. Rondo et al 
investigated mRNA expression of both lipogenic enzymes, SREBP-1, ACC and FAS and 
fatty acid oxidation enzymes, PPARα, ACO, CTP-1 and UCP-2. They did not observe any 
change in lipogenic enzymes but found increased concentrations of fatty acid oxidation 
genes. Rondo et al suggest that the discrepancy between the two studies can be either due 
to different species used (rats in Yamashita et al‟s study and mice in Rondo et al‟s study) or 
different diets used (normal fat in Yamashita et al‟s study and high fat in Rondo et al‟s study) 
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in the studies. During my first study using acetate encapsulated liposomes mice were fed 
with normal fat diet and in the second study mice were fed with high fat diet. Carrying out 
epigenetic studies in the liver samples collected could shed more light on these conflicting 
results. 
Given the positive results obtained with the acetate encapsulated liposomes, future studies 
are required with higher dose of acetate and over a longer period of time. This way we will 
be able to find out if the beneficial effects of acetate will intensify. In this thesis, animals were 
put on high fat diet on the day they started their liposome treatments. Therefore the purpose 
of the treatment is to prevent excess adiposity and therefore stop the diseases progress. 
Feeding animals with high fat diet over a long period, making them very obese and 
afterwards starting them on the liposome treatments will be able to reveal if the use of 
encapsulated acetate can reverse obesity and fatty liver disease. For example it is known 
that increased fat content is one of the precursors of insulin resistance (Galic et al., 2010). 
Furthermore since in this study fat content of animals on acetate treatment was reduced, it 
would be interesting to see if the insulin resistance can also be reversed as well. 
Recently a link between obesity and histone acetylation has been shown (Zhang et al., 
2011). The effects of acetate encapsulated nanoparticles on liver, which shows an improved 
lipid profile, may also be associated to the changes in histone acetylation and should 
perhaps be investigated. Finally, it would be interested to assess if the acetate utilised by the 
cells to acetylate histone come from an external source (extracellular) or intracellular. The 
use of acetate delivered by liposomal nanoparticle may help to elucidate this further. 
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